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1. lnductie van een hypometabole staat met waterstofsulfide (H2S) beschermt 
organen tegen een periode van zuurstofgebrek (dit proefschrift). 
2. Waterstofsulfide (H2S) heeft protectieve effecten bij ischemie, ook als er geen 
hypometabolisme wordt bereikt (dit proefschrift). 
3. Ge"isoleerde organen kunnen met waterstofsulfide (H2S) in een staat van laag 
metabolisme worden gebracht (dit proefschrift). 
4. Cystathionine y-lyase (CSE) is een endogene modulator van oxidatieve stress (dit 
proefschrift). 
5. De hoeveelheid cystathionine y-lyase (CSE) in een orgaan is van invloed op de 
uitkomst van transplantatie (dit proefschrift). 
6. Er bestaat een hogere macht die meekijkt met a lies wat we doen: de inlichtingendienst. 
7. Het is merkwaardig dat er een houdbaarheidsdatum te vinden is op schimmelkaas. 
8. De grootste tragedie in de wetenschap is de slachting van een prachtige hypothese 
door een lelijk feit (naar Thomas H. Huxley). 
9. Een paar maanden in het laboratorium kunnen een paar uur zoeken in de 
wetenschappelijke literatuur voorkomen (naar Frank H. Westheimer). 
10. Je kunt 100 jaar oud worden als je alle dingen opgeeft waarvoor je 100 jaar zou 
willen worden (naar Woody Allen). 
11. Schrijf een pakkende stelling en je naam zal altijd voortleven (onbekend). 
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Hydrogen sulfide (H2S) has historically been perceived as a highly toxic and foul smelling 
molecule (Table 1). Since the recent discovery of H2S as a physiological molecule produced in 
most cells of the mammalian body1•2, the perceived image of H2S has positively transformed. 
The amount of research performed on the subject has exploded in recent years, and has not 
shown signs of slowing down (Figure 1 and Figure 2). Over the past years, many new functions 
of H2S in (patho)-physiology have been discovered, and hope for therapeutic applications 
of this substance has grown, with several companies established that exclusively develop 
H2S-based therapeutics. However, the physicochemical properties of the molecule and the 
small therapeutic breadth/window hamper the translation to clinical applications. In addition, 
the former image of toxicity has not been erased, and bids for great caution in application of 
H2S. The physiology and antioxidative effects of H2S are extensively discussed in Chapter 1. 
Table 1 - Overview of the known toxic effects of hydrogen sulfide. 
Dose (parts per million) 
0.02 ppm - 0 .03 ppm 




100 ppm - 200 ppm 
300 ppm - 500 ppm 
500 ppm 




Offensive, unpleasant odor 
Maximum allowable concentration (MAC) for daily 8 hour exposure 
Irritation of the ocular conjunctiva 
Loss of smell / olfactory nerve paralysis 
Upper respiratory tract irritation 
Pulmonary edema 
Headache, dizziness, unconsciousness after 30 - 60 minutes of exposure 
Unconsciousness, respiratory paralysis eventually leading to death 
Rapid collapse, death within minutes 
Adapted from Beauchamp et al. 3 
Toxicity of H 2S 
The main focus of H2S research before the 1990's was it's toxicity, stemming from accidents 
in the industrial setting such as oil and gas refineries, and in the farming industry. Accidents 
involving high concentrations of H2S cause collapse, unconsciousness and respiratory paralysis, 
ultimately leading to death3. An overview of the effects of different concentrations of H2S on 
human subjects is given above in Table 1. 
Because of this toxic image, the use of H2S - even in laboratory setting - is carefully 
monitored because of safety concerns. However, measurement of H2S in the gaseous state is 
quite developed and reliable, and devices for ambient H2S monitoring can ensure the safety of 
the patients and the medical personnel involved. We therefore consider gaseous H2S or soluble 
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Figure 1 - Number of publications per year on H2S, CSE, CBS and MPST from 1945 to 2011. 
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Figure 2 - Number of publications on the H2S-producing enzymes CSE, CBS and MPST per year 
from 1945 to 2011. 
Data extracted from Web of Science. 
Endogenous production of H 2S 
In recent years, the role and functioning of H25 in physiology has become recognized. It is 
produced by three distinct enzymes in mammalian cells, namely cystathionine y-lyase (CSE), 
cystathionine �-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (MPST), and it 
INTRODUCTION 
functions as a gaseous signaling molecule, or gasotransmitter, similar to nitric oxide (NO) 
and carbon monoxide (CO). Its functions range from vasodilatory action as an endothelial 
derived hyperpolarizing factor (EDHF) to modulation of oxidative stress and signaling through 
posttranslational protein modification4·7• Although many of the effects of H2S have not been 
elucidated yet, it appears clear that H2S is an important mediator in cellular physiology. 
H2S-induced hypometabolism 
The current project was shaped following the discovery that gaseous H2S could induce a 
reversible, hibernation-like state in mice, which was dubbed suspended animation8• During H2S 
treatment, oxygen consumption and carbon dioxide production of these animals is reduced 
by 90-95%. Over time, core body temperature decreases to around 2° C above the ambient 
temperature. This massive reduction in oxidative metabolism is reversible after cessation of the 
H2S exposure, without apparent toxic effects. This state of hypometabolism could bring great 
protection during states of low oxygen supply, such as ischemia. We were interested in protecting 
organs from ischemic damage, and we pursued H2S as a promising candidate to achieve this. 
The mechanism behind H2S-induced hypometabolism has not been elucidated until now. 
One of the main hypotheses is the reversible inhibition of cytochrome c oxidase (COX), the 
terminal enzyme in the mitochondrial electron transport chain9• H2S can non-competitively 
and reversibly bind to COX at oxidized sites, inhibiting the oxidative capacity of the electron 
transport chain 1°. This causes mitochondrial depolarization and ATP depletion 11• In addition, H2S 
can be used as an electron donor in the electron transport chain during depletion of 02, which 
might be a mechanism for keeping only essential metabolic activity during hypoxia 12• 
In our view, the application of hypometabolism is primarily applicable in ischemia with 
predictable onset, since our data indicate that the hypometabolic state is more potent when 
induced before or at the time of hypoxia, and not afterwards. This made organ transplant 
models the most rational for testing our hypothesis. It is highly interesting to see whether 
hypometabolism could protect in models of myocardial infarction or stroke, but the clinical 
relevance and treatment effect is likely smaller, since delivering H2S to the affected area through 
the circulation is not possible during the ischemic event. 
Organ donation and ischemia / reperfusion injury 
One of the main determinants of outcome after solid organ transplantation is the amount of 
ischemia that the organ is exposed to13•14• The principal method for reducing the unfavorable 
effects of transplant anoxia is cooling the organ after removal from the donor. Cold ischemia 
greatly lengthens the time available between explantation and implantation in the donor. 
The effect of cooling is based on reducing metabolism and enzymatic activity in the organ. 
Cold storage does have detrimental effects as well, and some of those could be prevented by 
inducing hypometabolism using H2S, or maybe cooling the organ to room temperature while 
adding H2S to the preservation solution. Recent developments in machine perfusion of organs 
during preservation have improved outcome after renal transplantation. These developments 




AIM OF THIS THESIS 
The aim of this thesis was to investigate the therapeutic potential of H2S in the setting of 
ischemic and hypoxic disease. 
In Chapter 1 an outline of the known physiological functions of H2S is given, complemented 
with the current state of research on H2S in hypoxic models, and the developments that 
have occurred in recent years in the fields of H2S delivery and measurement. In Chapter 2, 
Chapter 3  and Chapter 4 we test our hypothesis that H2S-induced hypometabolism in protective 
in ischemic models of the kidney, liver and heart. Since the therapeutic window may vary 
between various organs and cell types, each chapter has its distinctive approach in regard 
to the timing, time course and dose of H2S. Chapter 5 investigates the antioxidant role of 
endogenous H2S production by CSE in ischemic settings in vitro, in vivo and in human renal 
transplant tissue, using models of CSE deficiency and overexpression. In chapter 6 we studied 
whether the expression of CSE and CBS, and thereby the possible endogenous production 
of H2S, is altered in preeclampsia, a vascular disease associated with placental hypoxia and 
endothelial dysfunction. Chapter 7 recapitulates the effects of brain death on transplanted 
organs, and the opportunities it presents for protecting donor organs from transplant-related 
ischemia. In Chapter 8, all results are summarized and discussed, followed by a view on the 
future possibilities of H25 related research and therapeutic applications. 
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THERAPEUTIC POTENTIAL OF H2S 
ENDOGENOUS PRODUCTION AND FUNCTION 
Hydrogen sulfide (H7S) is now considered to be the third gaseous signaling molecule - or 
gasotransmitter - together with nitric oxide (NO) and carbon monoxide (CO). It is produced 
from L-cysteine by cystathionine y-lyase (CSE) and cystathionine �-synthase (CBS), and from 
3-mercaptopyruvate by 3-mercaptopyruvate sulfurtransferase (MPST) (Figure 1). The interest 
in the field of H2S research has grown markedly in recent years, with greatly reduced focus 
on toxicity and increased attention for the many physiological functions of endogenously 
produced and exogenously administrated H2S. 
Physiological function 
The most widely studied function of endogenous H2S relates to its vasodilatory effects, of which 
the mechanism has now been partially clarified. The functional properties of H2S in the vascular 
bed can best be studied in genetically manipulated mice, such as the CSE·1 mice that has been 
developed in recent years, which need dietary cysteine to survive1•2• CSE deficiency causes 
hypertension, as evidenced by CSE-I- mice which show an increase in systolic blood pressure 
of~ 18 mmHg3• This increase in blood pressure is similar to the effects seen in endothelial nitric 
oxide synthase (eNOS) knockout mice4• CSE·1· mice have diminished endothelium dependent 
vasorelaxation which is likely related to the vasorelaxant effects of H2S. These effects are 
mediated through the opening of ATP-dependent K+ channels (KATP) in vascular smooth muscle 
cells5• Recently it has been shown that the mechanism behind the opening of KATP channels is 
the direct sulfhydration of the Kir6.l subunit of this channel by H2S, and this effect is absent 
in CSE-I- mice, indicating an essential role for CSE/H2S in this vasodilatation
6
. CBS regulates 
the cerebral microcirculation and CBS deficient mice show reduced or absent vasodilation in 
precapillary arterioles in response to hypoxia, while CSE deficiency has no effect7. 
CSE and CBS both are involved in the response to oxidative stress. CSE-I- animals are 
more susceptible to ischemic damage8, and overexpression of CSE in cardiac tissue protects 
from myocardial infarction9• This seems to be related to the reduction of destructive reactive 
oxygen species (ROS) by H2sa.
1o and the protection of mitochondrial integrity and function9• 
Mice deficient in CBS show increased amounts of oxidatively modified proteins in their 
livers11, indicating a role for H2S in the antioxidative response. CSE and CBS can be excreted 
by endothelial cells and hepatocytes, circulate in plasma and actively produce H2S from 
homocysteine in human blood12 and this extracellular CSE and CBS protect endothelial cells 
from redox stress. 
H2S is essential for vascular endothelial growth factor (VEGF) mediated angiogenesis. 
Exogenous H2S increases endothelial cell proliferation and migration, and deficiency of CSE 
causes impaired microvessel formation in aortic rings13• In CSE·1· mice, wound healing is 
impaired and treatment of rats with NaHS improves wound healing13•14• These beneficial effects 
were related to modulation of angiogenic mechanisms. The actions of endogenous H2S seems 
to be dependent on NO, and might act through a cyclic guanosine 5'-monophosphate (cGMP) 
mediated mechanism14• In addition, CSE seems to be involved in models of diabetes 15, possibly 
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Figure 1 - Overview of endogenous H2S production and the enzymes involved. 
Abbreviations: CSE - cystathionine y- lyase; CBS - cystathionine �-synthase; MPST - 3-mercaptopyruvate 
sulfurtransferase; CAT - cysteine aminotransferase; CDO - cysteine dioxygenase; DAO - D-amino acid 
oxidase. 
Deficiency of CBS can cause vascu lar  a n d  e ndothe l i a l  dysfunct ion a nd cerebra l interstitia l  
remode l ing 18•19, and i s  associated with i ncreased oxidative stress11 • Lack  of  CBS  produces 
hyperho mocyste inemia ,  in humans  as  wel l  as in m ice. The CBS+/- m ouse has been extensively 
used as a model for this d i sease. CBs·1· a n i m a l s  die at a very young  age (3-4 weeks after b i rth), 
and are not frequently used for resea rch p u rposes20• In Drosoph i l a, CBS is  necessary for the 
i ncreased l ifespan l i nked to dieta ry restrict ion21 • CBS is  encoded on  c h romosome 21, a nd patients 
with Down's syndrome have trip le  the a m o u nt of CBS protei n  in the i r  bra i n22 • It is sti l l  a topic of 
d iscuss ion whether th i s  is  related to the red uced mental ca pacity in th i s  syndrome. MPST is the 
least stu d ied of the H2S producing enzymes, a n d  has been mostly associated with the centra l 
nervous system - with a ctivity in the bra i n  a nd ret ina - and  the vascu l a r  endothel i u m23·25 • 
l ntra m itochondria l  M PST has been shown to produce H2S, where it is ab le  to mainta in  energy 
product ion by donating  e lectrons26•27• 
H2S can be used as a n  inorgan ic  energy su bstrate for mitochondria
27• U nder stress, such 
as  i ncreased i ntrace l l u l a r  calci u m  concentrations, CSE can tra ns locate to the mitochondria  
mediated by tra ns locase of the outer mem bra n e  20 (Tom20)28• It i s  hypothesized that 
t rans location of CSE to the m itochondria  ca n i ncrease mitochondri a l  H2S levels to be used as  an 
electron donor in  the e lectron tra nsport c h a i n .  
THERAPEUTIC POTENTIAL OF HiS 
Regulation of H 2S 
CSE and CBS expression are regulated through the specificity protein 1 (Spl ) transcription 
factor17•29-31 • Recent research suggests that microRNA 21 (miR21) reduces the expression of Spl 
and CSE by directly targeting Sp 1 32• ERK mediated phosphorylation of Spl reduces its activity3°. 
CSE expression through Spl can also be activated by TNFa33• Nrf2, a transcription factor that 
is activated by oxidative stress, can translocate the nucleus upon activation and bind to an 
antioxidant responsive element (ARE) to mediate gene transcription of protective genes such 
as glutathionine S-transferase (GST) or heme oxygenase 1 (HO-1)34• The CSE promoter contains 
an ARE, and thus the expression of CSE can be modulated by Nrf235 • Modulation of Spl or Nrf2 
might be a strategy to affect CSE expression and endogenous H2S production. Also, the CSE 
promoter contains an farnesoid X receptor (FXR) responsive element, activation of which 
induces expression of CSE and mutation blocks FXR mediated CSE expression36• It has been 
shown that CSE and CBS can be posttranslationally modified by sumoylation. The activity of 
CBS is decreased by sumoylation, and it can theoretically be involved in nuclear translocation, 
although this has not been directly shown for CBS or CSE37• 
Recently, a new pathway for the production of H2S from D-Cysteine has been uncovered,  
mainly by MPST in the cerebellum and kidney38, involving the activity of  D-amino acid oxidase 
(DAO). Cysteine aminotransferase (CAT) produces 3-mercaptopyruvate from cysteine, and 
could be involved in the regulation of H2S production39• Thioredoxin or dihydrolipoic acid 
(DHLA) are necessary for production of H2S from MPST40• CAT activity in retinal neurons is 
modulated by Ca2+39_ Cysteine dioxygenase (CDO) is responsible for the majority of cysteine 
catabolism. In models of CDO deficiency, the increase in cysteine metabolism causes excess 
H2S production through CSE and CBS, and related toxicity41A2_ For an overview, see Figure 1 .  
Ethylmalonic encephalopathy protein 1 (Ethel) has recently been implicated in the catabolism 
of sulfur compounds, as deficiency of Ethel causes sulfide toxicity in mice43. Interestingly, tissue 
specific knockout of Ethel in muscle, liver or brain caused localized signs of sulfide toxicity without 
increasing urinary thiosulfate, indicating that local levels as opposed to serum levels of H2S are 
important44, which could be due to the high volatility and reactivity of sulfide. These findings have 
already led to a promising therapy for ethylmalonic encephalopathy in humans using metronidazole 
to reduce intestinal H2S production by bacterial flora and N-acetylcysteine to neutralize H2S
45• 
One of the most interesting properties of H2S is the sulfhydration of proteins and modifying 
their activity, as touched upon before. This posttranslational protein modification, where an 
SH-group is added to a reactive cysteine residue, can change the activity of the target protein46• 
This mechanism is analogous to protein phosphorylation. It was first shown that 10%-25% of 
the abundant GAPDH protein was sulfhydrated in vivo, and that sulfhydrated GAPDH had 
higher activity. Since then, well studied proteins such as NF-KB, VEGFR2, PTPl B, H-Ras, the 
KATP-channel and Keapl were shown to be modified by H2S, with associated changes in protein 
activity6•33.47•51 _ This is a field still in its infancy, but it seems that it can become a meaningful 
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Figure 2 - Overview of endogenous CSE and CBS regulation. 
Abbreviations: CSE - cystathionine y-lyase; CBS - cystathionine [:>-synthase; ERK - Extracel l u lar  signal 
related kinase; TN Fa - tumor necrosis factor a l pha; Pl3K - phosphoinositide 3 kinase; Akt - protein 
ki nase B; Spl - specificity protein 1; Kea pl - kelch- l ike ECH-associated protein 1; Nrf2 - nuc lear factor 
(erythroid-derived 2)- l ike 2; ATF4 - Activating transcription factor 4; ER - endoplasmatic reticu lum.  
EXOGENOUS ADMINISTRATION OF H2S 
There a re cu rrently severa l o pt ions for a ltering H 2S leve ls  in experi menta l  sett ings :  
- Su lfide-sod i u m  sa lts (NaHS, Na2S) 
- Exposure to gaseous H2S 
- Slow-re leas ing H2S donors 
- Hybrids of H2S-donors and  known s u bsta nces 
- Cysteine a n a logues 
- Modu lati n g  the expression  or activity of H2S-produc ing enzymes 
The physicochemical properties of  H2S cause several problems for the appl ication in  biomedical 
experiments. In the large majority of the publ ished literature, one of the sod ium sa lts that release H2S 
in solution have been used (Na HS or Na2S) . The m ajor problem of us ing su lfide sa lts as H2S donors 





THERAPEUTIC POTENTIAL OF H2S 
Over the course of years, it has become clear that these sodium sa lts have d isadvantages, such as 
the rapid peak and concurrent decrease in H2S levels when d issolved or injected53•
56
• This makes it 
d ifficult to achieve control led, stable and therapeutic levels in vitro and in vivo. 
The development of s low-re leas ing H2S donors has improved the ab i l ity to achieve such a 
sta b le i ncrease in H2S level s52·54,56•57• Addition of NaHS or Na2S to a pH-neutra l  solution leads to 
an increase in HS· and  H2S levels, with the peak level occurr ing with in minutes, after wh ich  the 
H2S ra p id ly d issolves from solution, or  q u ickly reacts with proteins so that the amount of H 2S 
decreases to norma l levels in 30 m inutes to 3 hours52-54• Although some postu late that one of 
the two main  su lfide-sod ium sa lts is su perior to the other, the l ittle comparative work that has 
been performed shows no d ifference between the com pounds58• 
The exposure of anima ls or cel l s  to gaseous H2S poses some technical problems that main ly 
revolve around the toxicity and related safety measures that need to be taken when using 
pressurized H2S-containing gases. I n  addition, the corrosive nature of H2S prompts the need for 
specia l ized materials. The use of gaseous H2S can induce very stable states of hypometabol ism 
in mice59•60• Gaseous H2S can be used for smal l - and large anima l  experiments or for the exposure 
of cells or nematodes59•61•62• The actual concentration that is concurrently del ivered with different 
concentrations of gaseous H2S to target organs is however sti l l  a point that has not been elucidated.  
I n  recent years, two major developments in th is  fie ld have occurred. First, compounds that s lowly 
release H2S have been produced (see Table 1). These have made it possible to study the effects of long 
term heightened H2S levels in vitro and in vivo. This as opposed to the large and short peaks i n  H2S 
levels that are produced by the su lfide releasing sodium salts, where by daily injection the serum H2S 
levels are most l ikely very high for a short period and near  normal for the majority of the day. 
The second deve lopment is the creation of hybrids from known and widely used drugs with 
su lfide releas ing compounds.  These new conjugates can potentiate the effects of the orig ina l, 
or d im in ish the side effects of the old drug .  A large proportion of the hybrids cu rrently u nder 
deve lopment are NSAIDs.  For exam ple, ACS14 CS-asp i r i n), a H2S re leas ing form of asp iri n ,  has 
a broader i nh ib itory effect on p latelet agg regation com pared to aspirin,  showing effect on 
ADP- and thrombin receptor activating peptide (TRAP)- induced aggregation where asp ir in  has  
min ima l  effect.63 ATB-346, a H2S re leas ing form of naproxen, greatly reduces the gastrointestina l  
mucosa l  damage associated with NSAI D usage64•65• ACSlS (S-dic lofenac) i nh ibits angiogenesis, 
has strong anti- inflammatory effects in LPS- or Amyloid f3- induced infl ammation and  atten u ated 
the detrimenta l effects of ischemic myocard ia l  damage in rats52•66-68• Other exam ples a re ACS6 
(S-s i ldenafil), which has smooth m uscle relaxant effects on the corpus cavernosum, but a lso 
showed antioxidative effects i n  endothe l ia l  cel ls69•70• ACS83 (S- Levodopa) increased dopamine 
and GSH levels  i n  the bra in  and reduced the g l ia l  infl ammatory response71 • 
An a lternative development is the use of natu ra l ly occu rring cysteine ana logues such as 
d ia l lyl tr isu lfide (OATS, can be derived from gar l ic72) or S-propargyl cyste ine (SPRC). These 
compounds seem to increase H2S levels  for longer periods of time and have protective effects 
in models of ischemia54•73•74• 
Another option for H2S based treatments is modu lation of the expression or activity of 
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ACS2 / 33 / 43 H2S-releasing va lproic acid CTG Pharma I ncreased histone deacetylase inh ibition com pared to va lproic acid Perrino (2008) 
I nh ibited vascular outgrowth from tumor and muscle, reduced endothel ia l  I senberg (2012) 
prol iferation. 
ACS6 H2S-releasing s i ldenafi l CTG Pharma Antioxidative properties in  a rterial endothel ia l  cel l s  Muzaffar (2008) 
Similar effects to sildenafil on corpus cavernosum relaxation and reduces ROS. Shukla (2009) 
Attenuated Hey-induced cel l  death, a poptosis and ROS. Tang (2012) 
ACS67 H2S-releasing lata noprost CTG Pharma Reduced intraocular pressure in  model of glaucoma, increases GSH levels. Perrino (2009) 
Protected from retinal ischemia, reduces a poptosis and ROS. Osborne (2010) 
ACS83 / 84 / 85 / 86 H2S-releasing Levodopa CTG Pharma Increased dopamine and GSH levels in  the bra in .  Lee - JBC (2010) 
I mproved cel lu lar viabi l ity and reduced inflammatory response of g l ia l  Lee - JBC (2010) 
cells to activation. 
S-memantine H2S-relasing memantine CTG Pharma Improved neurological outcome and smal ler infarct volume in brain ischemia. Maruta ni (2012) 
Single H2S donors 
NaHS Sulfide-sodium salt Generic Releases H2S very rapidly 
Na2S Sulfide-sodium salt Generic Releases H2S very rapidly. Under development by lkaria under the name IK-1001 
GYY4137 Slow releasing H2S donor Cayman Chemical Reduced proliferation and cel l survival in  multiple cancer cel l  l ines. Lee (2011) 
Reduced in-vivo tumor growth of two leukemia cel l l ines.  Lee (2011) 
Attenuated hemodynamic and i nflammatory response to LPS. Li (2008) 
SG-1002 Mixture, main ly Sulfide-ring Su lfagenix Reduced cardiac hypertrophy after transverse aortic constriction in WT Kondo (2013) 
a nd csE·1· mice 
ADTOH Dithiolthiene Generic Reduced hemodynamic effects of GSH depletion, reduced gastric damage. Rossoni (2010) 
Increased GSH levels in  plasma, aorta and heart .  Sparatore (2009) 
OATS Dial lyl trisu lfide Generic Reduced ischemic damage in myocardial infarction, protected mitochondria. Predmore (2012) "C m 
SPC S-a l lyl -L-cysteine Generic Reduced oxidative stress in  rat model of myoca rdia l  infarction.  Wang (2010) -l 




Induced a poptosis and reduced tumor growth of gastric cancer cel ls  in-vivo Ma (2011) SPRC S-propa rgyl-cysteine Generic -l 
Reduced oxidative stress in rat model of myocardia l  infarction. Wang (2010) 
NACET N-acetyl-L-cysteine ethyl ester Generic Increased H2S levels in  plasma, is rapidly taken u p  by erytrocytes. Gu ista rin i  (2012) Q 
I 
N-(benzoylthio) Cysteine-activated H2S donor Generic I ncreased H2S levels only in  the presence of L-cysteine. Zhao (2011) V, 
benzamide 
Iv ! V, 
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CHAPTER 1 
These are however not h igh ly specific. Also, s ince the therapeutic effects of H 2S mostly are 
re lated to increased levels, use of these su bstances has been mostly shown to be detri mental 
in model systems. CSE inh ibitors a re OL- propa rgylg lycine (PPG) and �-cyano-L-Alan ine (BCA) . 
CBS inh ib itors are a m ino-oxyacetate (AOA) and hydroxyla m ine  (HA) .  S-adenosyl - L-meth ion ine 
can increase CBS activity in vivo75 • As mentioned before, mod u lation of Spl, N rf2, FXR or m iR21 
might be targets for modu lation of expression of CSE and CBS .  
Loss of  Ethel ,  a n  endogenous d ioxygenase, causes the d isease ethyl malonic encepha lopathy, 
and g reatly i ncreases H2S levels in serum and organs of Ethei -1 an ima ls43• Mod u lation of the 
activity of Ethel m ight cause increased leve ls  of H 2S in vivo. Another option is targeting cysteine 
d ioxygenase (COO), which is involved in cysteine cata bol i sm, and coo·1· and coo+/· an ima ls 
have increased t issue levels of su lfide42 and  show evidence of su lfide toxicity41 • However, a l l  
options to  increase endogenous H2S production can  lead to  toxic ity through depletion of 
cytochrome c oxidase (COX) and local  organ  damage, as shown in a conditiona l organ specific 
knockout model of Ethel44, where local Ethel deficiency caused increased levels  of H 2S and 
associated confined toxicity in the affected organs .  
Another i nteresti ng mechanism is i ntracel l u lar  trans location to modify protein fu nction.  
CSE can be trans located to mitochond ria, which might affect the function it exerts .  This 
process is regu lated by trans locase of the outer membrane  20 (Tom20)28• When this p rocess 
can be regu l ated it m ight lead to new thera pies to modu late the fu nction of CSE. Sumoylation 
of CBS and CSE has a l so been executed, where CBS decreases i n  activity when sumoylated, the 
effects on CSE have yet to be determined37, and it remains to be determined what the loca l ized 
effects a re of the associated nuclea r trans location. 
THERAPEUTIC POTENTIAL OF H2S IN OXIDATIVE STRESS 
One of the most prominent and wel l  studied properties of H 2S is the reduction in damage related 
to oxidative stress. Many groups have investigated the rol e  of H 2S in  ischemia/reperfusion injury 
( IRI) or in vitro oxidative stress, and as a consequence many d ifferent models and treatment 
reg imens have been used. The mechanism behind H2S induced protection has not been clearly 
elucidated, a lthough many different approaches have been investigated . It seems that H 2S has 
many different effects and it is not possib le to point to a s ing le mechanism that expla ins a l l  the 
effects i n  these models.  
In vivo models of ischemia 
Heart 
Myoca rd ia l  infarct ion (Ml) is one of the ma in  models used for the study of the protective 
effects of H2S in ischemia .  I ntravenous Na2S 24 hours before cardiac ischemia attenuated infarct 
size, serum tropon in  levels, l i pid hyd roperoxide levels and  apoptosis, whi le ca rdiac fu nction 
improved76• I nject ion of Na2S in  the left ventricu lar  l u men at reperfus ion attenuated myoca rd ia l  
infa rct size, tropon in  levels, infl am mation, apoptosis and card iac fu nction. Na2S preserves 
m itochond ria l  oxygen consu mption and - i nteg rity after myocard ia l  ischemia9• Other stud ies 
have shown s im i l a r  effects of Na HS or Na2S in models of Ml ,  us ing different models, treatment 
THERAPEUTIC POTENTIAL OF H2S 
regimens and modes of administration51•77-81 • In a mouse model with Na HS in drinking water for 
4 weeks after Ml, H2S protected against cardiac function loss and fibrosis, and Na HS increased 
the amount of collaterals formed 4 weeks after Ml82_ Na2S improved myocardial function 
after cardiac arrest and cardiopulmonary resuscitation (CA/CPR)83_ Na2S induced a significant 
improvement of the recovery of myocardial and endothelial function in a canine model of 
cardiopulmonary bypass with hypothermic cardiac arrest84_ From our own experiments, we have 
seen cardioprotective effects of gaseous H2S in hypometabolic as well as non-hypometabolic 
concentrations. Sub-hypometabolic concentrations of H2S prior to ischemia protect hearts 
from ischemia-induced fibrosis and inflammation, whereas inducing hypometabolism offers 
additional protection against short term myocardial necrosis85• 
Not only treatment with exogenous H2S seems to be protective, modulation of the 
endogenous production is a promising approach as well. Cardiac specific overexpression of 
CSE increases H2S production rate9 and improves survival and reduced ventricular dilatation 
and hypertrophy in a model of heart failure induced by permanent left coronary artery 
(LCA) occlusion. Daily administration of Na2S attenuated oxidative stress and mitochondrial 
dysfunction during the development of ischemia-induced heart failure86• After Ml, cardiac 
specific CSE overexpression reduced left ventricular dilatation and hypertrophy, and improved 
left ventricular function9• In rats NaHS reduced, while inhibition of CSE using PAG increased 
infarct size. PAG treated animals had increased inflammation after Ml 87•88• 
Kidney 
In renal ischemia/reperfusion injury, NaHS at clamping and during reperfusion attenuated 
the rise in serum creatinine and improved microvascular flow. Necrosis and apoptosis and 
inflammation are attenuated by NaHS89•90• IRI associated liver injury is attenuated by NaHS 
after renal IRl89• In another study bilateral renal ischemia caused mortality, renal failure and 
inflammation, which were prevented by a gaseous H2S-induced hypometabolic state (without 
hypothermia), but only when H2S was given before ischemia (pretreatment)
62
• Structural 
damage and apoptosis caused by IRI was nearly abolished by pretreatment and combined 
pre/posttreatment, while posttreatment alone had less but significant effects62• Transmission 
electron microscopy showed that H2S pre-/posttreatment prevented I RI-induced mitochondrial 
swelling and degeneration62 • In a model of porcine aortic occlusion, renal function loss was 
attenuated by Na2S, as were Oxidative DNA base damage, IL-6 and IL-lbeta levels
91
• 
In the kidney, production of H2S by CSE seems to modulate the effects of oxidative stress. In 
CSE-I- animals - which have low renal H2S levels - mortality, renal function loss and DNA damage 
is increased following bilateral ischemia reperfusion injury. These effects could be rescued by 
Na HS treatment8 • In human transplant biopsies, the level of CSE mRNA pre-transplantation was 
associated with improved outcome as measured by renal function after kidney transplantation 8. 
After bilateral renal ischemia, CSE protein, renal H2S production and plasma H2S levels are 
increased. NaHS injections reduces I RI-induced renal function loss92 • Bilateral IRI induced renal 
function loss was exacerbated by PPG treatment, while NaHS treatment attenuated these 





protect kidneys from ischemia as well, possibly with increased potency compared to L-cysteine 
probably by the production of H2S through D-amino acid oxidase (DAO) and MPST38• 
Brain 
In middle cerebral artery occlusion in rats, gaseous H2S for 2 days starting after reperfusion 
improved neurological outcome, and reduced infarct size and inflammation94. NaHS injection 
increased performance on maze escape latency and protected against histopathological damage 
in the hippocampal area in bilateral common carotid occlusion95. In models of stroke, not all studies 
show unequivocal protective effects, however. In global cerebral ischemia in rats low dose NaHS 
protected neurons, while high dose Na HS exacerbated neuronal damage96• Another study showed 
that infarct volume was increased in animals treated with Na HS. Both CBS inhibitors (AOAA and HA) 
and CSE inhibitors (BCA and PPG) reduced cortical H2S production, and all inhibitors reduced infarct 
volume 24 hours after ischemia (with the CBS inhibitors being more potent)97• 
In a mouse model of cardiac arrest and cardiopulmonary resuscitation (CA/CPR), Na2S 
improved survival, neurological function and neuronal survival. Serum H2O2 levels were 
reduced by Na2S shortly after CPR indicating antioxidative effects. Mice overexpressing CSE in 
cardiomyocytes had increased survival and neurological outcome after CA/CPR83• In another 
study, short term neurological outcome was better in the sulfide group, but was similar 1 week 
after CA/CPR. Here, apoptosis and neuronal death was not affected by Na2S98. Interestingly, a 
gain of function polymorphism in CBS has recently been associated with less delayed cerebral 
ischemia following aneurysmal subarachnoid hemorrhage in humans99• 
Liver 
In a model of total hepatic IRI in rats, posttreatment with NaHS reduced plasma ALT after 6 
h of reperfusion. Hepatic I RI associated renal and cardiac damage was attenuated by NaHS, 
as were plasma levels of MDA100. Pretreatment with gaseous H2S in of partial hepatic ischemia 
reduces necrosis, AST, ALT, apoptosis, granulocyte influx, I L-6, IL-lbeta and TNFa upregulation 
and ROS production. HO-1 expression was not associated with protection101. In partial hepatic 
ischemia, low dose Na2S treatment (0.3 and 1 mg/kg) protected from liver damage, while 2 
mg/kg increased damage, as measured by AST and ALT. H2S treatment preserved GSH stores 
and attenuated lipid hydroperoxide and Caspase3 cleavage 1°2 • Treatment with Na HS 30 minutes 
before and after reperfusion, AST and ALT levels were attenuated, while PAG treated animals had 
levels similar to control I RI animals. Histological damage was reduced by NaHS, and increased 
by PAG. Inflammation and lipid peroxidation were reduced by NaHS, but unaffected by PAG103 • 
NaHS suppressed hepatic autophagy in vitro and in vivo, and pharmacologically reducing 
autophagy further diminished the protective effect of NaHS, while rapamycin reversed the 
autophagyinhibitory effect and enhanced the protective effect of Na HS against I Rl 104. Interestingly, 
CBS I· mice have 30% increased oxidatively modified proteins in liver samples 11, indicating an 
antioxidative function of CBS and/or endogenous H2S under physiological circumstances. 
Shock 
In hemorrhagic shock in rats, gaseous H2S and intravenous Na2S greatly increased survival1°5 and 
injection of Na HS 10 minutes before reperfusion reduced superoxide levels in aorta and heart 1°6• 
THERAPEUTIC POTENTIAL OF H25 
In a porcine model of hemorrhagic shock, Na2S infusion improved survival compared to controls, 
and troponin levels were reduced in Na2S treated animals. Renal function (plasma creatinine and 
creatinine clearance) was improved by pre-/posttreatment with Na2S. IL-6 levels were reduced 
by pre-/posttreatment, and lung, liver and kidney histopathological scores were improved107. 
However, in another porcine study Na2S had no effect on survival or organ injury parameters 1°8. 
Fascinatingly, in full body hypoxia in mice (5% 02), animals survived for a median time of 
12 minutes and a maximum time of 17 minutes, while 20 minutes of gaseous H 2S pretreatment 
followed by 1 hour of 5% 02 did not cause any mortality or morbidity
6°, with one experiment 
showing survival for more than 6 hours. 
Lung 
In an ex vivo model of lung transplantation related IRI with cold storage in rabbits, NaHS was 
given during reperfusion. ROS levels were greatly decreased by NaHS treatment109·110. In cold 
storage and reperfusion of rabbit lungs treated with inhaled H2S, on reperfusion, pretreatment 
with inhaled H2S caused better oxygenation and ventilation and lower pulmonary artery 
pressure110. In isolated lung perfusion, H2S treatment attenuated histological damage caused by 
IRI, while PPG increased damage, and H 2S normalized markers of oxidative stress 1
11. 
Intestine 
NaHS reduces oxidative stress and structural damage, while it increased intestinal GSH levels and 
SOD activity in a model of rat intestinal IR112•113• In a model of jejuna! ischemia, NaHS treatment 
preserved villus height after reperfusion114. Leukocyte rolling and adhesion are attenuated by NaHS115. 
In vitro studies 
In models of hypoxia, NaHS attenuated apoptosis in endothelial cells as well as fibroblasts 116, 
and reduced ROS in hippocampal neurons117 and cardiomyocytes118. In two different cell 
types, CoCl2 induced chemical hypoxia induced cell death, apoptosis and ROS, which was 
attenuated by NaHS119·120. Na HS protects neuroblastoma cells from oxygen-glucose deprivation 
(OGD) / Na2SP4 induced cell death 121 . In neuroblastoma cells, Na HS concentration-dependently 
reduced formation of nytrotyrosine caused by ONoo-, and protected from cell death 122. H O Cl­
induced protein oxidation, lipid peroxidation and loss of cell viability were concentration­
dependently inhibited by NaHS123. Overexpression of CBS reduced Na2Sp4-induced apoptosis
121. 
NaHS protects primary rat astrocytes from HP2-induced cell death and ROS production, 
while inhibition of CBS decreased viability124. Also, NaHS protected photoreceptor cells from 
light-induced degeneration, reducing apoptosis and oxidative stress39. Isolated mitochondria 
exposed to hypoxia had better recovery of respiratory rate when treated with Na2S
9, and it 
protected from calcium induced mitochondrial swelling83. 
Na HS protected pancreatic beta-cells from Hp2 and cytokine induced apoptotic cell death 
125• 
In neuronal cells and astrocytes, NaHS protected oxidative stress and increased GSH levels 10·124. 
It is however acknowledged that H2S can directly react with Hp2, so the question is whether the 
effects seen are caused by direct reaction between the compounds in the medium 126. 
In CSE deficient vascular smooth muscle cells, hypoxia causes reduced viability and 





overexpression of CSE reduced antimycin-induced ROS- and mitochondrial superoxide 
production, which could be further reduced by additional NaHS8 • Na HS reduced cell death and 
LDH release after hypoxia, while inhibition of CSE using PAG increased these parameters88• 
Interestingly, the brain seems to be the organ where the protective effects of H2S are 
not as unequivocal. This could be due to a difference in H
2
S catabolism in the brain, which 
could influence the results. Also, it might be that the brain has another type of metabolism 
which is differentially affected by H2S, causing reduced protection or even increased damage. 
That the blood-brain barrier plays a role in this seems unlikely, since H2S can diffuse over lipid 
membranes without a transporter or channel. However, publication bias could be a factor here 
as well, with negative studies on H2S in other organs not being published causing an overly 
positive view on the effects of H2S. The vast amount of literature on H2S in the ischemic setting 
points toward a highly protective role of exogenous and endogenous H2S. Modulation of the 
amount of oxidative stress through sequestration of oxidants and modulation of mitochondrial 
ROS-production play an important role in the protection against hypoxic insults. In addition, 
the modulation of metabolism and reduction in oxygen demand of the end organ hold great 
promise for future applications. In addition, H2S modulates the secondary effects of ischemia, 
such as inflammation, apoptosis and fibrosis. These properties make it a very promising 
substance for the protection of organs against ischemia in the clinical setting. 
MEC HAN ISMS O F  TH E ANT I OXI DATIVE PRO P E RTI ES  O F  H 2S 
The major proposed mechanism behind the protective effects of H 2S in models of oxidative 
stress is the direct scavenging of reactive oxygen species and the increase in GSH levels that can 
be achieved, increasing the antioxidative capacity of the cell. Na HS directly scavenges 02· and 
HP2126, and it protects cells from the cytotoxic lipid oxidation product 4-hydroxyneonal (4-HNE), 
likely by scavenging128• Also, NaHS activates ROS scavenger CuZn-SOD in vitro and in a cell free 
system 118• Many studies have shown the positive effects H2S has on intracellular GSH levels. 
Na
2
S preserves mitochondrial integrity and oxygen consumption after myocardial ischemia9, and 
attenuated mitochondrial dysfunction during the development of ischemia-induced heart fa ilure86• 
The effects of NaHS were abolished in cells lacking mitochondria58• Modulation of mitochondrial 
activity might reduce the amount of mitochondrial superoxide production during stress. 
Induction of a hypometabolic state is one of the most fascinating aspects of H2S
59
• When 
given in subtoxic concentrations in gaseous form, mice exhibit a reversible hibernation-like 
state, showing >90% reduction in metabolic rate and core body temperature declines to near 
ambient temperature. This state has been shown to be highly protective, independent from the 
associated hypothermia60•62·85•101 • However, up until now, mixed results have been attained when 
trying to translate these results in rodents to larger mammals129-131 _  
Another mechanism might be H2S acting as an electron donor to the mitochondrial electron 
transport chain during periods of low oxygen availabi l ity26•132, causing at least some production 
of ATP for maintenance of cellular processes during hypoxia. I nterestingly, CSE can trans locate 
to the mitochondria upon cellular stress, where it can affect metabolism28, while MPST can also 
be localized to mitochondria26. 
THERAPEUTIC POTENTIAL OF H25 
The ATP-sensitive K+ channel (KArP) allows potassium to move to the intracellular compartment 
when opened. A great amount of studies show that the effects of H2S on vascular tone are at least 
partly dependent on activation of KArP channels (see the extensive review by Rui Wang133) .  Recent 
experiments have indicated that H2S can directly sulfhydrate the KArP channel and thereby activate 
it6• The reduction in infarct size in a model of rat Ml was attenuated by inhibition of mitochondrial 
KATP channels78• In neurons exposed to hypoxia, the protective effects of NaHS were inhibited by 
KATP channel blockade but not by specific mitochondrial KArP channel blockade121 • 
Another possible mechanism is the stimulation of angiogenesis and the formation of 
collaterals. H2S increased the amount of collaterals formed 4 weeks after Ml
82
, and after rat 
hind limb ischemia, Na HS increased regional blood flow and angiographic score after 4 weeks, 
with increased collateral formation, capillary density and vascular endothelial growth factor 
(VEGF) expression134• CSE siRNA blocked VEGF induced endothelial cell migration 13. In addition, 
wound healing is impaired in CSE-I- mice, and in aortic rings of CSE·/· animals, microvessel 
formation was reduced compared to WT, and could not be stimulated by VEGF13 • These effects 
are probably not responsible for the effects of H2S on the short term, but might be an additional 
route of beneficial properties . 
The similarities between H2S and NO / CO as gasotransmitters have led to the hypothesis that 
the effects of H2S might be mediated through NO and its synthetizing enzymes eNOS and iNOS. 
In eNos·1· mice, Na2S failed to improve survival after CA/CPR, although eNos-1· mice are more 
susceptible to CA/CPR so small effects might have been overlooked with the larger mortality and 
the relatively small amount of animals used83• NaHS induced eNOS and in human microvascular 
endothelial cells. Inhibition of NOS partially reduced the effects of Na HS on leukocyte rolling and 
adhesion, while in eNos·1• animals leukocyte rolling was not affected by Na HS but adhesion was 115. 
In all, there seems to be some interaction between H2S and NO, but which part of the effects of 
H2S are mediated or modulated through NO has yet to be determined. 
Heme oxygenase 1 (HO-1 ) is an enzyme involved in the catabolism of heme, and in the 
process produces CO. It has shown protective and antioxidant effects in many models 135• 
Inhibition of HO-1 or deficiency in HO-1·1· mice abolished the effects of NaHS on leukocyte 
rolling and adhesion after intestinal I RI, while activation of HO-1 had similar effects to NaHS136. 
In Nrf2·1· animals, Na2S pretreatment (single injection 24 hours before ischemia) failed to 
increase HO-1 expression as it did in wildtype animals, and the protective effects of Na2S in Ml 
were abolished76 • This shows that the effects of H2S pretreatment could be mediated through 
Nrf2 mediated expression of protective proteins. The direct effects of H2S when given directly 
before or after ischemia might be regulated differently. Also, another study indicated that HO-1 
expression was not associated with H2S-mediated protection 1°1• 
Heat shock protein 90 (HSP90) has been implicated as a protective protein that can 
stabilize intracellular proteins and is involved in apoptosis137• NaHS protected against CoCl2-
induced ROS, cell death and apoptosis, but not when combined with HSP90 inhibition in rat 
pheochromocytoma cells138• In a model of neuronal hypoxia, Na HS increased HSP90 expression, 
while inhibition of HSP90 abolishes the protective effects of NaHS121 • These data indicate that 




Table 2 - Proposed mechanisms for protective effects of H25. 
Direct scavenging of reactive oxygen/nitrogen species 
I ncrease in GSH level s  
Reduction of  m itochondria l su peroxide production 
Activation of ROS-scavengers (e.g.  MnSOD, CuZnSOD) 
Preservation of mitochond ria l integrity 
Acting as  an  electron donor in the electron transport chain 
Modu lation of mitochondria l  activity / Hypometa bolism 
Ind uction of hypothermia 
Modulation of vascu l a r  prol iferation 
Modu lation of leukocyte adhesion / rol l ing 
Modulation of cytokine produ ction 
Activation of KATP-channels 
Activation of calcium activated K• channels 
Modulation of protein activity through su lfhydration 
Modu lation of platelet fu nction 
Modu lation of hypoxia inducible factor (H I F) 
Modulation of N rf2 s igna l ing 
Increase in  eNOS / i NOS / HO-1 
I ncrease in HSP90 
Modulation of COX-2 activity 
Modulation of GSK3beta activity 
Modu lation of apoptotic s igna l ing 
Modulation of autophagy 
H2S MEASUREMENT 
The measurement of endogenous levels of H2S poses a large problem for the research community, 
since the volatility, reactivity and gaseous form make it difficult to assess the levels of H2S that 
are present intracellularly, extracellularly or in serum. The exact concentrations that are present 
in human serum have been a topic of heated discussion in the past years. For example, some 
argue that the most widely published levels (between 10 and 100 µM) would cause human blood 
to heavily smell like H2S
139•
140
• Experiments that have used very high concentrations thusly need 
to be interpreted with caution. However, the volatile nature of H2S at physiological pH, the 
ability to react with proteins and organic substances intracellularly, the capability to diffuse over 
membranes without transporter molecules 41 and the general difficulty of measurement of the 
substance make it difficult to interpret any result on the measurement of H2S. 
A recent advance that could change this is the development of fluorescent probes that are 
sensitive to H2S and that can be loaded into l iving cells. This field seems to have exploded in the 
past two years, catering to the need for measurement of intracellular H2S levels and changes, 
THERAPEUTIC POTENTIAL OF H2S 
where it likely matters most. Table 3 gives an overview of the probes that have been published 
in the past years, showing 24 separate probes that have been reported since 2011. No similar 
probes have been reported before 2011 according to our research. 
These probes are very interesting for providing insights in the changes of intracellular H2S. 
Most of these probes can be used in live cells for fluorescence imaging. One of the obstacles 
now is the slow reactivity of the probes to H2S, making them unusable for measuring fast 
changes in H2S levels. However, at least one of the published probes has a reaction time of 
around 30 seconds, indicating that there is progress on this aspect 142• 
TRA N S LAT I O N  TO T H E RA P E U T I C  A P P L I CAT I O N S  
Therapeutic window of H2S dose 
Some studies have shown that the effect of H2S can be very dose dependent, with too high 
doses showing no or even detrimental effects. In porcine cardiac arrest and resuscitation, high 
dose Na2S (lmg/kg) worsened cerebral damage and levels of troponin T, while 0.3 mg/kg had 
no effect143• In a model of partial hepatic ischemia, Na2S treatment (0.3 and 1 mg/kg) protected 
from liver damage, while 2 mg/kg increased damage102• These results infer that before clinical 
translation, meticulous dose-finding studies are required and possibly reliable serum-level 
measurement needs to be developed to monitor treatment. 
Timing of treatment 
Many different treatment protocols have been used, and one of the most variable parameters was 
the timing of the treatment with H2S. For example, Na HS injection 1 day prior to Ml in rats decreased 
infarct size, left ventricle internal diameter and anterior wall thickness. Injection of Na HS 3 days prior 
to Ml also showed protective effects, while Na HS 5 days prior to Ml had no effect. Posttreatment 
(after Ml, at day 0,1 and 2) had effects, but less when compared to pretreatment, and combination 
treatment had no additional effect144• In another study, single administration of Na2S did not affect 
IRI induced cardiac function loss, while daily administration for 1 week did86• Last, Na HS at 24 hours 
pre-ischemia, but not at 1 hour before ischemia or during reperfusion, reduced leukocyte rolling and 
adhesion post reperfusion76• This might be related to the activation of transcription factors such as 
Nrf2, since the preconditioning effect of H2S in cardiac Ml is absent in Nrf2-1· mice76• It is likely that 
the effects of H2S when given more than a couple of hours before ischemia are mediated through 
increasing the expression of other protective proteins, such as HO-1 in a Nrf2-dependent pathway76, 
while the more direct effects of H2S are mediated through some other mechanism since H2S levels 
are only elevated a short amount of time after bolus injection. Interestingly, CSE upregulation can 
also be dependent on Nrf2 signaling35, as can HSP90 and HO-l76• 
Pretreatment and posttreatment have both been effective in ischemic models, in some 
models pretreatment showed to be more effective62 • However, pretreatment is not clinically 
applicable in many situations, such as acute myocardial infarction or shock. In those models 
only posttreatment with H2S can be used since the patient only presents after the onset of 
ischemia. In the clinical setting this would mean oral or intravenous application, or injection 





T a b l e  3  - H
2
5  P r o b e s  - O v e r v i e w  t a b l e .  
P r o b e  L i v e  c e l l s  P r o p e r t i e s  S p e c t r u m  
N I R - H
2
S  Y e s  
C y t o p l a s m a t i c  f l u o r e s c e n c e .  R e a c t s  w i t h  L - c y s t e i n e  a n d  G S H  i n  c e l l - f r e e  s y s t e m .  E x :  6 5 0  n m /  E m :  7 0 8  n m  
C - 7 A z  Y e s  C y t o p l a s m a t i c  f l u o r e s c e n c e .  C a n  b e  u s e d  f o r  f o r m a l i n  fi x e d  t i s s u e  s e c t i o n s .  E x :  3 4 0  n m /  E m :  4 5 0  n m  
c p G F P - T y r 6 6 p A z F  Y e s  G e n e t i c a l l y  e n c o d e d  p r o t e i n s ,  e x p r e s s e d  t h r o u g h  t r a n s f e c t i o n .  D o e s  n o t  r e a c t  w i t h  E x :  4 8 0  n m /  E m :  5 1 0  n m  
L - c y s t e i n e  o r  G S H .  
C o u M C  Y e s  M i t o c h o n d r i a l  f l u o r e s c e n c e .  S h o r t  r e s p o n s e  t i m e  (  < 3 0 s ) .  E x :  4 7 5  n m /  E m :  5 1 0  /  6 5 2  n m  
F S l  Y e s  C a n  b e  u s e d  i n  l i v e  t i s s u e  u s i n g  t w o - p h o t o n  i m a g i n g ,  c y t o p l a s m a t i c  s t a i n i n g .  E x :  3 6 3  n m /  E m :  5 4 8  n m  
T p
P h .
M e  
Z n ( M u s )  2  
U n k n o w n  O n  H
2
S  e x p o s u r e ,  p r o b e  d e c r e a s e s  i n  f l u o r e s c e n c e  a n d  c h a n g e s  a b s o r b a n c e  o n  e x p o s u r e  t o  H
2
S  E x :  3 6 0  n m /  E m :  4 3 4  n m  
A b s o r b a n c e  a t  3 5 4  a n d  3 8 3  n m  
L l C u  Y e s  C a n  b e  u s e d  i n  l i v e  c e l l s ,  d e p e n d e n t  o n  i n t r a c e l l u l a r  C u ( I I ) .  
E x :  4 9 4  n m  /  E m :  5 2 3  n m  
L i  e t  a l .  p r o b e  l b  Y e s  C y t o p l a s m a t i c  f l u o r e s c e n c e .  R e a c t s  w i t h  L - c y s t e i n e  a n d  G S H  i n  c e l l - f r e e  s y s t e m .  E x :  3 8 0  n m /  E m :  5 15  n m  
S F l  Y e s  C y t o p l a s m a t i c  f l u o r e s c e n c e .  R e a c t s  w i t h  N O  a n d  0
2
•  i n  c e l l - f r e e  s y s t e m .  E x :  4 9 2  n m /  E m :  5 2 5  n m  




a n d  0
2
•  i n  c e l l - f r e e  s y s t e m .  
E x :  4 9 0  n m /  E m :  5 2 5  n m  
L i u  e t  a l .  p r o b e  6  Y e s  C y t o p l a s m a t i c  a n d  n u c l e a r  f l u o r e s c e n c e .  D o e s  n o t  r e a c t  w i t h  L - c y s t e i n e  o r  G S H .  
E x :  4 7 6  n m /  E m :  5 13  n m  
H S N 2  Y e s  C y t o p l a s m a t i c  f l u o r e s c e n c e .  D o e s  n o t  r e a c t  w i t h  L - c y s t e i n e  o r  G S H .  
E x :  4 3 2  n m /  E m :  5 4 2  n m  
D N S - A z  U n k n o w n  D o e s  n o t  r e a c t  t o  o t h e r  a n i o n s ,  u s e d  f o r  m e a s u r e m e n t  o f  H
2
5  c o n c e n t r a t i o n  i n  b l o o d .  E x :  3 4 0  n m /  E m :  5 3 5  n m  
R e f e r e n c e  
C a o  ( 2 0 7 2 )  
B  C h e n  ( 2 0 1 2 )  
5  C h e n  ( 2 0 7 2 )  
Y  C h e n  ( 2 0 1 3 )  
D a s  ( 2 0 7 2 )  
G a l a r d o n  ( 2 0 7 2 )  
H o u  ( 2 0 7 2 )  
L i  ( 2 012 )  
L i p p e r t  ( 2 0 7 1 )  
L i p p e r t  ( 2 011) 
L i u  ( 2 0 7 2 )  
M o n t o y a  ( 2 0 1 2 )  
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Cytoplasmatic fluorescence. Detects H2S produced from CBS in cel l  free reaction .  Reacts 
with GSH and L-cysteine. 
Cytoplasmatic fluorescence. Reacts slightly with GSH and 2-mercaptoethanol in cel l  free system.  
Cytoplasmatic and nuclear fluorescence. Detects H2S production from MPST. No reaction 
to ROS, GSH or L-cysteine. 
551 U nknown Sensitive micel le system.  Reacts with 520/, S2Os2°, HSQ3· 
Wan et a l .  probe l Yes 
Cy-NO2 Yes 
Xu et a l .  p robe El Yes 
Xuan et a l .  probe l Yes 
Cytoplasmatic fluorescence. Can be u sed in l iving zebrafish.  
Cytoplasmatic fluorescence. Hyghly specific in  cel l  free system. 
Sta ining pattern seems nuclear. Does not react with GSH, L-cysteine or homocysteine in 
cel l  free system. 
Cytoplasmatic fluorescence. Reacts with NADH but not ROS, L-cysteine or GSH. Slow kinetics. 
Yu et al. probe Yes Carbon dot based. Cytoplasmatic fluorescence. 
Zhao et a l .  probe l U nknown Absorbance reduces on reaction with H2S .  Reacts to GSH and L-cysteine in cel l  free system. 
P I -N3 Yes Cytoplasmatic fluorescence. Reacts with L-cysteine a nd GSH in cel l -free system.  
Spectrum Reference 
Ex: 300 n m / Em: 388 nm Qian (2012) 
Ex: 465 nm / Em: 51 0 nm Qian (2012) 
Ex: 491 nm / Em: 51 6 n m  Sasakura (2011) 
Ex: 404 nm / Em: 540 n m  Tian (2013) 
Ex: 535 nm / Em: 620 nm Wan (2013) 
Ex: 755 nm / Em: 789 nm Wang (2012) 
Ex: 295 n m / Em: 487 nm Xu (2012) 
Ex: 440 nm / Em: 544 n m  Xuan (2012) 
Ex: 425 n m / Em:  526 n m  Y u  (2012) 
I 
Absorbance at 527 nm Zhao (2012) m 











Other  situations comprise predictab le  moments of ischemia, ma in ly during surg ica l  
i nterventions such as  organ transpla ntation, momenta ry aortic occlus ion or  temporary 
occ lu sion of cerebra l  a rteries during the c l ipping of cerebra l  aneurysms.  In the sett ing of organ 
t ranspla ntation, the bra in  dead organ donor ca n be treated with i ntravenous or  gaseous H 2S.  
A lso, the organ can be exposed to H2S d u ring mach ine perfus ion, a treatment system which has 
a l ready shown c l in ica l  potentia l  i n  protecting donor organs145•146• Last, the organ reci pient can 
be t reated with H 2S post-transplantation .  
Mode of ad ministration 
Experimenta l stud ies have shown many methods of admin istration for H2S treatment, and each 
has its adva ntages and d isadvantages for eventua l  c l in ica l app l ications.  Gaseous H 2S is d ifficu lt 
to hand le  safely, corros ive, toxic in h igher concentrations and very ma lodorous .  This means it 
can on ly be app l ied in wel l  venti lated rooms or in i ntu bated persons with specia l ized equ ipment. 
I t  can however cause very long and stab le  hypometabol ic states i n  m ice59•60, ind icating that long 
term sta ble level s  are reached with gaseous H 2S. 
The sol ub le su lfide sod ium sa lts (Na HS and Na2S) have very rapid dynamics, which ma kes it 
ha rd to ach ieve steady concentrations in vivo53•56• Continuous i ntravenous admin istration m ig ht 
ach ieve constant levels, but has shown a sma l l  therapeutic wi ndow in experimenta l stud ies. 
S low re leas ing donors of H2S are i n  development and cou ld cou nter some of these problems, 
but remain  to be proven safe for human use as of this moment. Offering H2S through the 
d ri nking water, as  has been done in  experi menta l settings, is not recommended in  the human 
s ituation because of  the horrendous taste and  sme l l .  One new development that has shown 
potentia l  is the use of natu ra l ly occu rri ng cysteine  ana logues, such as DATS and DADS. These 
can increase H2S levels  over longer periods of t ime, and cou ld  be ta ken oral ly. Also, DATS and 
DADS ca n be derived from garl ic, so large amounts of garl ic o r  maybe even garl ic concentrates 
cou ld  be used as  a food su pplement. 
Last is  the modu lation of endogenous production, which is at the moment problematic, s ince 
the best known modu lators are inh ibitors of CSE and CBS, whi le most studies show that the activity 
of these proteins needs to be increased to be beneficia l .  Adenovirus mediated overexpression 
i s  an  option, but no g roups are investigati ng this for human appl ications to the best of our  
knowledge. Modu lation of  Ethel or  CDO is only hypothetical at the moment, and the detrimenta l 
effects of the loss of Ethel do not bode wel l  for long term modu lation of this protein 43• 
I n  a l l , H2S is a h igh ly  promis ing molecu l e  that has only g iven us a sma l l  peek into its b road 
functiona l ity. The protective effects i n  ischemia  and oxidative stress a re strong, and the 
development of H2S based therapeutics cou ld  g reatly i m prove outcome of surgica l ly ind uced 
ischemia and ischemic d isease. 
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CHAPTER 2 
A BS T RACT 
Hydrogen sulfide (H2S) has been historically perceived as a dangerous and toxic gas until 
the recent discovery that this substance can induce a hypometabolic, hibernation-like state 
in mammals when given in subtoxic concentrations. Reducing the demand for oxygen using 
pharmacological means is a novel and p romising strategy for minimizing hypoxia-induced 
inju ry, such as the ischemia/reperfusion inju ry that is unavoidable during the renal transplant 
process. We show that H2S can reduce metabolism in-vivo, ex-vivo and in-vitro. Furthermore, 
we demonstrate the beneficial effects of H2S -induced hypometabolism in a model of bilateral 
renal ischemia/reperfusion injury using three different treatment strategies. The results 
demonstrate striking p rotective effects on su rvival, renal function, apoptosis and inflammation 
and indicate that a state of reduced metabolism induced by H2S might be valuable in protecting 
kidneys that suffer from hypoxia. 
H2S-HYPOMETABOLISM PREVENTS RENAL DAMAGE 
INTRODUCTION, RESULTS AND DISCUSSION 
The toxicity of H2S has long been studied because of its involvement in deadly industrial and 
agricultural accidents1. Recently, an unknown property of the gas was revealed, namely the 
ability to induce hypometabolism in naturally non-hibernating mammals2,3• Mice exposed to 
subtoxic concentrations of gaseous H2S rapidly and reversibly enter a hibernation-like state. 
During H2S -treatment, metabolic parameters rapidly decrease: a ~60% reduction in CO2-
production and 02-consumption within minutes of exposure (Figure lA), which can decline even 
further to more than 90%2-4• In addition, the core body temperature decreases to near-ambient 
temperature and heart rate and breathing frequency are significantly lower2 . The demand for 
oxygen is reduced to such an extent that H2S -treated mice can survive in 5% oxygen for over 
6 hours, while untreated controls die within 15 minutes4• In-vitro, H2S can reversibly reduce 
mitochondrial oxygen consumption5•6 and mitochondrial membrane potential (Figure l B). 
Ex-vivo H2S can reduce 02-consumption and total ATP content of the isolated perfused kidney 
(Figure l C, D). H2S also has antioxidant capacity, either by direct scavenging of reactive oxygen 
or nitrogen species or indirectly by increasing cellular glutathione levels3• We hypothesized 
that a state of extremely low metabolism induced by exposure to gaseous H2S would provide 
protection during periods of ischemia and reperfusion by reducing the demand for oxygen. 
To investigate the protective potential of H2S -induced hypometabolism we used a model 
of bilateral renal ischemia/reperfusion in the mouse. We evaluated four different treatment 
regimens (Figure l E), comparing pretreatment, posttreatment and pre- and posttreatment 
with 100 ppm H2S (n=6-7 per group). In both pretreated groups, C57BL/6 mice were first treated 
with H2S for 30 minutes to induce hypometabolism. Our initial experiments showed that the 
induction of hypometabolism typically takes place within the first 10 minutes of exposure 
(Figure lA). After the pretreatment period, renal blood flow was interrupted for 30 minutes 
by placing non-traumatic vascular clamps over both renal pedicles. To study the effects of H2S 
on reperfusion damage alone, posttreatment with H2S started 5 minutes before removal of the 
clamps, and lasted for 35 minutes. The pre- and posttreatment group received H2S starting 
30 minutes before ischemia until 30 minutes after reperfusion. To separate the effects of H2S 
from the already well known protective effects of hypothermia, core body temperature of all 
animals was maintained at 37° C during and after the procedure. Induction of hypometabolism 
in H2S treated animals was confirmed by lowered breathing frequency and CO2-production, 
measured using closed system respirometry (Figure 1 F, G). 
Bilateral ischemia caused excessive renal damage in the control group, leading to an 
impaired 3-day survival caused by renal failure (Figure 2A). Both groups in which mice were 
pretreated with H2S had 100% survival after three days (p<0.001), while mice that only received 
H2S during reperfusion showed similar survival to the control group (p=ns). Serum creatinine 
and urea measurements were performed to quantify the renal function loss associated with 
bilateral renal ischemia/reperfusion. Control and posttreatment animals showed highly 
elevated levels of both creatinine and urea (Figure 2B, Supplementary Figure 1), while animals 
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Figure 1 - Metabolic suppression by H25 and experimental design. 
(A) Exposure to 100 ppm H2S causes a rapid reduction i n  CO2-production of a s ingle mouse. (B) N RK-52E 
proximal  tubu lar  ce l ls loaded with the mitochondria l  membrane potential ind icating fluorescent dye 
JC-1 were exposed to different concentrations of Na HS (a donor of H1S in solution) for 20 minutes. **p 
< 0.01 (C, D) Rat kidneys in an isolated perfused kidney setup were exposed to 1 mM Na HS (n=4) for 30 
minutes, and 02-consumption and ATP were compared to controls (n=3) . *p < 0.05. 
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Figure 1 [Continued] 
(E) Schematic of experimental design showing different H2S treatment regimens. (F) Relative CO2-
production of animals during the period of ischemia, corrected for body weight (n=7). **p < 0.01 (G) 
Average breathing frequency of animals 5 minutes before ischemia, during ischemia, and 30 minutes 
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Figure 2 - H2S -induced hypometabolism prevents mortality and renal damage after renal ischemia. 
(A) Three-day survival of animals after reperfusion. (B) Renal function as measured by serum 
creatinine after 1 day of reperfusion. *p<0.05 vs. Control, tp<0.001 vs. Sham (C) Apoptosis after 1 day 
of reperfusion was scored in sections stained for active Caspase 3 us ing immunohistochemistry. 
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(D) Structural damage as assessed in PAS-stained sections after 1 day of reperfusion. *p < 0.05 vs. Control, 
***p < 0.001 vs. Control, tp<0.001 vs. Sham (E) I nflux of leukocytes and granulocytes into the renal interstitium 
was scored in sections stained for MAC-1 (solid bars) or Ly-6G (dashed bars) using immunohistochemistry. 
*p < 0.05 vs. Control (F-1) Representative photomicrographs of Ly-6G stained sections. (J-N) Representative 
PAS-stained renal sections with necrotic area artificially colored red, indicating the extent of necrotic 




measurements indicate massive renal failure in the control and posttreatment groups, which is 
the most likely cause of the diminished survival in these groups. 
We assessed structural renal damage in Periodic acid-Schiff (PAS) stained sections and found 
a similar pattern to the renal function measurements as expected. Massive acute tubular necrosis 
was detected in control animals at day 1, whereas mice in both pretreated groups had no or minimal 
renal damage (Figure 2D, J-N, Supplementary Figure 3). Posttreatment with H2S showed a significant 
reduction in tubular damage compared to controls, although it was not as extensive as in pretreated 
animals. After 3 days, a similar pattern was seen (Supplementary Figure 2). Posttreatment did not 
have significant protective effects at this time point, although these results are confounded to some 
extent, since animals with large amounts of renal damage had already deceased at this point. 
Active Caspase 3 staining using immunohistochemistry indicated that ! RI-induced 
apoptosis is also prevented by H2S-pretreatment. (Figure 2C, Supplementary Figure 4). A 
less pronounced but statistically significant effect was seen in the Posttreatment group. 
Real-Time PCR measurements showed that mRNA expression of pro-apoptotic BAX was 2. 5 
times higher in control kidneys compared to sham operated animals (Supplementary Figure 
SA). Expression was not significantly increased in animals pretreated with H2S. The expression 
of anti-apoptotic BCL-2 did not differ between groups (Supplementary Figure SB) indicating 
that the anti-apoptotic effects of H2S are not mediated through induction of BCL-2 mRNA 
expression. Whether H2S directly or indirectly inhibits increased expression of BAX is not clear. 
Transmission electron microscopy of a limited number of samples implies that H2S treatment 
protected against loss of mitochondrial integrity and mitochondrial swelling (Supplementary 







and it is not known whether H2S can directly modulate apoptotic pathways, or that increased 
mitochondrial integrity and reduced mitochondrial stress caused by reduced mitochondrial 
activity caused the reduction in Caspase 3 activity in the posttreatment group. 
We studied the inflammatory component of ischemia / reperfusion injury by 
immunohistochemical staining for MAC-1 (CDllb, which is present on macrophages, monocytes, 
granulocytes and natural killer cells10) and Ly-6G (which is expressed on mature granulocytes). 
(Figure 2E-I, Supplementary Figure 7). The influx of MAC-1 and Ly-6G positive cells was greatly 
reduced by H2S -pretreatment (p<0.05), but was not significantly affected by posttreatment. 
These results indicate that the reduction in metabolism prior to ischemia is highly protective 
in reducing ischemia-induced injury with predictable onset, such as during transplantation or 
surgical intervention. The mechanism of H2S-induced hypometabolism is unknown as of yet, 
but is most likely mediated through reversible inhibition of complex IV (cytochrome oxidase)11, 
the terminal enzyme of the mitochondrial electron transport chain. Inhibition of this complex 
might be the mechanism of the reduction in mitochondrial membrane potential caused by H2S­
treatment. It seems unlikely that H2S directly and effectively inhibits necrotic-, apoptotic- and 
inflammatory pathways after an ischemic insult. The observation that protection is greatest 
when H2S is given before and during, but much less when given directly after the hypoxic 
period, supports the notion that the reduction in oxygen demand during hypoxia prevents the 
activation of these detrimental pathways. The moderate effects of H2S in the posttreatment 
H25-HY POMETABOLISM PREVENTS RENAL DAMAGE 
group could be caused by the inhibition of ROS production by decreasing mitochondrial 
activity. Protection could also be mediated through direct antioxidative action3 or increased 
glutathione levels caused by H2S3• 
Recent literature shows beneficial effects of gaseous H2S on survival in models of hypoxia4 
and hemorrhagic shock12 • Other groups have studied the protective effects of soluble forms of 
H2S (such as Na HS or Na2S) in models of ischemia. These studies show beneficial effects of H2S 
on renal-13, cardiac-5, hepatic-14 and pulmonary ischemia15• One paper suggests an association 
between H2S treatment and reduced activation of multiple signal transduction molecules, such 
as p38, ERK and JNK. However, a direct relationship between H2S and kinase activation was not 
proven. We found that phosphorylation of ERKl/2 was stimulated by ischemia in our model, but 
no modulation was seen in H2S -treated animals (Supplementary Figure 8). Our study shows 
a novel relation between H2S treatment and hypometabolism, which has not been previously 
investigated. The protective effects of H2S -treatment post-hypoxia are less pronounced in our 
experiments. However, a recent paper indicated that injection of Na2S just prior to reperfusion 
in a model of myocardial infarction caused a great reduction in infarct size and protected 
mitochondrial integrity and function5• This indicates that posttreatment with H2S might still be 
a promising intervention in cutting back on the detrimental effects of hypoxia after the event. 
We conclude that hypometabolism induced by gaseous H2S is a novel treatment regimen with 
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Supplementary Figure 1 - Renal function as measured by serum urea after 1 day of reperfusion. 
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Supplementary Figure 2 
(A) Structu ra l  damage as assessed in PAS­
sta ined sections after 3 days of reperfusion.  
**p<0.001 vs. Control .  (B) Rena l  fu nction 
as measured by serum creati n ine a nd (C) 
serum u rea after 3 days of reperfus ion.  
*p<0.05 vs. Control .  
H25-HYPOMETABOLISM PREVENTS RENAL DAMAGE 
Sham 
Control 
Pre- and posttreatment 
Pretreatment 
Posttreatment 
Supplementary Figure 3 - Representative photomicrographs of PAS-stained renal tissue from all 
groups after 1 day of reperfusion. 
Sham kidneys show normal morphology, while control kidneys show necrosis (arrows) and cast 
deposition (arrowheads). Normal morphology is seen in kidneys from the pre- and posttreatment 
group. Kidneys from the pretreatment group show only minimal necrosis, while posttreatment 
kidneys show intermediate amounts of damage. 
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Supplementary Figure 5 
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(A) BAX mRNA expression and (B) BCL-2 mRNA expression after 1 day of reperfusion as assessed by 
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Supplementary Figure 6 - Transmission electron microscopy images of a tubule i n  a control and 
a pre-and posttreated kidney. 
The controls showed large, swollen mitochondria, loss of mitochondrial integrity and loss of mitochondrial 
crypts (arrowheads). Pre- and posttreatment kidneys showed normal mitochondrial morphology. 
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A Interstitial Macrophages, day 3 
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Supplementary Figure 7 
(A) I nterstitial macrophages and (B) interstitial granulocytes after three days of reperfusion in kidney 
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Supplementary Figure 8 - Representative photomicrographs of renal sections from al l  treated 
groups, stained for phosphorylated ERKl/2 (pERKl/2) using immunohistochemistry. 
I ncreased activation  compa red to sham leve ls is seen in a l l  groups  exposed to I R I ,  however, no 
modu lation by H2S treatment cou ld be detected. 
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MATE R IALS  A N D  M ET H O D S  
Animals 
Male C57BL/6 mice (6-8 week old, Harlan, Zeist, the Netherlands) and male inbred Fisher F344 
rats (250-300 gram, Harlan, Zeist, the Netherlands) were housed under standard conditions 
with a 12h Jight:dark cycle at our animal research facility with ad libitum access to water and 
murine chow. Experimental procedures were in agreement with institutional and legislator 
regulations and approved by the local committee for animal experiments. 
Respirometry 
Measurement of animal CO2-production and 02-consumption was performed using an 
advanced, modular respirometry system (TR-3 system, Sable Systems, Las Vegas, NV, USA). Air 
or H2S /Air mixture was pushed through a mass flow controller (Model 840, Sierra Instruments, 
Egmond, the Netherlands) set to 200 ml/min. Animals were placed in a downstream, airtight 
respirometry chamber with heat pads. The excurrent gas was subsequently lead through a 
CA-l0a dual wavelength infrared sensor CO2-analyzer (Sable Systems) and a custom-made 
PA-l Oa paramagnetic 02-analyzer with stainless steel inner tubing (Sable Systems). Data 
acquisition was performed using a U l-2 interface and ExpeData vl.0.24 software (Sable Systems). 
Compressed air and 500 ppm H2S / N2 (Air Products, Amsterdam, the Netherlands) were mixed 
in a 4:1 ratio, producing a 100 ppm H2S /17% 02 mixture. Control animals received room air. CO2-
production was corrected for body weight and normalized to mean control values. 
Renal ischemia/reperfusion 
Both renal pedicles were clamped for 30 minutes using non-traumatic vascular clamps through 
a midline abdominal incision under general anesthesia (0.07 ml/10 g mouse of 1.25 mg/ml 
midazolam (Roche Diagnostics Corp), 0.08 mg/ml fentanyl citrate, and 2 .5  mg/ml fluanisone 
(Janssen Pharmaceutica)). After removing the clamps, kidneys were inspected for restoration 
of blood flow and the muscle and skin layers were sutured with 5-0 stitches. Body temperature 
was monitored with a rectal probe and maintained at 37° C using heat pads and lamps. Sham 
operated animals received the exact same procedure, excluding the placement of the clamps 
on the renal pedicles. Breathing frequency was regularly counted. Subsequent to closure of the 
abdomen, all mice received a subcutaneous injection of 50 µg/kg buprenorphin (Schering­
Plough) for analgesic purposes and were allowed to recover from surgery at 35° C in a ventilated 
incubator. Mice were sacrificed 24 and 72 hours after reperfusion. At the time of sacrifice 
mice were anesthetized using 2,5% isoflurane in 02, blood was collected in heparin containing 
tubes and stored at -80° C, and kidneys were perfused with saline and harvested. A midcoronal 
kidney slice was fixed in 4% paraformaldehyde, processed for paraffin embedding and used for 
immunohistochemical analysis. 
Plasma biochemical analysis 
Renal function was determined by measuring creatinine and urea in plasma samples using 
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Histopathological scoring 
The extent oftubulo-interstitial damage was determined in Period Acid-Schiff (PAS)-stained sections, 
which were blindly scored. The ratio of necrotic cortical tubule surface area to total cortical surface 
area was determined at a l00x magnification. The necrotic area calculated in this manner correlated 
linearly with serum creatinine with an R2 of 0,7677 and with serum urea with an R2 of 0,6997. 
l m m unohistochemistry for Caspase 3, Ly-6G and pERKl/2 
lmmunohistochemical staining for active Caspase 3 and granulocytes was performed as described 
beforel 6. In short, for active Caspase 3, paraffin embedded sections were stained using rabbit 
anti-human active Caspase 3 polyclonal antibody (Cell Signaling), followed by HRP-conjugated 
goat-anti-rabbit lgG (lmmunovision Technologies). Positive tubular epithelial cells were counted 
in 10 non-overlapping fields at 400x magnification. For granulocytes, paraffin embedded sections 
were stained for Ly-6G using rat-anti-mouse Ly6G/C-FITC lgG2b antibody, followed by rabbit­
anti-FITC and HRP-conjugated goat-anti-rabbit antibodies. Positive interstitial granulocytes were 
counted in 30 non-overlapping fields at 400x magnification. For phosphorylated ERKl/2, paraffin 
embedded sections were stained using Phospho-p44/42 MAPK (ERKl/2) (Thr202/Tyr204) rabbit 
monoclonal antibody (Cell Signaling) followed by HRP-conjugated goat-anti-rabbit lgG and HRP­
conjugated rabbit-anti-goat lgG antibodies (DAKO, Glostrup, Denmark). 
Macrop hage immunohistochemistry 
lmmunohistochemical staining for macrophages was performed on 4 µm cryosections using 
anti MAC-1 antibody (ab6332, Abeam, Cambridge, MA, USA) incubated for 1 hour at 1 :250 
dilution, followed by HRP-conjugated rabbit-anti-rat and subsequently HRP-conjugated goat­
anti-rabbit antibodies. Positive interstitial macrophages were counted in 30 non-overlapping 
fields at 400x magnification. 
Qualitative Real-Time Polymerase Chain Reaction 
RNA was extracted from frozen human kidney biopsies using the TRIZOL method (lnvitrogen, 
Carlsbad, CA) . DNAse treatment was performed using Turbo DNAse-free (Ambion, Austin, TX). 
cDNA was synthesized using Superscript I I  RT and random hexamer primers (lnvitrogen). A 
relative quantification P CR was performed to determine gene expression (Applied Biosystems, 
Foster City, CA). GAPDH was used as housekeeping gene. We used gene expression assays from 
Applied Biosystems: 
BAX: Mm00432050_ml 
B CL-2: Mm00477631_ml 
GAPDH:  Mm99999915_gl. 
P CR was performed in a total volume of 20 µI containing l0ng cDNA template and 10 µI PCR­
mastermix (Eurogentec). The Thermal Profile was 1 5  minutes at 95° C, followed by 40 cycles 
of 1 5  seconds at 95° C and 1 minute at 60° C. The average Ct-values for the target genes were 
subtracted from the average GAPDH Ct-values to yield the delta Ct. Results were expressed as 
2-60· normalized to mean sham values. 
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Cell culture 
The normal  rat k idney-52E (N RK-52E, ATCC) cel l  l ine is an immorta l ized l i ne  featur ing the 
characteristics of rat rena l  p roxima l  tubu la r  cel l s .  Cel l s  were cu ltured i n  Du l becco's modified 
Eagle's medium (DMEM; G ibco BRL, Pa is ley, U K) conta in ing 4,5 g/I g lucose, 5% fetal calf serum 
(FCS; Bodinco, Alkmaar, the Nether lands), penici l l i n  (1 00 U/ml) streptomycin (1 00 µg/m l).  
Cel ls  were cu ltured u sing 75 cm2 col lagen coated flasks (Corn ing,  Schiphol-Rijk, Netherlands) 
in a hum id ified atmosphere of 5% CO2 at 37
°C .  
JC-1 measurements 
Cytofluometric analysis of mitochondrial membrane potential was performed by using the 
J-aggregate forming l ipophi l ic cation 5,5',6,6'-tetrach loro-1,1 ',3,3'-tetraethyl-benzimidazolyl­
carbocyanine iodide (JC-1, l nvitrogen, Leek, Netherlands). JC-1 penetrates the cytosol of eukaryotic 
cel ls and exh ibits potentia l-dependent accumulation specifica l ly in mitochond ria, indicated by a 
fluorescence emission sh ift from green (~529 nm) to red ( ~590 nm). Consequently, mitochondria l  
depolarization is indicated by a decrease in the red/green fluorescence intensity ratio. Cel ls grown 
to 80-90% confluence were harvested and seeded in a 24-wel l  plate at a density of ~10.000 cel ls/ 
wel l  in  500 µL med ium.  After overnight culture, cel l s  were washed with PBS and incubated with JC-1 
in serum-free DMEM for 15 minutes at 37°C in the dark with 15 µg/ml JC-1 . After incubation, cel ls 
were washed three times with PBS and med ium without FCS was added. A basel ine measurement 
of the fl uorescence was performed using a spectrophotometer (Victor 3, PerkinE lmer, Groningen, 
the Netherlands) at 485 nm excitation/535 nm emission and at 530 nm excitation/590 nm emission. 
Different concentrations of Na HS (Sigma-Aldrich, the Netherlands) were added to the med ium and 
fluorescence was remeasured after 20 minutes. Data were corrected for background fluorescence 
by subtracting va lues measured in cel ls not loaded with JC-1, and the change in of590 nm to 535 n m  
fluorescence ratio compared to untreated cel ls was calculated. 
Isolated Perfused Kidney (I PK) 
The I PK setup used was identical to the one described previous ly by our g roup17• Rats were 
anesthetized us ing 2,5% isoflu rane / 02 and cannu las  were p laced in the rena l  a rtery, rena l  
vein and u reter. After p lacement in  the ! PK- setu p, the kidney was  continuous ly perfused via 
the rena l  a rtery with warmed (37°C) and oxygenated (95% 02 and 5% CO2 gas m ixture) Krebs­
Hensele it-bicarbonate (KHB) solution at a pH of 7.4 ± 0 .05 and a pO2 > 100 kPa, by us ing a ro l ler 
pump ( lsmatec mv-ca/04; lsmatec, G lattbrugg, Switzerland) de l ivering a constant flow of 8 m l/ 
min throughout the experiment. The composition of the KHB  was as fol lows: 1 18  mM NaC l; 
4.7 mM KCI; 2 .5 mM CaCl2; 1 .2 mM KH2PO4; 1 .2 mM MgSO4; 25 mM NaHC03; 1 0  mM g l ucose. 
After con necting the kidney, f low was g radua l ly increased to 8 m l/min .  Vascu l a r  responses 
were mon itored by an e lectromechanica l  pressu re transducer (Cobe; Arvada, CO) connected 
to a computer prog ram (LabView, Nationa l I nstruments, Austin, TX). After an equ i l ib ration 
period of 25 to 30 m in, when rena l  vascu la r  resistance had sta b i l ized, pO2 was measured us ing 
an ABL700 b lood gas ana lyzer (Radiometer Medical ,  Denmark) i n  pre- and postrena l  sam ples 





these samples were taken, NaHS (Sigma Aldrich, the Netherlands) was added to the perfusate 
to reach a final concentration of 500 µM Na HS in the H2S -treated group. After 30 minutes 
of Na HS perfusion, pO2 measurements were taken, and cortical tissue was removed an snap­
frozen in liquid N2 for ATP measurements. 
ATP measurement 
Measurement of ATP was performed using the ATP Bioluminescence CLS-II kit (Roche Applied Science, 
Almere, the Netherlands) according to the manufacturers' protocol. ATP levels were corrected for 
total protein using the Lowry protein measurement system (Bio-Rad, Hercules, CA, USA) 
Transmission Electron Microscopy 
Investigation of mitochondrial structure and integrity was performed according to standard 
procedures on formalin/glutaraldehyde fixed renal samples. 
Statistical analysis 
Data were analyzed using Graph Pad PRISM S.0 (Graph Pad, San Diego, USA) or SPSS 14.0 (SPSS inc., 
Chicago, IL, USA) using Mann-Whitney U tests, One-Way ANOVA or Kruskall Wallis tests where 
appropriate. Bonferroni or Dunns postcorrection was applied where multiple comparisons 
were made. Normality was tested using the Kolmogorov-Smirno test. For the histopathological 
scoring, both kidneys of each animal were analyzed and a mixed-effects model was used taking 
the animal of origin into account. p<0.05 was considered statistically significant. All data are 
expressed as the mean ± SEM (Standard Error of the Mean) unless otherwise indicated. 
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Hydrogen sulfide (H2S) can induce a reversible hypometabolic state, which could protect 
against hypoxia. In this study we investigated whether H2S could protect livers from ischemia/ 
reperfusion injury (IRI). 
Male C57BL/6 mice were subjected to partial hepatic IRI for 60 minutes. Animals received 0 
(IRI) or l O0 ppm H25 (IRI  + H2S) from 30 minutes prior to ischemia until 5 min before reperfusion. 
Core body temperature was maintained at 37° C. Animals were sacrificed after 1, 6 or 24 hours. 
Hepatic ischemia caused extensive hepatic necrosis in the IRI animals which coincided with 
an increase in ALT and AST serum levels. Animals treated with H2S showed attenuated serum 
ALT and AST levels and reduced necrotic lesions after 24h. IRI animals had increased Bcl-2 mRNA 
expression and increased active Caspase 3 protein, which were both significantly lower in H25 
treated animals. Increased TNFa and IL-6 mRNA in the IRI livers was significantly attenuated 
by H2S treatment, as was hepatic influx of Ly-6G positive granulocytes. Hepatic superoxide 
production after ischemia was attenuated by H2S treatment. 
In hepatic ischemia/reperfusion injury, gaseous H2S treatment is highly protective, 
substantially reducing necrosis, apoptosis and inflammation. Gaseous H25 is therefore a very 
promising treatment for reducing IRI during hepatic transplantation. 
H25 PROTECTS FROM HEPATIC ISCHEMIA 
I N TRO D U CT I O N  
Hepatic ischemia/reperfusion injury (IRI) is the result of transient blood flow deprivation, often 
seen during surgical intervention and liver transplantation. The detrimental effects of I RI have 
clinical consequences in the transplant setting, attributing to organ failure and rejection1-3• 
From animal experiments it has become clear that the hepatic response to IRI has different 
facets. In the early phase there is substantial production of reactive oxygen- and nitrogen 
species (ROS and RNS), causing necrosis and apoptosis4•5• In addition, the response to injury 
will resu lt in upregulation of adhesion molecules, influx of leukocytes and further activation of 
Kupffer cells, which induces increased production of ROS and of pro-inflammatory cytokines, 
such as tumor necrosis factor a (TNFa) and interleukin 6 (IL-6)5 • 
Hydrogen sulfide (H2S), mostly known for its toxic properties6, is a widely studied molecule. 
In recent years, however, H2S has matured from a dangerous and malodorous gas to a 
physiologically important signaling molecule7• The functions of H2S range from vasodilatation6-11, 
inhibiting platelet aggregation12, regulating bile excretion13, stimulating angiogenesis14 and 
neuromodulation14-16 to scavenging of free radicals17-19• It is now, in addition to nitric oxide 
(NO) and carbon monoxide (CO), acknowledged as the third gasotransmitter, sharing many 
functions with these gases20• 
In addition to these physiological properties, one of the most captivating discoveries 
concerning H2S in recent years is its abi lity to induce a reversible, hibernation-like state in naturally 
non-hibernating mammals21 • Subtoxic concentrations of gaseous H2S rapidly reduce metabolic 
parameters in mice, slowing down 02 consumption and CO2 production by -60% within 5 minutes, 
and more than 90% after 6 hours of treatment. Core body temperature, heart rate and breathing 
frequency all decline to a great extent during treatment. When exposure to H2S is stopped, 
animals recover rapidly without any apparent toxic effects. Although the mechanism behind H2S 
-induced hypometabolism is unknown as of yet, one of the involved proteins likely to be involved 
is cytochrome c oxidase, the terminal enzyme in the mitochondrial electron transport chain. 
H2S can reversibly inhibit mitochondrial oxygen consumption and ATP production by binding to 
cytochrome c oxidase22•23• In addition to protective effects of H2S mediated ROS scavenging, this 
process lowers the demand for 02 and prevents mitochondrial ROS production. 
To pharmacologically reduce the demand for 02 is an attractive strategy to attenuate the 
effects of IRI, such as during the unavoidable periods of hypoxia during liver transplantation. 
The liver is very susceptible to I RI, and can only be preserved outside of the body without major 
influence on long term outcome for up to 16 hours by using hypothermia and preservation 
solutions24 • If metabolism in the liver can be reversibly lowered, the time the liver can be 
preserved might be increased, hepatic function after transplantation could be improved and 
acute and chronic rejection could be reduced. In this study, we therefore investigate whether 





MATER IALS  A N D M E T H O D S  
Animals 
Male C57BL/6 mice (6-8 week old, Harlan, Zeist, the Netherlands, n=S per group) were housed 
under standard conditions with a 12h light:dark cycle at our animal research facility with ad libitum 
access to water and murine chow. Experimental procedures were in agreement with institutional 
and legislator regulations and approved by the local committee for animal experiments. 
Respirometry 
Measurement of animal CO2-production was performed using a modular respirometry system 
(TR-3 system, Sable Systems, Las Vegas, NV, USA). Air or H2S / Air mixture was pushed through 
a mass flow controller (Model 840, Sierra Instruments, Egmond, the Netherlands) set to 200 
ml/min. Animals were placed in a downstream, airtight respirometry chamber with heat pads. 
The excurrent gas was lead through a CA-l Oa dual wavelength infrared sensor CO2-analyzer 
(Sable Systems). Data acquisition was performed using a U l-2 interface and ExpeData vl.0.24 
software (Sable Systems). Compressed air and 500 ppm H2S / N2 (Air Products, Amsterdam, 
the Netherlands) were mixed in a 4:1 ratio, producing a 100 ppm H2S / 17% 02 mixture. Control 
animals received room air. CO2-production was corrected for body weight and normalized to 
mean control values. 
H2S treatment 
Animals were treated with 100 ppm H2S or air for 25 minutes in our respirometry system (as 
described above) to induce a hypometabolic state. They were then transferred to the operating 
table, where they received 100 ppm H2S or air through a standard anesthesia cap during the 
procedure until 5 minutes before reperfusion. After that, all animals received only ambient air. 
Hepatic ischemia/reperfusion 
The left hepatic artery and portal vein were clamped for 60 minutes using non-traumatic vascular 
clamps through a midline abdominal incision under general anesthesia (75 mg/kg ketamine, 1 
mg/kg domitor), causing ischemia in the median and left lateral hepatic lobes. After removing the 
clamps, the liver was inspected for restoration of blood flow and the muscle and skin layers were 
sutured with 5-0 stitches. Body temperature was monitored with a rectal probe and maintained 
at ~37° C using a heating pad and lamps. Sham-operated animals were subjected to the same 
procedure, excluding the placement of the clamps. Subsequent to closure ofthe abdomen, all mice 
received a subcutaneous injection of SO µg/kg buprenorphine (Schering-Plough) for analgesic 
purposes and were allowed to recover from surgery at 35° C in a ventilated incubator. Mice were 
sacrificed 1, 6 or 24 hours after reperfusion. At the time of sacrifice mice were anesthetized using 
2. 5% isoflurane in 02, blood was collected in EDTA containing tubes, centrifuged for 10 minutes 
at 1000 ref and serum was collected and stored at -80° C. Livers were perfused with 0.9% NaCl 
solution and ischemic and non-ischemic lobes were collected. Half of each lobe was fixed in 
4% paraformaldehyde, processed for paraffin embedding and used for immunohistochemical 
analysis. The other half was snap frozen in liquid nitrogen and stored at -80° C. 
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Dihydroethidine (superoxide) staining 
Frozen liver sections (4 µm) were dried for 20 minutes under a room temperature blower 
and subsequently incubated for 30 minutes at 37° C with 12, 5 µM dihydroethidine (l nvitrogen) 
dissolved in PBS. Images were acquired at 20x magnification and analyzed using N CBI lmageJ. 
Plasma biochemical analysis 
Hepatic damage was assessed by measuring aspartate transaminase (AST), alanine transaminase 
(ALT) and lactate dehydrogenase (LDH) in plasma samples using standard methods by our 
hospital research services. 
Histopathological scoring 
The extent of hepatocellular damage and necrosis was determined in haematoxylin-eosin 
(HE) stained sections. Whole slides were scanned using an Aperio ScanScope GS (Aperio 
Technologies, Vista, CA, USA). Total hepatic area and necrotic hepatic area were determined 
using the Aperio lmagescope software, and the ratio of necrotic hepatic surface area to total 
hepatic surface area was determined. The necrotic area calculated in this manner correlated 
linearly with serum AST (24h) with an r2 of 0,9252 and with serum ALT (24h) with an r2 of 0,8792. 
Immunohistochemistry for active Caspase 3 and Ly-6G 
lmmunohistochemical staining for active Caspase 3 and granulocytes was performed as described 
before25• I n  short, for active Caspase 3, paraffin embedded sections were stained using rabbit anti­
human active Caspase 3 polyclonal antibody (Cell Signaling), followed by HRP-conjugated goat-anti­
rabbit lgG (lmmunovision Technologies). For granulocytes, paraffin embedded sections were stained 
for Ly-6G using rat-anti-mouse Ly6G/ C-FITC lgG2bantibody (AbCam, Cambridge, MA, USA), followed 
by rabbit-anti-FITC and HRP-conjugated goat-anti-rabbit antibodies. Full slides were scanned using 
an Aperio ScanScope GL (Aperio Technologies, Vista, CA, USA) and analyzed for positive pixel area 
(Ly-6G) or positive pixel intensity (Caspase 3) using the Aperio Positive Pixel Analysis v9.l algorithm. 
Qualitative Real-Time Polymerase Chain Reaction 
RNA was extracted from frozen livers using the TRIZOL method (l nvitrogen, Carlsbad, CA, U SA). 
DNAse treatment was performed using Turbo DNAse-free (Ambion, Austin, TX, USA). c DNA 
was synthesized using Superscript II RT and random hexamer primers (l nvitrogen). A relative 
quantification PCR was performed to determine gene expression (Applied Biosystems, Foster 
City, CA). f3-actin was used as housekeeping gene. 
The primers used were as follows: 
Heme Oxygenase-1 (HO-1) 
Forward: CGAGGGAAACCCCAGATCA 
Reverse: T TGCCAACAGGAAGCTGAGA 







Bcl-2 Associated X protein (BAX) 
Forward: CAAGAAGCTGAGCGAGTGTCTC 
Reverse: AATCATCCTCTGCAGCTCCATATT 






alpha Smooth Muscle Actin (aSMA) 
Forward: GAGAAAATGACCCAGA TT ATGTT TGA 
Reverse: GGACAGCACAGCCTGAATAGC 
Collagen l a  
Forward: GGAGAGTACTGGATCGACCCTAAC 
Reverse: CTGACCTGTCTCCATGTTG CA 
Hypoxia Inducible Factor-1 alpha (HIF-l a) 
Forward: CTCAGAGGAAGCGAAAATGGA 
Reverse: CAGTCACCTGGTTGCTGCAATA 
PCR was performed in a total volume of 20 µI containing 10 ng cDNA template and 10 µI PCR­
mastermix (Eurogentec). The Thermal Profile was 15 minutes at 95° C, followed by 40 cycles of 15 
seconds at 95° C and 1 minute at 60 °c. The average Ct-values for the target genes were subtracted 
from the average �-actin Ct-values to yield the delta Ct. Results were expressed as 2-Mct. 
Statistical analysis 
Data were analyzed using Graph Pad PRISM 5.0 (GraphPad, San Diego, CA, USA) or SPSS 14.0 (SPSS 
Inc., Chicago, IL, USA) using, the Mann-Whitney U test or the Kruskall Wallis test where appropriate. 
Dunns postcorrection was applied where multiple comparisons were made. Normality was tested 
using the Kolmogorov-Smirno test. p<0.05 was considered statistically significant. All data are 
expressed as the mean ± SEM (Standard Error of the Mean) unless otherwise indicated. 
RESULTS 
Respirometry 
Measurement of CO2 production using the respirometry system indicated that mice enter a 
hypometabolic state within 5-10 minutes after the start of exposure to 100 ppm H2S (Figure 
lA). Our experiments indicate that CO2 production is stable over longer periods of time when 
core body temperature is maintained. On the basis of these results, we chose a pretreatment 
period of 30 minutes for our ischemia experiments, to ensure that the mice would enter a stable 
state of hypometabolism (Figure 18). CO2 production of the animals just prior to the start of the 
ischemia procedure was measured in control and H2S treated animals, verifying that mice had 
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entered a hypometa bol ic state in  our  I RI experiments. Relative CO2 production was reduced by 
38% (p<0.001) i n  H2S treated an ima ls ( Figu re l C) .  
Necrosis 
Necrotic hepatic surface a rea in the ischemic lobes was s ig n ificantly i ncreased after 24 hours 
of reperfus ion in the IR I  g roup (p<0.05), whi le  H2S treatment attenuated the onset of necrosis 
(F igure 2A). On average, after 6 hours of reperfusion, IR I  an ima l s  had 7.4% necrotic su rface a rea, 
wh i le  H2S -treated a n ima ls  had 13.2% (p=ns). After 24 hours, the IRI g roup had 46.2% necrotic 
a rea, wh i le  treatment with H2S had only 7.5% necrotic a rea (p<0.01 ) .  Examples of the rel ative 
necrotic a reas are shown in Figu re 2B, in which necrosis was a rtificia l ly colored red . 
Serum AST, ALT and LOH 
Serum levels  of  AST and  ALT were both sig n ificantly h igher i n  the IR I  g roup at 1 ,  6 and 24 hours after 
reperfusion compared to sham-operated an ima ls  (F igure 3A, B). Thi s  increase was s ignificantly 
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Figure 1 - H2S induced hypometabolism and experimental design. 





Control 100 ppm H2S 
(A) CO2-production of three separate, awake mice before and duringtreatmentwith l00 ppm H2S. Exposure 
to H2S rapidly reduces CO2 production in these animals, indicating the induction of a hypometabolic state. 
(B) Experimental design, showing the H2S treatment regimens used (dashed l ine indicates treatment with 
100 ppm H2S). (C) Average CO2 production of anesthetized control and H25-treated mice at the end of the 
pretreatment period, just before ischemia. H2S treated animals had significantly lower CO2-production, 
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Sham 1 hour 6 hours 24 hours 
Figure 2 - H2S reduces hepatic necrosis induced by ischemia. 
(A) Relative necrotic area in haematoxyl in-eosin (HE) stained hepatic sections, showing massive 
necrosis in the IRI group after 24 hours of reperfusion, which was significantly lower in the livers 
of H2S treated animals. (8) Representative images of H E  stained hepatic sections from all different 
treatment groups. Necrotic area was artificial ly colored red. (** - p<0.01 vs. I RI, # - p<0.05 vs. Sham). 
in AST was 68.2% at lh (p<0.05) and 75.4% after24h (p<0.05). The reduction in ALT was 50.9% after 
l h  (p<0.05) and 87.5% after 24 hours (p<0.05). LDH levels in the serum of IRI mice was significantly 
increased at 1 and 6 hours after reperfusion, wh ich was significantly attenuated by H2S treatment 
at 1 hour (25.1% lower, p<0.05), but not at 6 or 24 hours of reperfusion (Figure 3C). 
Apoptosis 
lmmunohistochemistry for active Caspase 3 showed a substantial increase in apoptotic cells 
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Figure 3 - Serum AST, ALT and 
LOH levels are attenuated by 
+ + H2S treatment. 
6 hours 24 hours (A,B) Serum AST and ALT levels 
IRI show an increase at 1, 6 and 24 
hours after ischemia, which 
was significantly reduced by 
pretreatment with H 2S at 1 and 
24 hours of reperfusion. At 6 
# hours there was no significant 
difference between I RI + H2S 
-treated animals and the IR I  
group. (C) Serum LDH levels 
were i ncreased in I RI animals at 
1 and 6 hours after reperfusion. 
H2S significantly attenuated the 
increase at 1 hour of reperfusion, 
but not at 6 hours. (* - p<0.05 vs. 
I RI, # - p<0.05 vs. Sham). 
+ + 





prevented by H2S treatment (p<0.05, Figure 4A). Livers from H2S -treated animals had active 
Caspase 3 staining intensity comparable to sham-operated animals. Representative examples 
of active Caspase 3 staining are shown in Figure 48-E. mRNA expression for the anti-apoptotic 
gene Bcl-2 were also significantly increased in the ischemic lobes of I RI animals after 24 hours 
(Figure 4F), while this increase was not seen in I RI + H2S treated animals (p<0.05), indicating 
a sustained mitochondrial integrity. BAX gene expression was also significantly lower in H2S 
treated animals (Figure 4G). 
I nflammation 
TN Fa mRNA expression was significantly increased in the ischemic hepatic lobes of IRI animals 24 
hours after reperfusion (p<0.05, Figure SA). No significant increase of TN Fa mRNA was seen in I RI 
+ H2S treated animals (p<0.05). Hepatic IL-6 mRNA levels were massively increased in I RI animals, 
while no increase was detected in IRI + H25 treated animals (p<0.05, Figure SB). Similarly, IL-l f3 
mRNA levels were induced 24 hours after ischemia, and this increase was completely prevented 
by H2S treatment (Supplementary table 1). IL-18 levels were not differentially expressed in any 
group (Supplementary table 1). Massive influx of Ly-6G positive granulocytes as assessed by 
immunohistochemistry was observed at 24 hours after reperfusion in I RI animals, while IRI + 
H2S treated animals had greatly reduced increase in granulocytes in the ischemic hepatic lobes 
(p<0.01, Figure S C). Figure 5D-G show representative sections of Ly-6G stained hepatic sections, 
demonstrating the extent of granulocyte influx into the necrotic areas in I RI animals. 
Superoxide production 
Su peroxide levels in the hepatic sections were significantly increased in IRI animals at 6 and 24 
hours after reperfusion (Figure 6, p<0.01). H2S treatment significantly attenuated the increase 
in superoxide at 6 and 24 hours. (p<0.01). 
H0-1, aSMA and Collagen -la gene expression 
The expression of heme oxygenase-1 (HO-1) mRNA was increased after 6 hours of reperfusion, in 
ischemic lobes as well as in non-ischemic lobes. H2S did not significantly modulate this increase 
at the 6h time point. At 24 hours, mRNA expression was significantly increased in ischemic lobes 
of IRI animals (p<0.05), but not in non-ischemic lobes (Figure 7A, B). H2S treatment significantly 
reduced the expression of HO-1 at the 24h time point in ischemic lobes, and relative to the non­
ischemic lobe (p<0.05, Figure 7 C). 
Early expression of pro-fibrotic genes was assessed by investigating mRNA expression of 
aSMA and Collagen-la (Supplementary table 1). The expression of both genes in the ischemic 
lobes was reduced in IRI + H2S treated animals compared to IRI after 24 hours of reperfusion 
p<0.01), although the changes in expression relative to the non-ischemic lobes were not 
significantly modulated. 
H I F-la gene expression 
No significant differences in HIF-l a gene expression were detected in ischemic or non-ischemic 





































Figure 4 - H25 treatment reduces apoptosis of hepatocytes. 
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B 
Sham 
(A) I RI induced massive apoptosis of hepatocytes, as measured by active Caspase 3 
immunohistochemistry. H2S treatment prevented the onset of apoptosis in the ischemic lobes. (B-E) 
Representative images of hepatic sections stained for active Caspase 3 using immunohistochemistry. 
mRNA levels of the anti-apoptotic gene Bcl-2 (F) and pro-apoptotic BAX (G) indicate the activation 
of the mitochondrial  apoptosis pathway in livers exposed to IRI. mRNA levels were significantly 
lower in H2S treated animals. (* p<0.05 vs. IRI, # - p<0.05 vs. Sham). m 
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Figure 5 - H25 treatment reduces inflammation and influx of granulocytes. 
(A) Influx of Ly-6G positive granulocytes was assessed using immunohistochemistry. Influx of 
granulocytes was very high and was completely prevented by H2S pretreatment. (B) Hepatic 
express ion of TN Fa mRNA is increased 24 hours after reperfusion and is significantly lower in H 2S 
treated animals at 6 and 24 hours of reperfus ion. (C) I L-6 mRNA expression is massively higher after 
24 hours of reperfus ion and is not induced in H2S treated animals. (D-G) Representative images of ► 
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DISCUSSION 
Hepatic ischemia/reperfusion injury in mice can be prevented to a great extent by inducing 
a hypometabolic state with gaseous H2S. In al l  of the dimensions of hypoxic injury that were 
investigated - including necrosis, apoptosis, inflammation and reactive oxygen species - H2S 
treatment reduced deleterious effects, in some parameters to such an extent that damage was 
comparable to sham levels. 
Several studies have reported on the use of H2S in hypoxic injury, and the majority of studies show 
beneficial effects of H
2
S treatment in models of shock26, cardiac arrest27 and in cardiac-22•28, intestinal-29, 
pulmonary-30 and renal ischemia31•32• Two studies have shown beneficial effects of H2S in hepatic IRl33• 
34
• These studies use soluble salts as donors of H2S in solution (Na2S or Na HS), and show that H2S can 
reduce apoptosis and hepatic damage after IRI. They differ in the time of administration, however, 
one paper injecting before ischemia, and the other just before reperfusion. The unique perspective 
our study offers is the use of gaseous administration of H
2
S and the induction of a hypometabolic 
state, linking the protective properties of H2S to the reduction in the 02-demand of the liver. 
The increase in serum ALT, AST and LDH levels at 6 hours of reperfusion was equal in I RI and 
IRI + H2S treated animals. This finding may well be related to the hepatic necrosis that was found 
at 6 hours of reperfusion, and suggests that H
2S cannot prevent all damage caused by hepatic 
IRI. Alternately, this could be a toxic effect of H2S. Unfortunately, we did not include a group of 
sham-operated animals terminated 6 hours after the procedure, which would likely have shed 
more light on this observation. However, we believe it is unlikely that H
2S would induce such 
a massive increase in ALT, AST and LDH without showing any histological signs of necrosis, 
apoptosis or inflammation in sham operated animals. 
The reduction in active Caspase 3 staining seen in H2S treated animals indicated that 
H2S can prevent the activation of apoptosis pathways. Since H2S has been shown to protect 
mitochondrial integrity during hypoxia22•31, we investigated if the mitochondrial apoptosis 
pathway would be activated in IRI animals. For this purpose, we measured the expression of 
Bcl-2 and found a significant increase in Bcl-2 mRNA after I RI .  This increase was not found in 
livers from the I RI + H2S group, indicating that the onset of mitochondrial degradation by IRI 
was prevented by H2S treatment. 
Treatment with H2S prevented the production of TNFa and IL-6 mRNA after ischemia. 
This reduction in the production of cytokines may have contributed to the massively reduced 
influx of granulocytes to the necrotic areas in the liver. Treatment with H2S lowered the influx 
of granulocytes after renal ischemia/reperfusion injury31 • H2S has also been implicated before 
in modulating leukocyte adhesion35 through a mechanism involving the activation of KATP 
channels, although we did not test the role of KArP channels in this study. Nevertheless, there 
► hepatic sections stained for granulocytes using Ly-6G antibody. Similar levels of granulocytes were 
seen in sham and H2S treated animals, while the IRI group had very high influx of granulocytes, 
especially in the necrotic areas, as can be clearly seen in SF. Arrowheads depict granulocytes in 
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Sham 1 hour 6 hours 24 hours 
Figure 6 - Hepatic superoxide is reduced by H2S treatment. 
(A) Su peroxide production in hepatic sections as assessed by DHE  fl uorescent imaging is s ignificantly 
increased after I RI at 6 and 24 hours. Treatment with H2S s ignificantly reduced the extent of ROS at 
these timepoints. (B) Representative images of D H E  fl uorescence at a l l  t imepoints. (** p<0.01 vs. I RI , 
# - p<0.05 vs . Sham). 
i s  no increase in  g ra n u locyte influx in  H2S t reated a n ima l s  after 24 hours of reperfusion, wh i le  
there is an  increase i n  necrotic a rea, i nd icati ng that a lthough there is necrotic damage to  these 
l ivers, there is red uced act ivation of s igna l s  that ca use the i nfl u x  of leu kocytes. 
The reduction in  D H E  fl uorescence after I RI in H2S treated a n ima l s  ind icates a red uced 
amount of ROS i n  the l iver. H2S can have d i rect scavenging effects on  ROS, but can a lso h ave 
i nd i rect effects, through  i ncreas ing the a mount of red uced g l utathione (GSH) .  Whether  
d i rect or ind i rect ROS-scavenging mechan isms a re at  p lay here was not investigated.  Another 
mechan ism that cou l d  be involved is that red u ct ion in  oxidative metabol ism and mitochondr ia l  






H0-1 mRNA (Non-ischemic lobe) 
## 













































H25 PROTECTS FROM HEPATIC ISCHEMIA 
Figure 7 - H0-1 gene expression 
levels in ischemic and non­
ischemic hepatic lobes. 
(A, B) H0-1 mRNA expression 
is induced in non-ischemic and 
in ischemic lobes at 6 hours of 
reperfusion, indicating an effect 
not caused by ischemia. At 24 
hours, expression of H0-1 is 
significantly higher in IRI compared 
to the IRI + H2S group. (C) The ratio 
of ischemic to non-ischemic lobe 
expression of H0-1 indicates that 
induction of H0-1 is not involved in 
the protective mechanism of H2S. 
(* - p<0.05 vs. IRI, # - p<0.05, ## -




Heme oxygenase-1 converts heme into biliverdin and CO, and is known as an enzyme that 
can be protective in models of oxidative stress36• It is known that gene expression of H0-1 is 
rapidly induced after hepatic ischemia/reperfusion injury37• Increased expression of H0-1 has 
been implicated as one of the mechanisms behind H2S mediated protection in models of 
ischemia28•38•39• H2S treatment did not induce the expression of H0-1 in sham-operated animals. 
We found a large increase in expression of H0-1 in ischemic as wel l  as non-ischemic lobes 6 
hours after the ischemia/reperfusion procedure, which was not modulated by H2S treatment. 
This effect on H0-1 gene expression is most likely not caused by ischemia of the liver, but by the 
stress of the surgical procedure, anesthetics and/or analgesics, since expression in ischemic 
and non-ischemic lobes was simi lar. The significant increase in H0-1 expression in ischemic 
lobes after 24 hours of reperfusion, however, was attenuated by H2S treatment, indicating that 
H0-1 expression is not implicated in the protective mechanism of H2S in this model, but can be 
regarded as a marker of cellular or oxidative stress. 
To investigate the main components of ischemia/reperfusion injury - necrosis, apoptosis, 
inflammation and fibrosis - we also investigated pre-fibrotic processes by looking at aSMA 
and Collagen-la mRNA expression. There was significant modulation of the expression of 
both genes by H2S in ischemic lobes, which indicated that treatment with H2S might be able to 
prevent the onset of fibrotic mechanisms. However, when we corrected for the expression in 
the non-ischemic lobe there were no significant differences in expression. Also, the expression 
compared to sham-operated animals was not significantly changed, indicating that 24 hours of 
reperfusion is probably too early to assess ischem ia induced fi brotic mechanisms after ischemia. 
The mechanism behind the protective effects of hydrogen sulfide in hypoxic conditions 
might be related to its inhibitory effects on mitochondria. H2S treatment can protect 
mitochondria from degradation, and improve viability in models of hypoxia and ischemia22•31 • 
This could well be related to the inhibition of cytochrome c oxidase, or the scavenging of 
mitochondrial ROS. Fascinatingly, the induction of a hypometabolic state using H2S can protect 
mice from an hypoxic atmosphere; where control mice died within 20 minutes after the onset 
of hypoxia, H2S treated mice could survive for up to 6 hours40• This implies that the protection 
that we have seen during ischemia are possibly due to a reduced 02 demand, thereby providing 
defense against hypoxia in the livers. In addition, it appears that H2S can be used as an electron 
donor in mammalian cells41 • When H2S inhibits mitochondrial cytochrome c oxidase, cells might 
be able to use H2S as an energetic substrate for anaerobic metabolism, allowing a low level 
of energy production during hypoxia. In addition, H2S -induced vasodilatation might have a 
role in the protective effects of H2S. Nevertheless, from the study presented in this paper it is 
impossible to say which combination of the many known effects of H2S is responsible for the 
effects seen. We were unable to provide di rect evidence towards the mechanisms that underlie 
H2S mediated protection, only associative data. 
The clinical potential of H2S is diverse, and H2S donors or H2S-releasing compounds are being 
tested in different clinical settings now, including myocardial infarction, cardiopulmonary bypass 
and inflammatory conditions such as arthritis and inflammatory bowel disease. lschemic conditions 
could greatly benefit from H2S treatment. During surgical intervention H2S might be valuable to 
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protect tissue from ischemia caused by temporary arterial clamping. However, some caution is 
required before these results can be translated to the human setting, since some of the effects of 
H2S on mice could not be reproduced in larger animals, such as sheep42• However, others were able 
to induce lower core body temperature, 02-consumption and CO2-production in pigs
43
• 
In our view, oneofthefirst feasibleclinical applications of gaseous H2S lies in the pretreatment 
of the brain dead (heart beating) organ donor. In addition to protecting the organ from ischemic 
damage, H2S might also modulate the deleterious effects brain death has on organs that are to 
be transplanted44• However, the effects of brain death on H2S-induced protection against IRI 
will need to be investigated. The fact that H2S has protective effects in diverse organs makes 
H2S a promising candidate to treat multi-organ donors prior to procurement. H2S treatment 
will perhaps not only limit the extent of injury that occurs during the process of transplantation, 
but it might also increase the time livers can be preserved between explantation from the 
donor and implantation into the recipient. However, the potentially toxic effects of H2S should 
be carefully monitored when used in a clinical setting. 
In all, these data indicate that pretreatment with gaseous H2S is a highly protective method 
to prevent ischemia/reperfusion injury of the liver, which makes it a promising candidate for 
use in a transplantation setting. 
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Supplementary Table 1 - mRNA expression of m ultip le genes in ischemic and non-ischemic lobes. 
lschemic : 
Treatment Non-ischemic lobe l schemic lobe Non ischemic ratio 
Gene Group Mean SD P-va lue Mean SD P-value Mean SD P-value 
HO-1 Sham 2.94 1 .62 ns 2.70 0.48 ns 1 .07 0.44 ns 
Sham + H2S 3.51 1 .71 2 .61 0.81 0.79 0.20 
I RI - l h 4.05 1 .00 ns 4.16 0.86 ns 1 .09 0.40 ns 
IRI + H2S - lh  4.89 2.12 3.37 1 .39 0.78 0.38 
I RI - 6h 31 .21 18 .41 ns 35.98 19.76 ns 1 .37 0.69 ns 
I RI + H2S - 6h 41 .39 25.99 34.87 11 .59 0.99 0.33 
I RI 24h 2.67 1 .09 ns 8.75 5.97 0.016 3.69 3.06 0.016 
I RI + H2S - 24h 2.81 1 .23 2.96 1 .44 1 .15 0.58 
Mean SD P-value Mean SD P-value Mean SD P-value 
TNFa Sha m 1 .13 0.44 ns 1 .99 1 .18  ns 1 .78 0.78 ns 
Sham + H2S 0.87 0.66 1 .67 1 .41 1 .97 1 .01 
I RI - l h  1 .17 0.23 ns 3.59 3.21 ns 2.84 2.22 ns 
I RI + H2S - lh  1 .31 0.63 3.54 1 .74 2.76 0.84 
I RI - 6h 2.49 1 .27 ns 4.32 1 .79 ns 2.07 0.92 0.Q28 
I RI + H2S - 6h 2.82 1 .72 2 .79 1 .06 1 .09 0.37 
I RI - 24h 1 .56 1 .05 ns 7.00 3.27 0.004 4.94 1 .91 0.004 
I RI + H2S - 24h 0.94 0.96 1 .12  0.80 1 .91 0.96 
Mean SD P-va lue Mean SD P-value Mean SD P-value 
I L-6 Sham 0.22 0.08 ns 0.40 0.1 8 ns 1 .56 0.43 ns 
Sham + H2S 0.26 0.10 0.46 0.22 1 .62 0.43 
I RI - l h 1 .90 1 .63 ns 2.63 1 .17 ns 2.91 3.07 ns 
I RI + H2S - lh  2 .35 1 .03 2.38 0.64 1 .29 0.82 
I RI - 6h 0.46 0.24 ns 0.93 1 .36 ns 2.48 3.40 ns 
I R I + H2S - 6h 1 .24 1 .80 1 .64 1 .55 3.41 5.02 
I RI - 24h 0.24 0.12 ns 6.08 8.33 0 .048 37.00 62.03 0.016 
I RI + H2S - 24h 0.40 0.1 6 0.33 0.16  0.84 0.61 
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Supplementary Table 1 - Continued 
BJ lschemic : 
Treatment Non-ischemic lobe lschemic lobe Non ischemic ratio 
Gene Group Mean SD P-value Mean SD P-value Mean SD P-value 
I L-1!3 Sham 0.37 0.33 ns 0.33 0.27 ns 0.94 0.26 ns 
Sham + H2S 0.37 0.41 0.29 0.23 0.94 0.18 
IRI - l h 0.47 0.20 ns 0.69 0.49 ns 1 .41 0.74 ns 
IRI + H2S - lh 0.50 0.16 0.74 0.11 1 .57 0.28 
IRI - 6h 0.26 0.15 ns 0.42 0.11 ns 1 .97 0.85 ns 
I RI + H2S - 6h 0.55 0.62 0.68 0.83 1 .31 0.72 
IRI - 24h 0.17 0.04 ns 1 .22 1 .07 0.02 7.19 6.73 0.004 
IR I  + H2S - 24h 0.24 0.10 0.24 0.09 1 .05 0.20 
Mean SD P-value Mean SD P-value Mean SD P-value 
I L-18 Sham 1 .01 0.43 ns 0.86 0.21 ns 0.91 0.18 ns 
Sham + H2S 0.98 0.45 0.85 0.30 0.91 0.22 
I RI - l h  1 .28 0.33 ns 0.91 0.18 ns 0.76 0.25 ns 
IRI + H2S - l h  1 .25 0.17 0.93 0.13 0.76 0.20 
IRI - 6h 1 .40 0.21 ns 0.91 0.22 ns 0.65 0.15 ns 
I R I + H2S - 6h 1 .31 0.55 0.77 0.10 0.67 0.26 
IRI - 24h 0.75 0.32 ns 0.58 0.13 ns 0.82 0.18 ns 
I RI + H2S - 24h 0.80 0.36 0.69 0.36 0.91 0.30 
Mean SD P-value Mean SD P-value Mean SD P-value 
BAX Sham 1 .16  0.18 ns 1 .24 0.15 ns 1 .09 0.20 ns 
Sham + H2S 1 .08 0.27 1 .1 0  0.23 1 .04 0.19 
I RI - l h  1 .19 0.36 ns 0.99 0.45 ns 0.82 0.35 ns 
I Rl + H2S - l h  1 .02 0.26 0.90 0.11 0.94 0.33 
I RI - 6h 1 .10  0.26 ns 1 .14 0.19 ns 1 .07 0.20 ns 
I R I + H2S - 6h 1 .38 0.16 1 .12 0.49 0.79 0.23 
IRI - 24h 1 .15 0.18 ns 1 .65 0.24 0.004 1 .44 0.05 0.004 
IR I  + H2S - 24h 1 .14 0.13 1 .04 0.12 0.92 0.13 
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Supplementary Table 1 - Continued 
lschemic : 
Treatment 
Non-ischemic lobe lschemic lobe Non ischemic ratio 
Gene Group Mean SD P-value Mean SD P-value Mean SD P-value 
aSMA Sham 0.42 0.33 ns  0.1 6 0.01 ns 0.50 0.22 ns 
Sham + H2S 0.29 0.06 0.1 6 0.02 0.58 0.22 
I RI - l h 0.58 0.33 ns 0.34 0.13 ns 0.63 0.18 ns 
I RI + H2S - l h  0.49 0.09 0.40 0.13 0.88 0.32 
IRI - 6h 0.51 0.27 ns  0.31 0.13 ns 0.72 0.48 ns 
I R l + H2S - 6h 0.42 0.12 0.30 0.08 0.73 0.19 
IRI - 24h 0.29 O.Ql ns 0.29 0.09 0.008 1 .04 0.31 ns 
I RI + H2S - 24h 0.20 0.06 0.17 0.02 0.98 0.38 
Mean SD P-value Mean SD P-value Mean SD P-value 
Collagen la Sham 1 .78 2 .01 ns  2.35 1 .21 ns 2.82 2.80 ns 
Sham + H2S 0.71 0.22 1 .40 1 .32 1 .74 1 .02 
I RI - l h 1 .38 0.38 ns 1 .24 0.46 ns 0.96 0.48 ns 
I R l + H2S - l h 1 .49 0.31 2.03 0.87 1 .37 0.62 
I RI - 6h 2.41 2.49 ns 0.77 0.41 ns 0.55 0.44 ns 
I RI + H2S - 6h 1 .65 1 .20 1 .28 0.93 0.78 0.12 
I RI - 24h 0.97 0.37 ns 3.73 0.52 0.006 4.41 2.11 ns 
I RI + H2S - 24h 0.78 0.37 1 .63 0.85 2.31 1 .60 
Mean SD P-va lue Mean SD P-value Mean SD P-value 
H I F-l a  Sham 2.02 0.27 ns 2.01 0.09 ns 1 .01 0.16  ns  
Sham + H2S 2.06 0.40 1 .84 0.33 0.91 0.24 
I RI - l h 1 .55 0.51 ns 1 .50 0.31 ns 1 .04 0.27 ns 
I RI + H2S - l h  1 .91 0.45 1 .55 0.16  0.83 0.12 
I RI - 6h 3.15 0.68 ns 2.96 0.79 ns 0.98 0.35 ns 
I RI + H2S - 6h 3.61 0.62 3.59 1 .02 0.99 0.19 
I R l - 24h 1 .56 0.37 ns 2.06 0.50 ns 1 .38 0.50 ns 
I RI + H2S - 24h 1 .53 0.65 1 .85 0.39 1 .55 1 .03 
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CHAPTER 4  
ABSTRACT 
lschemia-reperfusion injury (I RI) is a major cause of cardiac damage following various pathological 
processes. Gaseous hydrogen sulfide (H25) is protective during I RI by inducing a hypometabolic 
state in mice which is associated with anti-apoptotic, anti-inflammatory and antioxidant 
properties. We investigated whether gaseous H25 administration is protective in cardiac IRI and 
whether non-hypometabolic concentrations of H2S have similar protective properties. 
Male C57BL/6 mice received a 0, 10, or l00 ppm H2S-AIR mixture starting 30 minutes prior to 
ischemia until 5 min pre-reperfusion. I RI was inflicted by temporary ligation of the left coronary 
artery for 30 min. High-resolution respirometry equipment was used to assess CO2-production 
and blood pressure was measured using internal transmitters. The effects of H2S were assessed 
by histological and molecular analysis. 
Treatment with 100 ppm H2S decreased CO2-production by 72%, blood pressure by 14% 
and heart rate by 25%, while treatment with 10 ppm had no effects. At day 1 of reperfusion 10 
ppm H2S showed no effect on necrosis, while treatment with 100 ppm H25 reduced necrosis 
by 62% (p<0.05). Seven days post-reperfusion, both 10 ppm (p<0.01 ) and 100 ppm (p<0.05) H2S 
showed a reduction in fibrosis compared to IRI animals. Both 10 ppm and 100 ppm H25 reduced 
granulocyte-influx by 43% (p<0.05) and 60% (p<0.001), respectively. At 7 days post-reperfusion 
both 10 and 100 ppm H2S reduced expression of fibronectin by 63% (p<0.05) and 67% (p<0.01) 
and ANP by 84% and 63% (p<0.05), respectively. 
Gaseous administration of H25 is protective when administered during an cardiac ischemic 
insult. Although hypometabolism is restricted to small animals, we now showed that low 
non-hypometabolic concentrations of H25 also have protective properties in IRI. Since I RI is a 
frequent cause of myocardial damage during myocardial infarction and cardiac transplantation, 
H2S treatment might lead to novel therapeutic modalities. 
H2S-HYPOMETABOLISM PROTECTS FROM CARDIAC ISCHEMIA 
I N TRO D U CTI O N  
l schemia-reperfusion inj u ry ( I RI) is the most importa nt cause of myocard ia l  damage and 
subsequent hea rt fa i l u re .  Although I RI is most frequently caused by acute myocardia l  infa rction 
(Ml) with (early or  late) reperfusion, it ca n a lso be observed fol lowing surgica l  procedu res 
such as card iopu lmonary bypass or cardiac transp lantationY Myocard ia l  I RI causes a cute 
tissue responses characterized by i nfl ammation and up regu lation of infl ammatory med iators . 
This process u ltimately leads to i rreversib le  fi b rotic damage.3-4 Desp ite major therapeutic 
developments, cardiovascu l a r  d isease remains the leading cause of death in  the western world. 5 
Hyd rogen su lfide (H2S) has d rawn considerable  attention for its ro le in va rious (patho) 
physiologica l  processes. I t  is, in  addition to nitric oxide and carbon monoxide, acknowledged 
as the th ird gasotransmitter, shar ing many fu nctions with these gases.6 H2S is endogenous ly 
produced and exerts fine, modu latory control over cel l u l a r  functions by infl uencing an a rray of 
intrace l l u l a r  s igna l ing processes. H2S-producing enzymes and H2S-p lasma level s  a re reduced 
in  various d iseases.1•9 Exogenously admin istered H2S ca n revers ib ly induce a hypometa bol ic 
state in  mice, d u ring which it rap id ly reduces 02-consumption, CO2-p roduction, core body 
tem peratu re, heart rate and  breath ing frequency.10•11 
The most probab le mechanism for these properties is the reversib le inh ib ition of 
mitochondria l  02-consumption and ATP-production through non-permanent b inding of 
su lfide to the termina l  enzyme i n  the e lectron transport chain, cytoch rome c oxidase (com plex 
IV).12 It was thought that the reduced demand for oxygen d u ring hypometa bol ism might be 
one of the protective mechan isms during ischemia.  However, H2S is a lso considered protective 
during other processes c ritica l ly involved in  myocard ia l  I RI such as oxidation, infl ammation and 
apoptosis. These cytoprotective featu res of H2S make it an  attractive candidate for therapeutic 
reduction of the damaging effects of hypoxia .13•14 
The i nfl uence of gaseous  admin istration of H2S and the effects of hypometabol ic and non­
hypometabol ic concentrations on the outcome of myocard ia l  IR I  remains to be e lucidated . 
Some stud ies have explored the beneficia l  effects of sol ub le H2S donors such as NaHS and 
Na2S in  myocard ia l  I RI and other mode ls  of cardiac da mage.15•18 The preference for gaseous 
administration a bove injection with H2S donors l ies within accu rate management of the 
concentrat ion.  As opposed to injection with so lub le  H2S donors, gaseous H2S is less difficult  to 
dose and has a short wash -out period, leaving its positive effects behind.11 Moreover, gaseous 
admin istration has proven to induce a hypometabol ic  state, whi le this has not been shown for 
intra -peritoneal  or int ra-venous admin istration of so lub le  H2S.10•11 Althoug h  H2S does not appea r  
to  have hypometabol ic effects i n  ambiently cooled l a rge mammals, thereby questioning 
its thera peutic app l ications in  humans, the beneficia l  effects of non-hypometa bol ic 
concentrations of H2S have not been studied.
19•20 Since min imizing myocard ia l  I RI has b road 
c l in ica l  imp l ications and may have beneficia l effects on  card iac surgica l  outcomes 1, we therefore 
investigated whether gaseous H2S-treatment attenuates myocard ia l  I R I  in mice and whether 





MATERIALS AND METHODS 
Ethics Statement 
Procedures were in agreement with institutional and legislator regulations and approved by the 
Committee on the Ethics of Animal Experiments of the University Medical Center Groningen. 
Utmost effort was utilized to prevent suffering and minimize the numbers of mice required for 
each experiment. 
Animals 
Male C57BL/6 mice (6-8 weeks, Harlan, Zeist, the Netherlands) were housed at our animal research 
facility under standard conditions with a 12h light:dark cycle with free access to water and chow. 
Telemetry 
Blood pressure was measured telemetrically (n=4) using transmitters (TAll PA- Cl0; Data 
Sciences International, St Paul, MN, USA). Devices were placed through a midline abdominal 
incision under anesthesia (2% lsoflurane) and mice were placed on a heating pad to maintain 
body temperature at 37° C. The catheter was placed in the aorta and the transmitter body in 
the abdominal cavity. Animals recovered 7 days before com mencing measurements. Data were 
recorded as 10-second averages every minute using Dataquest ART data acquisition system 
(Data Sciences International). Animals were treated with room air or a H2S / air mixture in our 
respirometry system during measurements. For comparison of blood pressure and heart rate, 
the average of 20 minutes baseline measurement and 20 minutes of 10 ppm and 100 ppm 
H2S treatment was determined. A crossover design was used in which all animals received all 
treatments in randomized order. 
Respirometry 
Measurement of CO2-production was performed as described before.21 Compressed air and 
500 ppm H2S / N2 (Air Products, Amsterdam, the Netherlands) were mixed in a 4:1 ratio and 
in a 49:1 ratio resulting in a 100 ppm H2S / 17% 02 mixture and a 10 ppm H2S / 17% 02 mixture, 
respectively. CO2-production was corrected for body weight and normalized to mean control 
values. Animals (n,,,11) were treated in a crossover model in randomized order and all received 
room air, 10 ppm H2S and 100 ppm H2S on different days. Baseline CO2 measurements with room 
air were performed for 30 minutes followed by treatment with either a 10 or 100 ppm H2S / 17% 
02 mixture for 30 minutes. Recovery with room air was measured for 30 minutes. 
Myocard ial ischemia/reperfusion and H 2S treatment 
Mice were intubated and mechanically ventilated (n,,,77) with an Oz/ N2 mixture in a 4:1 ratio, an 
02 / 100 ppm H2S / N2 mixture in a 4:1 ratio or a 02 / 10  ppm H2S / N2 mixture in a 49:1 ratio at a 
frequency of 180/min with a tidal volume of 250 µI using a rodent ventilator (Harvard Midivent 
model 849). Treatment regimens (Sham n"'15; IRI n=20; 10 ppm n"'21; 100 ppm n=21 ) were 
randomly assigned and started 30 minutes prior to ischemia until 5 minutes pre-reperfusion. 
Myocardial IRI was inflicted by temporary ligation of the left anterior descending coronary 
artery (6-0 prolene suture) for 30 min through an incision in the fourth intercostal space under 
H2S-HYPOMETABOLISM PROTECTS FROM CARDIAC ISCHEMIA 
anesthesia (75 mg/kg ketamine, 1 mg/kg medetomidine). After removing the ligature the heart 
was inspected for restoration of blood flow and muscle and skin layers were sutured with 5.0 
vicryl. Body temperature was monitored with a rectal probe and maintained at 37° C using heat 
pads. Sham operated animals underwent the same procedure, except the placement of the 
ligature. Post-operatively, all mice received a subcutaneous injection of 50 µg/kg buprenorphin 
(Schering-Plough) for analgesic purposes and were allowed to recover from surgery at 37° C in 
a ventilated incubator. After 1 and 7 days mice were anaesthetized with 2% isoflurane in 02 for 
collection of blood and organs. Blood was collected in heparin containing tubes, centrifuged 
for l O  minutes at 1000 ref and plasma was collected and stored at -80°C. The hearts were rapidly 
excised and mid-papillary slices were fixed in 4% paraformaldehyde, paraffin-embedded and 
sections were cut for immunohistochemical analysis. Apical parts of the heart were snap frozen 
in liquid nitrogen and stored at -80° C for molecular analysis. 
Plasma analysis 
Cardiac damage was assessed by measuring high sensitive (hs) Troponin-T in plasma samples using 
a standard electrochemiluminescence immunoassay (Roche) in the clinical chemical laboratory. 
Histopathological scoring 
At 1 day of reperfusion the extent of necrosis was determined in haematoxylin-eosin stained 
sections. At 7 days of reperfusion the extent of fibrosis was determined in Masson stained sections. 
Both were examined in a blinded fashion. Sections were scanned using an Aperio ScanScope 
GS (Aperio Technologies, Vista, CA, USA). Total cardiac area, necrotic cardiac area and fibrotic 
cardiac area were determined using Aperio lmagescope software, and the ratio of necrotic 
cardiac surface area and fibrotic surface area to total cardiac surface area were determined. 
Representative photomicrographs were artificially colored indicating the extent of damage.11•21 
lmmunohistochemistry for Ly-6G 
For granulocytes, paraffin-embedded sections were stained for Ly-6G using rat-anti-mouse 
Ly6G/C-FI TC lgG2b antibody (Ab Cam, Cambridge, MA, USA), followed by rabbit-anti-FITC and 
H RP-conjugated goat-anti-rabbit antibodies. Slides were scanned using an Aperio ScanScope 
GL (Aperio Technologies, Vista, CA, USA) and analyzed for positive pixel area (Ly-6G) using the 
Aperio Positive Pixel Analysis v9.l algorithm. 
Qualitative Real-Time Polymerase Chain Reaction 
RNA extraction, DNAase treatment21 and cDNA synthesis22 were performed as described. A 
relative quantification PCR was performed to determine gene expression (Applied Biosystems, 
Foster City, CA). �-actin and GAPDH were used as housekeeping genes. 
The primers used were: 
Fibronectin (NM_Ol0233.l) 
Forward: AGGAAATGTACTGAATG CTAGTACCCA 







Reverse: ACCCCACTAGAC CA CTCATCTACAT 
NOX2 (NM_007807.4) 
Forward: GATGCAATAAGACTAGGCACAAACC 
Reverse: CCA TCTCATAACCAGAATAACTCAGGATA 
NOX4 (NM_Ol 5760.4) 
Forward: TGCACCAAACACAGAAGCACA 
Reverse: AGCAGGGTATCA CTCCATGAA TTC 
PCR was performed i n  a volume of 20 µI contain i ng 10  ng cDNA and 15 µI PCR mastermix 
(SYBR GREEN Applied Biosystems; 5 ml P/N 43091 55). The Thermal Profile was performed as 
described.22 The average Ct-values for fibronectin, ANP, NOX2 and NOX4 were subtracted from 
the average �-actin Ct-values and the average of �-acti n  and GAPDH Ct-values to yield the 
delta Ct. Results were expressed as 2-llct_ 
Cell culture 
The H9c2 cell l ine (ATCC) is an immortalized l ine with characteristics of rat heart myoblasts. Cells 
were cultured in Dulbecco's modified Eagle's medium (DMEM; Lonza, Germany) contain ing 4. 5 
g/I glucose, 10% fetal calf serum (FCS; Bodinco, Alkmaar, the Netherlands), L-glutamine and 
penicill in  (100 U/ml) streptomycin (100 µg/ml) (Lonza, Germany). Cells were cultured using 75 
cm2 collagen coated flasks (Corning, Schiphol- Rijk, Netherlands) in  a humidified atmosphere of 
5% CO2 and 95% 02 at 37
° C. 
In vitro model of oxidative stress 
H9c2 cells grown to 80-90% confluency were harvested using 3 ml trypsin EDTA (200 mg/I) after 
washing twice with Hank's Buffered Salt Solution (HBSS) (Lonza; Germany). Cells were cultured 
in a 24-well plate at a density of -10.000 cells/well i n  0. 5 ml medium. After 24 hours cells were 
loaded with 1 5  µM Dihydroethidine (DHE). Culture plates were placed in a humidified chamber 
with 5% CO2 on an automated i nverted fluorescent microscope system (TissueFAXS system, 
TissueGnostics GMBH, Vienna, Austria) which makes sequential photomicrographs of 9 area's 
in each well every 5 minutes. After baseli ne measurements, cells were exposed to Antimycin (50 
µg/mL) and Na HS (donor of H2S in solution) in a concentration of 1 mM. Fluorescence intensity 
of every cell was analyzed usi ng the TissueQuest software (TissueGnostics). 
Statistical analysis 
Data were analyzed using Graph Pad PRISM 5.0 (GraphPad, San Diego, CA, USA) usi ng two-way 
ANOVA, Mann -Whitney U ,  Friedman or Kruskall Wallis tests where appropriate. Bonferroni  or 
Dunns post-hoc analysis was applied where multiple comparisons were made. Normality was 
tested using the Kolmogorov-Smirnov test. p<0.05 was considered statistically significant .  All 
data are expressed as mean ± SEM (Standard Error of the Mean) unless otherwise indicated. 
H25-HYPOMETABOLISM PROTECTS FROM CARDIAC ISCHEMIA 
RESULTS 
Effect of H2S on CO2 production, blood pressure and heart rate 
Within 15 minutes of treatment with 100 ppm H2S induced a state of hypometabolism, 
concomitant with a reduction in CO2-production by an average of 72% compared to basal 
levels (p<0.001). Cessation of H2S resulted in a rapid recovery of CO2-production, where CO2 
concentrations raised to basal levels within 30 minutes (p<0.001). 100 ppm H2S lowered blood 
pressure by 14% (103 vs. 120 mmHg, p<0.05) and heart rate by 25% compared to baseline (502 
vs. 670 beats per minute, p<0.05) 10 ppm H2S had no effect on CO2 production, blood pressure 
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Figure 1 - High concentrations of H25 induce a state of hypometabolism. 
Within 15 minutes (A) CO2-production decreased by 72% (***p<0.001 ) in mice (n=ll) subjected to 
100 ppm H2S. Exposure to 10 ppm H2S (n=ll) did not induce a reduction in CO2 production in these 
animals. Cessation of gaseous H2S resulted in rapid recovery, within 30 minutes CO2 levels returned 
back to baseline concentrations (***p<0.001). Administration of 100 ppm H2S (n=4) resulted in a 
14% decrease in (B) mean arterial pressure and a 25% decrease in (C) heart rate (*p<0.05). However 





H2S reduces myocardia l da mage 
At 1 day of reperfusion cardiac IRI induced significant necrosis (Figure 2A) in animals exposed to 0 
ppm H2S when compared to sham animals (p<0.001) as indicated by infarct size. 10 ppm H 2S did not 
reduce the size of the necrotic area, while 100 ppm H2S reduced infarct size by 62% (p<0.05) (Figure 
2B). In mice treated with 10 ppm H2S hs Troponin-T levels were not reduced 1 day post-reperfusion, 
while 100 ppm H2S reduced hs Troponin-T levels by 47% (p<0.05) compared to IRI animals (Figure 
2C). Fibrosis, as measured by collagen deposition in Masson stained sections (Figure 3A) at 7 days of 
reperfusion, was markedly increased in animals treated with 0 ppm H2S when compared to sham­
operated animals (p<0.001). Treatment with either lO  or lO0 ppm of H2S reduced collagen deposition 
to comparable levels (10 ppm: 59%, p<0.01; 100 ppm: 57%, p<0.05) (Figure 3B). Cardiac mRNA levels of 
fibronectin, a marker of myocardial fibrosis, were massively increased in 0 ppm H2S treated animals 
(p<0.01), while no increase was detected in animals of both H2S treated groups (10 ppm H2S p<0.05; 
100 ppm H2S p<0.01) (Figure 3C). Seven days post-reperfusion hs Troponin-T levels were reduced 
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Figure 2 - Cardiac damage is reduced by 100 ppm H2S at 1 day of reperfusion. 
100 ppm 
(A) Representative photomicrographs of haematoxylin-eosin stained cardiac sections with necrotic 
area artificially colored red, indicating the extent of necrotic damage found in each group at 1 day of 
reperfusion. (B) Cardiac IR induced a significant amount of necrosis in IRI animals exposed to 0 ppm H2S 
(### p<0.001 vs. sham). In animals treated with 100 ppm H25 necrosis was reduced by 62% (* p<0.05 vs. 
IRI) where as 10 ppm H2S had no effect on necrosis. (C) At 1 day of reperfusion hs Troponin-T levels were 
elevated in IRI animals exposed to 0 ppm H2S (## p<0.01 vs. sham). In  the 100 ppm H2S treated group hs 
Troponin-T levels were reduced compared to 0 ppm treated animals (* p<0.05), 10 ppm H 2S had no effect. 
H2S-HYPOMETABOLISM PROTECTS FROM CARDIAC ISCHEMIA 
AN P-gene expression 
mRNA expression of atrial natriuretic peptide (AN P), a marker for induction of the fetal gene program, 
was significantly increased in hearts of mice treated with O ppm H2S compared to sham-operated 
animals at 7 days of reperfusion. In hearts of 10 and 100 ppm H2S treated mice the relative ANP 
expression was significantly reduced compared to mice treated with O ppm H2S (p<0.05) (Figure 3E). 
Inflammation 
One day post-reperfusion, Ly-6G-positive granulocytes were increased 12-fold in animals 
treated with O ppm H 2S compared to sham-operated animals (p<0.001). Exposure to 10 ppm and 
100 ppm H2S reduced granulocytes by 43% (p<0.05) and 60% (p<0.001), respectively (Figure 4). 
NOX2 and NOX4 gene expression 
To investigate ROS-related genes in vivo, we measured mRNA expression of nicotinamide 
adenine dinucleotide phosphate oxidase 2 and 4 (NOX2 and NOX4). At 1 day of reperfusion 
no significant differences were found in NOX2 and NOX4 mRNA expression. Seven days post­
reperfusion, NOX2 and NOX4 expression were significantly increased in hearts of mice treated 
with O ppm H2S compared to sham operated animals (NOX2: p<0.05, NOX4: p<0.01). NOX2 
and NOX4 expression were not amplified in hearts of mice treated with 10 and 100 ppm H 2S 
compared to mice treated with O ppm H 2S (p<0.05) (Figure SA and B). 
Effect of H 2S on ROS production in vitro 
Antimycin A induced ROS production in cultured H9c2 rat cardiomyoblasts was significantly 
reduced by treatment with NaHS. Live cell imaging of DH E fluorescence showed a massive 
increase in cytoplasmatic ROS production during treatment with Antimycin, whereas addition 
of NaHS to the medium markedly reduced this fluorescence signal (p<0.001) (Figure 6). 
DISCUSSION 
The major finding of this study is that administration of hypometabolic concentrations of 
gaseous H2S during myocardial IR limits the extent of myocardial damage. Furthermore, non­
hypometabolic concentrations of H2S do not seem protective in the early phase after myocardial 
infarction, but attenuate ischemia associated processes such as fibrosis and ROS formation. 
Gaseous administration of H2S appears to be an effective way to attenuate the outcome of 
myocardial I RI , with multiple mechanisms seemingly underlying the protective properties. 
H2S is cytoprotective during hypoxia in multiple organs. Beneficial effects of H 2S treatment 
have been reported in models of shock23 and intestinal-24, pulmonary-25, hepatic-21•26 and renal 
ischemia.11 The cardio-protective effects of H2S have been demonstrated in models of myocardial 
injury. However, most of these studies use injection with soluble H2S donor compounds such as 
sodium hydrosulfide (NaHS) or sodium sulfide (Na2S), while no results have been published on 
gaseous H2S.15"18•27 Gaseous administration might be applicable in patients who are being ventilated 
because of cardiogenic shock, a state of brain death or during transplantation procedures. Inhaled 
H2S has beneficial effects in endotoxin induced systemic inflammation28 and in experimental 
m 
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Figure 3 - Cardiac damage is reduced by 10 and 100 ppm H25 at 7 days of reperfusion. 
(A) Representative photomicrographs of Masson stained card iac sections with fibrotic area artificia l ly 
colored red, ind icating the extent of fibrotic damage found in each group at 7 days of reperfusion. (B) 
Card iac IR induced a s ignificant amount of fibrosis in I RI an imals  exposed to 0 ppm H2S (### p<0.001 
vs. Sham).  In  an imals  treated with 10  ppm and 1 00 ppm H2S fibrosis was sign ificantly reduced (** p<0.01, 
* p<0.05 vs. I RI ) .  (C) Expression of fibronectin at 7 days of reperfusion was increased in  I RI an imals (## 
p<0.01 vs . sham). Treatment with 10 and 100 ppm H2S reduced the expression of fi bronectin (* p<0.05, 
** p<0.01 vs. I RI) .  (D) Seven days post- reperfusion hs Troponin-T levels were elevated in I RI an imals 
exposed to O ppm H2S (# p<0.01 vs. sham). Both 1 0  and 100 ppm H2S reduced hs Troponin-T levels by 
59% and 75%, respectively, as compared to ani mals treated with O ppm (* p<0.05, ** p<0.01 vs . I RI) .  (E) 
Expression of ANP m RNA at 7 days of reperfusion was increased in  I RI animals (## p<0.01 vs. Sham). 
Treatment with 10  and 1 00 ppm H2S reduced the expression of AN P (* p<0.05 vs . I RI) .  
Figure 4 
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Figure 4 - H2S reduces cardiac IRI induced inflammation. 
There was a marked increase in granulocyte influx after cardiac ischemia (p<0.001) compared to 
sham animals. Exposure to 10 ppm and 100 ppm H2S significantly reduced the influx of granulocytes 
in the infarct area (10 ppm p<0.05; l00pm p<0.001). Below are representative images from these 
stainings: (A) Sham (B) I RI, 0 ppm H2S (C) I RI ,  10 ppm H2S (D) I RI, 100 ppm H2S. 
Parkinson's disease.29 We previously showed protective effects of gaseous H2S during renal and 
hepatic I Rl .11•21 The benefits of gaseous administration compared to injections with soluble H2S 
donors lay within the management of the concentration. As opposed to injection with H2S donors 
it is possible to administer the gas continuously with a stable dose over longer periods of time. 
Furthermore, when treatment is stopped the effects vanish rapidly while leaving its positive 
therapeutic effects behind. Also, gaseous administration at higher concentrations has proven to 
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Figure 5 - H2S attenuates NOX2 and 
NOX4 upregulation. 
Expression of (A) NOX2 and (B) NOX4 
mRNA was increased in I RI animals at 7 
days post-reperfusion (NOX2: # p<0.05, 
NOX4: ## p<0.01 vs. Sham). Treatment 
with 10 and 100 ppm H2S reduced the 
expression of both genes (* p<0.05 vs. I RI) . 
After 1 day of reperfusion no differences 
were observed between all groups. 
0 ppm 10 ppm 1 00 ppm 
lschemia 
As p revious ly shown, 1 00 p p m  H2S i n duces a hypom etabo l ic  state a n d  lowers b lood p ressure, 





30 A suspended a n im at ion - l ike 
state i n duced by H2S p rotects m ice from letha l  hypoxia for periods up to 6 h o u rs3
7
, suggesti ng 
that the  induct ion of reg u lated,  revers ib le  and we l l -co ntro l led  hypometabo l i sm i n  o rgans  
ho lds cl i n ica l  p ro mise i n  i schemi a - re perfus ion  related damage  where oxyge n  demand  exceeds 
oxygen ava i l ab i l ity. A lthou g h  there was no d ifference i n  card i ac  necros is  between the 10 
ppm treated g ro u p  and O ppm treated gro u p, t reatment with 1 00 ppm s ig n ifica ntly reduced 








CD u C CD 
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ROS-production in H9c2 cells 













Figure 6 - H2S reduces ROS production in cultured cardiomyoblasts. 
(A) Antimycin (50 µg/ml) significantly induced ROS production in H9c2 cells from 24 minutes 
onwards compared to untreated control cells . Addition of 1 mM Na HS prevented the increase in ROS 
production. (# p< 0.001 vs. control; * p<0.001 vs. Na HS) (B) Representative photomicrographs of DH E  
stained H9c2 cells treated with antimycin and NaHS showing less DHE  staining (red) in the NaHS 





with th is  fi nd ing .  This suggests that H2S in non-hypometabol ic concentrations is not effective 
in preventing short-term necrosis caused by ischemia, and that the add itiona l  va l ue  of H 2S­
i nduced hypometabol ism l ies i n  the ea rly phase of I RI .  Although, the protective effects of 
1 00 ppm H2S on necrosis m ight a l so be caused by a larger amount of H 2S lead ing to i ncreased 
ant i -oxidant effects, it is d ifficult to d i sting u ish between the effects of hypometa bol ism and 
other  effects attributed to a h igher dose. However, i nduc ing a suspended an imation- l i ke 
state m ight be restricted to sma l l  an ima l s  l i ke rodents. The a ppl icabi l ity of hypometabo l i sm in 
l a rger  an imals  is sti l l  u nder debate and we a re fa r from developing therapeutic app l ications in 
red uc ing metabol ic rate in the c l i n ical  sett ing  with the use of H2S.19•20•32•33 
There a re a n u m ber of potentia l m echanisms through which H2S may exert its 
card ioprotective effects. Both 10 and 1 0 0  ppm of H2S were proven ant i - infl ammatory as 
evidenced by reduced granu locyte infl ux i nto necrotic a reas. Treatment with H2S a lso lowered 
the infl ux of granu locytes after rena l  I R l .11 Furthermore, H2S inh ibits neutroph i l  adhesion 
and  activation in  response to inflam matory stimu l i  and suppresses the re lease of the pro­
i nfl a m matory med iator tu mor necrosis factor-a l pha. 34•35 Other  studies report that H2S med iates 
pro- infl ammatory effects by potentiating s u lfide p roduction in neutroph i ls36 and med iating 
leu kocyte activation.37 Although g ranu locyte infl ux seems to be reduced by treatment with H 2S, 
l iteratu re is  i nconclus ive on the contribut ion of neutroph i l  i nvas ion to fina l  myocard ia l  infa rct 
s ize and  appears not to be a dominant factor. 38 
We show that treatment with H2S protects aga inst fi brosis at day 7 of reperfus ion, as 
evidenced by reduced col lagen deposit ion and fibronectin  expression. I nteresti ng ly, the 
amount of necrosis d iffers between 10 and 1 00 ppm H2S at day 1 of reperfusion, but this does 
not tra nslate i nto d ifferences in fi brotic a rea s ize after 7 days. This  ind icates that treatment 
with both concentrations of H2S attenuate the onset of fib rosis .  The prevention of fi bros is  is 
in accorda nce with previous l iterature showing decreased cardiac remode l l ing and fi bros is  in 





40 Although we fi nd 
reduced fi brosis with both concentrations of H2S, a bala nced development of fi bros is  rema ins 
essentia l .  Suppressed fi bros is  with no reduction in �he extent of necrosis p redisposes to infa rct 
expansion and tissue ruptu re.41 Since 1 0  ppm H 2S does not affect necrosis 1 day post- reperfus ion, 
the anti-fi brotic effects at day 7 of reperfus ion a re not beneficia l  per se. 
Another functiona l  property of H2S relates to the i nh ib ition of ROS production, s ince the 
imba l ance in redox status and oxidative stress contributes to fib rosis .42 ROS-generating N OX2 
and N OX4 a re both increased after ischemic events i n  experim enta l models and thei r deficiency 
is p rotective in these models .43•44 Seven days post- reperfusion, we found attenuated expression 
of NOX2 and NOX4 in both H2S treated g rou ps ind icat ing less ROS production in  vivo. We did 
not fi nd an a lteration of these genes at 1 d ay of reperfus ion, which is  i n  concordance with 
previous  l iteratu re concern ing N OX2.45 Although it is not possib le  to d istingu ish  whether 
these components or ig inate from the myocard i um or from phagocytes migrated into the 
myocard ium, these resu lts point towards i nc reased oxidative stress i n  the infarcted heart, and 
a poss ib le beneficia l  i nvolvement for the effects of H2S at the later time point.  Furthermore, 
ROS p roduction was ma rked ly red uced in H 2S treated card iomyoblasts in an in vitro model  of 
H2S-HYPOMETABOLISM PROTECTS FROM CARDIAC ISCHEMIA 
Antimycin induced oxidative stress, indicating direct scavenging or reduction in production of 
ROS by mitochondria. H2S has direct scavenging effects on ROS, but also has indirect effects 
via activation of antioxidant mechanisms, such as increasing glutathione levels.46•47 Another 
mechanism that could be involved is the capacity of H2S to modulate cellular respiration, as 
the inhibition of mitochondrial respiration has been shown to protect against myocardial IRI 
by limiting ROS production in mitochondria.48 Antioxidant effects of H2S may be of critical 
importance for the treatment of myocardial IRI because oxidative stress plays a prominent role 
in the development of cardiac damage and remodeling.42 
The effect of exogenous H2S on blood pressure is still under debate. In vivo and ex vivo 
studies revealed conflicting responses to H2S treatment_
49·53 The effects of H2S on heart rate 
are also ambiguous; ranging from no change54 to decreased heart rate in others.50 Ufnal et al. 
noticed an increased heart rate upon Na HS infusion, however dependent on H2S concentration 
in cerebrospinal fluid.55 In additional support of this last view, suppression of H2S production 
either pharmacologically56 or genetically57 leads to an increase in blood pressure. These 
opposing results might be attributable to differences in dose and route of administration. 
In this study we show that 100 ppm of gaseous H2S significantly lowers blood pressure and 
heart rate which might have affected cardiac workload and oxygen demand. Since we did not add 
a group with similar decrease in heart rate and blood pressure or a hypometabolic group with 
normal heart rate and blood pressure, we can not exclude this phenomenon to be responsible 
for the improved outcome. Aside from other protective effects of H2S, it is thought that the 
reduced demand for oxygen during hypometabolism might be one of the protective mechanisms 
during ischemia based on the fact that oxygen availability and oxygen expenditure are more 
balanced. On the other hand the protective effects can not solely be explained by these effects 
since 10 ppm H2S does not alter heart rate and blood pressure and has positive effects on several 
damage parameters. Another approach might be local delivery of H2S by H2S-donors thereby 
circumventing its systemic effects, which has previously been shown to be protective.15 However, 
the highly volatile nature of H2S and the associated difficulties in measuring this compound make 
it difficult to determine the exact dose and how long its effects endure, when given locally. 
In conclusion, gaseous administration of H2S protects the heart from IRI, likely through 
reduction of myocardial ROS production and the inhibition of inflammation, necrosis and 
fibrogenesis. Hypometabolism-inducing concentrations of H2S seem to have additional 
protective effects on necrotic cell death shortly after ischemia. H2S treatment might be of 
clinical use in myocardial ischemia or cardiac transplantation, where it could lead to reduced 
myocardial damage related to hypoxia. 
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Hydrogen sulfide (H2S) is now recognized as the third endogenous gasotransmitter, with similar 
physiological functions to nitric oxide and carbon monoxide. In this study, we investigated whether 
endogenous production of H2S by cystathionine y-lyase (CSE) has protective effects - similar to 
treatment with exogenous H2S - in a renal ischemia setting. We found that CSE is abundantly 
expressed in the kidney, while CSE knockout animals had markedly reduced renal production of 
H2S. CSE deficiency was associated with increased damage and mortality after renal ischemia/ 
reperfusion injury ( IRI). Treatment with exogenous H2S rescued CSE knockout mice from mortality 
and injury associated with renal ischemia. In addition, overexpression of CSE in vitro reduced 
the amount of reactive oxygen species produced during stress. Finally, CSE expression in renal 
transplant donors was positively associated with superior outcome after transplantation. These 
results indicate a role for CSE as a modulator of oxidative stress through the production of H2S. 
CSE MODULATES OXIDATIVE STRESS 
I NT RO D U CT I O N  
In recent years, the fundamental physiological role of hydrogen sulfide (H2S) has gradually been 
uncovered. H2S is now acknowledged as the third endogenously produced gaseous signaling 
molecule, in addition to nitric oxide (NO) and carbon monoxide (C0)1 • H2S is generated from 
the amino acid L-cysteine by three distinct enzymes: cystathionine y-lyase (CSE), cystathionine 
�-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (MPST)2 • In the cardiovascular 
system, CSE is the most abundantly expressed protein, and is responsible for the majority of 
endogenous H2S production3. The physiologic properties of endogenously produced H2S are 
remarkably similar among the different gasotransmitters. H2S functions as an endothelial­
cell derived relaxing factor (EDRF) similar to N04• Accordingly CSE deficient mice (CSE·1·) 
develop hypertension3, analogous to mice lacking endothelial nitric oxide synthase (eNOS)5 
and css•1· mice6• In addition, endogenously produced H2S is involved in cellular proliferation7, 
angiogenesis8, inflammation9•1 0  and regulation of protein activity through S-sulfhydration11·13 _ 
Exogenous treatment with H2S can induce a reversible hypometabolic, hibernation­
like state14• The proposed mechanism behind H2S -induced hypometabolism is through 
the reduction of mitochondrial activity by reversible binding to cytochrome c oxidase, the 
terminal enzyme in the electron transport chain15• During hypoxia, H2S treatment ameliorates 
the reduction in the function and integrity of mitochondria16-18• The lower demand for oxygen 
during hypometabolism can protect animals from hypoxia or shock, and organs from ischemia/ 
reperfusion injury16•17•19•20• Exogenous H2S can play a detoxifying role during oxidative stress by 
directly scavenging reactive oxygen/nitrogen species (ROS/RNS) as well as increasing the 
formation of the antioxidant glutathione (GSH)21•22• 
In this study we found that CSE deficiency in mice led to reduced renal H2S production 
and was associated with increased mortality and severity of damage after renal ischemia/ 
reperfusion injury. Administering exogenous H2S rescued these mice from mortality and injury 
associated with renal ischemia. Our in vivo experiments together with in vitro cell studies in 
which CSE is overexpressed highlight the fundamental role CSE has in regulating the amount of 
ROS associated with hypoxic stress. In addition, we notably found that CSE mRNA and protein 
levels were shown to be associated with kidney outcome after transplantation. Together, our 
data reveal CSE as a modulator of oxidative stress induced following renal ischemia. 
R ES U LTS 
Localization of CSE in control hu man renal tissue 
In human renal tissue, CSE protein was localized to glomeruli and tubulo-interstitium. Glomeruli 
were homogenously positive for CSE. Non-endothelial (CD31-negative) glomerular cells 
showed positive staining in addition to (CD31-positive) endothelial cells, indicating expression 
in mesangial cells and/or podocytes. (Figure lA). CSE was seen in tubular epithelium - proximal 
as well as distal (Figure 1B), peritubular capillaries (Figure l C), and vascular endothelium (Figure 
l D). The protein was observed in an unidentified intracellular staining pattern, showing a distinct 





cells (Figure 1 B). TissueFAXS analysis showed that 75% of renal cells were positive for CSE (Figure 
l E). Moreover, when we investigated endothelial cells, we found that 87% of endothelium was 
positive for CSE (Figure 1 F). Transplant biopsies showed similar localization and staining pattern 
as the control renal tissue (data not shown). 
CSE  m RNA levels are modu lated after renal ischemia in rats 
The expression of CSE mRNA was modulated after ischemia in control rat kidneys. Early time points 
show an increase in renal CSE mRNA (90 minutes), after which expression decreased to significantly 
lower levels compared to basal levels (Figure 2A). At 1, 2 and 4 days after ischemia mRNA levels were 
decreased after which mRNA levels normalized to basal values after 9 days and afterwards (Figure 
2A). The expression of CBS was modulated in a temporally similar pattern (Figure 2B). 
CSE but not CBS mRNA expression levels were altered during the transplant process 
CSE mRNA levels were significantly increased after reperfusion (p<0.01) (Figure 2C). Expression levels 
were (Median [range]): procurement 0.67 [0.03-1.66], pre-implantation 0.41 [0.08-1.75], reperfusion 
0.93 [0.15-3.65]. CBS mRNA levels were not modulated during the transplant process (Figure 2D): 
Procurement 0.20 [0.001-1.99], pre-implantation 0.23 [0.007-1.09], reperfusion 0.20 [0.02-0.86]. 
Modu lation of CSE p rotein levels d uring the transplant process 
CSE immunofluorescence was performed on a limited number of renal transplant biopsies 
(n=27). No differences in protein levels were detected between pre-implantation and 
reperfusion time points (Figure 2E). 
CSE  deficient mice have reduced renal H 2S production 
Kidneys from untreated wildtype (WT) and CSE knockout (CSE·1·) animals were examined to 
confirm that CSE deficiency caused reduced production of H2S in renal tissue. Renal weight 
did not significantly differ between WT and CSE·1· mice (data not shown). CSE-I- mice had a 91% 
reduction in renal H2S production compared to WT mice (p<0.05, Figure 3A). 
Increased mortal ity after bi lateral renal ischemia in CSE deficient mice 
Mortality after IRI was significantly higher in the CSE-I- animals, where 35% (5/14) of animals 
died within the first 24 hours, while WT animals showed 0% (0/14) mortality during this period 
(p<0.05, Figure 3B). CSE·/· animals could be rescued by pretreatment with NaHS, with 11% (1/9) 
mortality compared to 0% (0/9) in WT animals (p=ns, Figure 3 C). 
CSE deficient mice d isp lay more severe kidney damage and decreased renal 
function after I R I com pared to WT mice 
No necrosis was detected in kidneys of sham-operated mice, while all kidneys subjected to IR 
showed tubular necrosis in the cortico-medullary transition area. CSE+ animals showed 60% 
higher levels of necrosis compared to WT animals (p<0.01, Figure 3D, representative examples in 
Figure 3F, representative photomicrographs in Supplementary figure 1). The amount of necrosis 
was reduced by treatment with Na HS regardless of genotype. Renal function as measured by 
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Figure 1 - Local ization of CSE in control human rena l  tissue. 
Representative examples of the localization of CSE (green) and the colocalization with CD31 positive 
cells (red). CSE is localized in (A) the glomerulus (endothelial and mesangial cells), (B) tubules, (C) 
peritubular capillaries (colocal ization of CSE with CD31 is seen as yellow in the merged images, and 
is marked by white arrowheads. Image is a magnification from (B)) and (D) vascular endothelial cells 
(white arrowheads). I n  (D), a specific autofluorescence of the elastic laminae is demarcated in dashed 
l ines. CSE is expressed in proximal and distal renal tubules (A,B,C) in an unidentified subcellular 
stain ing pattern.  Original magnification: 630X. (E) TissueFAXS analysis of the total amount of CSE­
expressing cel ls in the kidney of six control kidneys, indicating that 75% of renal cells express CSE. 
(F) Of all renal endothelial cells, the large majority express CSE. (G) The variation between control 
patients in the abundance of CSE and CD31 expressing cells. 
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P r o c u r e m e n t  P r e - i m p l a n t a t i o n  R e p e r f u s i o n  
F i g u r e  2  - T i m e - c o u r s e  e x p r e s s i o n  o f  C S E / C B S  a f t e r  i s c h e m i a / r e p e r f u s i o n .  
R e n a l  e x p r e s s i o n  o f  ( A )  C S E  a n d  ( C )  C B S  a t  v a r i o u s  t i m e  p o i n t s  i n  t h e  fi r s t  2 1  d a y s  a ft e r  r e n a l  i s c h e m i a  i n  r a t s  ( n
=
S - 6  a n i m a l s  p e r  g r o u p ) .  C S E  m R N A  i s  i n c r e a s e d  
i n  t h e  a c u t e  s t a g e ,  a n d  b o t h  a r e  r e d u c e d  i n  t h e  m e d i u m - l o n g  t e r m ,  a n d  n o r m a l i z e d  a f t e r  9  d a y s  ( *  - p < 0 . 0 5 ;  * *  - p < 0 . 0 1 ;  * * *  - p < 0 . 0 0 1 ) .  ( B )  C S E  p r o t e i n  
a b u n d a n c e  a s  m e a s u r e d  b y  W e s t e r n  b l o t ,  s h o w i n g  s i g n i fi c a n t l y  r e d u c e d  C S E  p r o t e i n  a t  4 ,  1 4  a n d  2 1  d a y s ( *  - p < 0 . 0 5 ;  * *  - p < 0 . 0 1 ,  n
=
3 - 5  a n i m a l s  p e r  g r o u p ) .  U n d e r  
e a c h  b a r  r e p r e s e n t a t i v e  p r o t e i n  b a n d s ,  a l l  f r o m  t h e  s a m e  b l o t .  E x p r e s s i o n  o f  C S E  m R N A  ( D )  a n d  C B S  m R N A  ( F )  i n  h u m a n  d o n o r  b i o p s i e s  a t  d i f f e r e n t  t i m e  
p o i n t s  d u r i n g  t h e  t r a n s p l a n t  p r o c e s s .  C S E  e x p r e s s i o n  a t  r e p e r f u s i o n  i s  s i g n i fi c a n t l y  i n c r e a s e d  c o m p a r e d  t o  p r e - i m p l a n t a t i o n ( * *  - p < 0 . 0 1 ) .  ( E )  N o  s i g n i fi c a n t  









CSE MODULATES OXIDATIVE STRESS 
animals compared to WT animals after IRI. Pretreatment with Na HS significantly improved renal 
function in CSE-I- animals (p<0.001, Figure 3E). In sham-operated animals creatinine levels were 
similar, indicating that renal function in untreated CSE-I- is not impaired (Figure 3E). 
Renal inflam mation after renal ischemia/reperfusion 
Granulocyte influx as measured by Ly-6G immunohistochemistry showed an increase in 
granulocytes after ischemia in both WT and CSE-I- animals, which was abrogated by NaHS 
treatment regardless of genotype. There was no difference in the amount of granulocytes 
between WT and CSE·1· animals (Figure 3G). 
CSE mice display increased levels of DNA damage after ischemia/reperfusion 
In order to determine the extent of oxidative damage after IRI we carried out immunofluorescence 
staining for yH2AX, a marker for DNA double strand breaks (DSBs) on kidney sections from 
CSE deficient and WT mice. yH2AX plays an important role in the DNA damage response and 
is necessary for the initial rapid phase of DSB repair. pyH2AX is a proven marker of oxidative 
stress23. We found phosphorylated yH2AX positive cells in the cortical tubular cells of mice after 
I RI the amount of positive cells was significantly higher in CSE-I- mice compared to WT mice (Figure 
4A). Pretreatment with NaHS reduced the amount of pyH2AX positive cells in both WT and CSE 
deficient mice but did not reduce the amount of positive cells to sham injury levels (Figure 4A). 
Proliferation after renal ischemia/reperfusion 
Ki67 staining indicated that CSE·1· animals did not have increased proliferation after IR I  (Figure 
4B). The amount of Ki67 positive nuclei was significantly increased after NaHS treatment in 
combination with IRI in CSE-I- animals, but not in the WT animals (Figure 4B). 
Renin is not differentially expressed in wildtype and CSE·/- mice 
lmmunohistochemistry for renin showed its expression in the juxtaglomerular cells. When the 
amount of glomeruli with renin-positive juxtaglomerular cells were counted, no significant 
differences between the groups were found (Figure SA). The number of renin-positive 
juxtaglomerular cells per glomerulus did not differ between groups (Figure SB). The lack of renal 
H2S production in CSE-I- mice does not affect renin levels, nor does the treatment of wildtype or 
CSE·1· animals with Na HS. IRI also does not affect renin levels 24 hours after ischemia. 
Cell viability, EGFP fluorescence and CSE protein abundance after transfection 
Transfection with the pl RES2- EGFP or pl RES2-EGFP- CSE plasmids did not affect viability of 
HEK293 cells between 1 and 4 days after transfection (Figure 6A). Both plasmids increased the 
amount of EGFP fluorescence between 1 and S days after transfection, reaching a peak between 
3-4 days (Figure 6B). The amount of EGFP fluorescence was not significantly different between 
the two plasmids. Western blot at 72 hours after transfection showed no effect of mock­
transfection with pIRES2-EGFP on CSE protein, while the pl RES2-EGFP- CSE plasmid induced a 
6-fold increase in the band density for CSE (Figure 6C). The amount of H2S in the supernatant 
medium of the p lRES2-EGFP- CSE transfected cells did not significantly differ from the H2S levels 
in the control and pl RES2-EGFP transfected groups (Figure 6D). 
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Figure 3 - Renal H2S production, survival, rena l  function, necrosis and inflammation in CSE-I- mice 
after ischemia/reperfusion. 
(A) Renal H2S production rate is sign ificantly lower in CSE·/· mice compared to WT mice (* - p<0.05, n=4 
per group). (B) Animal survival after renal  I RI is impaired in the CSE-I- animals (p<0.05, n=14 per group). 
(C) Treatment with Na HS rescues CSE·1 mice from I RI- induced mortality (p=ns, WT: n=7; CSE -I· : n=9). (D) 
The amount of renal cortical necrosis is significantly higher i n  CSE-I- mice (n=9) compared to WT (n=l4), 
while pretreatment with Na HS reduces necrosis in both WT (n=7) as well as CSE /· mice (n=8) (** - p<0.01; 
*** - p<0.001, WT Sham: n=9; CSE-I- Sham: n=8). (E) Plasma creatinine levels ind icate reduced renal function 
after ischemia in CSE-I· (n=9) compared to WT mice (n=14). Na HS treatment protected CSE I mice (n=8) 
from the I RI- induced decline in renal  function (* - p<0.05; *** - p<0.001, WT Sham: n=9; CSE·1 Sham: n=8). 
(F) Representative examples of PAS-stained coronal rena l  sections from WT and CSE·/· animals with the 
necrotic area artificially colored red. (G) I nflux of Ly-6G-positive granulocytes was not affected by CSE 
deficiency (CSE·1·: n=9, WT: n=14). Granu locyte influx was reduced in both WT (n=7) and CSE-I- an imals 
(n=8) after Na HS pretreatment (** - p<0.01; *** - p<0.001, WT Sham: n=9; CSE I Sham: n=8) . 
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Figure 4 - Expression of pyH2AX and Ki67 in WT and cse·1· animals after ischemia/reperfusion. 
(A) Abundance of the phosphorylated DNA-repair protein yH2AX is significantly higher in CSE·/· animals 
after I RI (n=9) compared to WT animals (n=14), indicating an increased amount of DNA double strand 
breaks, possibly related to oxidative DNA damage. (B) After I RI, the expression of the nuclear proliferation 
marker Ki67 is not increased in CSE-I- animals (n=9) compared to WT (n=14), but significantly increased 
after Na HS pretreatment and IRI combined (n=8, WT Sham: nc9; CSE·1· Sham: n=8). 
Effects of exogenous NaHS and CSE overexpression on mitochondrial and overall 
superoxide 
Antimycin A-induced oxidative stress as measured by DHE fluorescence in HEK293 cells was 
concentration dependently reduced by treatment with NaHS. Antimycin induced a 48 fold 
increase in DHE fluorescence which was significantly attenuated by Na HS at 10 µM, 100 µM and 
1 mM (Figu re 6E). Mitochondrial superoxide production as assessed by MitoSOX fluorescence 
showed a similar pattern, with a 13.5 fold increase in fluorescence, which was significantly lower 
when treated with 10 µM, 100 µM or 1 mM Na HS (Figure 6G). 
Treatment with Antimycin A showed an increase in DHE (Figure 6F) and MitoSOX (Figure 6H) 
fluorescence in all groups. Fluorescence intensity was similar in control and plRES2-EGFP transfected 
groups, while cells overexpressing CSE showed a significantly reduced amount of fluorescence. The 
reduction was 60% when measured using DHE (Figure 6F, red bar), and 74% using MitoSOX (Figure 
6H, red bar). Treatment with 1 mM of Na HS reduced the amount of fluorescence of both probes in all 
groups except the CSE overexpressing cells loaded with MitoSOX (Figure 6H, red bars). 
Association of CSE and CBS mRNA expression pre-transplantation and renal 
function after transplantation 
CSE mRNA levels at organ procurement were positively associated with renal function 14 days 
after transplantation, as measured by glomerular filtration rate (GFR). Linear regression analysis 
showed that the association significantly deviated from zero (p=0.007), and the goodness of 
fit (R2) was 0.3146 (Figu re 7A). Relative CBS mRNA levels did not associate with renal function 
after transplantation, showing no significant deviation from zero (p=0.16) and low goodness of 
fit with an R2 of 0.0262 (Figure 78). 
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Figure 5 - No difference in renin expression between genotypes or between treatment groups. 
(A) Percentage of g lomeru l i  which had ren in -positive juxtaglomeru la r  cel ls and (B) amount of ren in­
positivejuxtag lomeru lar  ce l l s  per  glomeru lus  i n  the d ifferent groups d id  not d iffer. (C) Representative 
examples of g lomerul i  with ren in-positive juxtag lomerular cel ls .  Orig ina l  magnification 200x. 
Figure 6 [Opposite page] (A) Cell via bi l ity was not affected by transfection with pl RES2-EGFP or ► 
p l RES2-EGFP-CSE vectors. (B) EGFP fl uorescence i ntensity after transfection, showing peak values 
between 72-96 hours after transfection with both control and CSE vector. (C) CSE protein as measured 
by western blot showed an increase of 6x after 72 hours after transfection with plRES2-EGFP-CSE 
vector (*** - p<0.001), while there was no increase i n  CSE expression i n  the plRES2-EGFP transfected 
cells compared to controls (representative bands from the same gel a re shown). (D) No d ifferences in  
supernatant H2S were measured . (E)  Antimycin induced cytoplasmatic ROS production as measured 
by D H E  fluorescence was significa ntly and concentration dependently attenuated by treatment with 
NaHS (### - p<0.001 vs -NaHS, -Antimycin; * - p<0.05; *** - p<0.001 vs -NaHS, +Antimycin) .  (F) DHE 
fluorescence is not affected by transfection with the pl RES2-EGFP vector, but  sign ificantly reduced by 
transfection with p l RES2-EGFP-CSE.  Treatment with NaHS further reduces DHE fluorescence intensity 
in a l l  g roups (* - p<0.05; *** - p<0.001). (G) Mitochondria l  superoxide production, as measured with the 
fluorescentMitoSOX probe, is significantly and concentration dependently reduced by Na HS treatment 
(# - p<0.05; ### - p<0.001 vs -NaHS, -Antimycin; ** - p<0.01 vs -NaHS, +Antimycin). (H) p l RES2-EGFP 
transfection does not affect MitoSOX fluorescence after antimycin treatment, while plRES2-EGFP-CSE 
transfection significantly reduces the a mount of mitochondria l  superoxide produced (* - p<0.05; *** 
- p<0.001) .  Add ition of NaHS did not produce sign ificant additional effects in the pl RES2-EGFP-CSE 
transfected ce l ls .  Data a re representative of at least three independent experiments. 
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Figure 7 - Association between renal CSE/CBS mRNA and outcome after human renal transplantation. 
(A) Renal CSE mRNA level at organ procurement is associated with the glomerular filtration rate at 
14 days after transplantation, with higher expression associating with better renal function (R2=0.315, 
p<0.001, n=33). Renal CBS levels at procurement are not associated with outcome after renal 
transplantation (R2=0.026, p=ns, n=32). Lines denote best fit, with the dashed l ines representing the 
95% confidence interval for best fit. 
DISCUSSION 
Over the past decades, the perceived image of H2S has transformed from that of a dangerously 
toxic molecule to that of an endogenously produced gas affecting many physiological processes. 
The similarities between H2S and the other gasotransmitters are numerous
1
·2• In this study, we 
show that the endogenous production of H2S reduces the damage associated with renal ischemia/ 
reperfusion injury. In previous papers, others and we have previously demonstrated the highly 
protective effects of exogenously applied H
2
S treatment in similar models of ischemia16•17•19•24-27• 
From the present study it now becomes clear that after renal hypoxic stress, CSE functions as an 
endogenous mediator of the antioxidant response, most likely through the production of H2S. 
This study shows that CSE is abundantly present in the normal human kidney, with widespread 
expression in the tubules. We found that the majority of renal tubules stain positive for CSE, which 
aligns with a previous study indicating that CSE activity was found in all segments of the renal 
tubule, with the highest activity in the proximal straight and distal tubules28• The large majority 
of renal endothelial cells express CSE. In CSE deficient mice, renal H2S production was reduced 
by more than 90%, indicating that CSE is the most essential H2S producing enzyme in the kidney. 
There was a clear association between the absence of CSE expression in the CSE-I- mice and an 
increase in renal damage after IRI. Mortality, renal failure and tubular necrosis were significantly 
increased when renal H2S production was low. Treatment with exogenous Na HS rescued these 
animals from death and renal failure. The absence of CSE expression did not influence the 
CSE MODULATES OXIDATIVE STRESS 
Table 1 - Characteristics of the human kidney donors analyzed in the different analyses performed 
in this paper. 
Sex (Male:Female) 
Age, years (Mean [Range]) 
Donor type (Living :Brain dead) 
Cold ischemia time, minutes (Mean [Range]) 
Warm ischemia time, minutes (Mean [Range]) 
Delayed graft function 





39 [13-91 ] 
11 
9 
inflammatory response. This indicates that endogenous production of H2S does have the anti­
inflammatory effects that the concentrations afforded by exogenous H2S treatment has in this 
model16• Others have shown the inhibitory effects of endogenously produced H2S by CSE on 
leukocyte adhesion 9. We have no indication of the actual plasma concentrations and, perhaps 
more relevant, the intracellular concentrations caused by CSE/CBS/MPST activity relative to 
those brought by exogenous H2S. This means that, in this model, the concentrations needed 
to produce anti-inflammatory effects might be too high to be reached by endogenous H2S 
production. The known inhibitory effects of H2S on inflammatory processes are likely absent 
in the CSE-I- mice, so increased influx of leukocytes was expected in this model, especially with 
the increased renal damage in the CSE-I- mice. The results indicate that CSE deficiency can also 
influence the inflammatory response to injury through an unknown mechanism. 
Excessive generation of ROS following injury damages proteins, DNA, mitochondria and lipids 
and can stimulate the immune system leading to organ damage29• Hydroxyl radicals can also react 
with nearby tissues, resulting in cellular DNA damage30• Phosphorylated yH2AX is a well-known 
marker of DNA damage and, in particular, of DSBs31. Phosphorylated yH2AX is the first step in 
recruiting and localizing DNA repair proteins. We found more DSBs as detected by yH2AX staining 
in the kidneys of CSE mice after IRI compared to WT. Pretreatment of NaHS was associated with 
reduced amounts of DNA damage together with all the other parameters of renal injury. Our present 
results show severe DNA damage in CSE·1· mice was associated with a reduced but not significant 
number of Ki67 positive cells (hence; cell proliferation) when compared to WT mice. 
Proliferation is affected by CSE, as Ki67 immunofluorescence showed. CSE activity or the 
availability of H2S seems to be a necessity for the induction of proliferation in this model, as 
IRI by itself does not induce Ki67 expression in CSE-I- animals, but the combination of I RI and 
Na HS treatment induces high expression of this protein. Interestingly, treatment of wildtype 
animals with NaHS during IRI seems to inhibit proliferation, which correlates with the amount 
of renal cell damage in this experiment, indicating that the protective effects seen in wildtype 
animals are not due to an increase in regeneration. These results contrast earlier work, where 
CSE deficiency caused overproliferation in vascular smooth muscle cells 7. 
Since CSE-I- animals develop higher blood pressure compared to wildtype after 6 weeks (a rise 
of about 10 mm Hg at 7 weeks)3, the differences between groups could be related to differences 
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in renal perfusion before or after the ischemic event. To investigate this, we measured renin 
expression in the juxtaglomerular apparatus (Figure 5 A-C). We found no differences between 
wildtype and CSE-/- mice, nor between IRI and Na HS treated groups. This indicates that there were 
no large differences in renal perfusion between the groups, and that the increase in renal damage 
after IRI in the CSE-/- animals, nor the protective effects of NaHS can be explained by altered 
perfusion. Ming et al. recently showed that H2S can inhibit renin expression in a 2KlC model, 
but it did not affect expression in sham or unclipped kidneys32 • We noted no effect of NaHS on 
renin expression, suggesting that H2S can inhibit an increase in renin levels, but does not affect 
normal renin levels. However, renin protein levels have to be regarded as a crude marker for renal 
perfusion, for which changes van can only be detected with large perfusion differences. 
In vitro experiments showed that exogenous H2S treatment concentration-dependently 
reduced the amount of intracellular ROS production when stimulated with Antimycin. A 
significant effect was reached at low concentrations. Overexpression of CSE showed a reduction 
in oxidative stress that was similar to ~ 10 µM of Na HS. This concentration is close to the most 
quoted physiological range of 30-300 µM in human serum, but the actual physiological 
concentration in mammals is still up for discussion33 • The addition of 1 mM NaHS showed a 
further reduction in DHE fluorescence, which might indicate that overexpression of CSE did 
not induce supraphysiological concentrations in this particular model. The fact that we did not 
find a significant increase in supernatant H2S concentration after CSE overexpression is not 
unexpected, since H2S rapidly evaporates from solution at physiological pH
34 or from serum33 • 
Whether H2S directly scavenges ROS, increases the intracellular GSH levels or reduces 
the amount of ROS produced through modulation of mitochondrial ROS production was not 
assessed by this study. H2S can exert all these effects
2
, so the protective and antioxidant effects 
demonstrated here could be the result of multiple mechanisms acting simultaneously. One 
previous study assessed the effects of CSE overexpression in a murine model of myocardial 
infarction. Myocardium-specific overexpression of CSE nearly doubled H2S production and 
reduces myocardial infarct size by 47%17• Other studies have shown the effects of inhibitors of 
CSE and CBS in ischemic models, but the specificity of these inhibitors is subject to discussion35• 







Interestingly, recent data suggests that under stress CSE can translocate to mitochondria, and 
H2S produced by mitochondrially located CSE can be used as a substrate for the production of 
ATP39• This might be an additional protective mechanism in the setting of ischemia/hypoxia. 
The association between the mRNA expression of CSE and the outcome after human renal 
transplantation is an indication that CSE could have protective effects in human ischemia/ 
reperfusion injury similar to those we have found in murine models. The observation that CBS is 
not differentially expressed during the transplant process, nor is associated with outcome after 
transplantation, indicates a central role for CSE in human renal tissue. We found an increase in 
mRNA expression of CSE shortly after reperfusion in humans, which was similar to the results 
from rats. The decrease in CSE expression found at the later time points after reperfusion in 
the murine model could not be confirmed in the human study due to the absence of biopsies 
late after reperfusion. The question remains whether this early decrease is associated with 
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a functional mechanism where CSE is downregulated or inhibited during renal repair and 
regeneration, or the inflammatory response to injury. 
Taken together, our data reveal a key role for CSE in the regulation of oxidative stress 
induced following renal ischemia, most likely through the production of H2S. The modulation 
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Supplementary Figure 1. Representative photomicrographs showing structural damage caused by 
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CONCISE MATERIALS AND METHODS 
Collection of hu man material 
Human renal transplant biopsies were obtained from brain-dead or living donors (n = 50) at three 
different time points: just before donation (before start of preservation), at the end of cold ischemia 
and approximately 45 min after reperfusion in the recipient. Control kidneys were taken from the 
unaffected part of kidneys from patients undergoing nephrectomy for renal cell carcinoma (n=6). 
Ani mals 
CSE deficient mice (CSE-I-) were generated using conventional techniques as described before3• 
Wildtype C57BL/6J littermates (WT) were used as control animals. Male Wistar rats (250-300 g) 
were used for time-course experiments. 
I RI protocol 
Renal ischemia/reperfusion in mice was performed as described previously1 6. In short, both 
renal pedicles were clamped for 30 minutes using non-traumatic vascular clamps through 
a midline abdominal incision under general anesthesia (ketamine/xylazine). Core body 
temperature was maintained at 37° C in all groups using heat pads and lamps. Na HS injection (1 
mg/kg) was given intraperitoneally 15 minutes before clamping. Mice were terminated after 1 
day of reperfusion and samples were collected. 
Cell culture experi ments 
To generate CSE overexpressing cells, human embryonic kidney 293 (HEK293) cells were 
transfected with the p lRES2-EGFP (mock) or pl RES2-EGFP-CSE vector in 24- or 96-well plates. For 
induction of ROS, Antimycin A (50 µg/ml) with or without Na HS (1-1000 µM) was given for 30 min. 
Subsequently, cells were incubated with 15 µM dyhidroethidine or 5 µM MitoSOX for 1 5  minutes. 
Renin measurement 
Ren in immunohistochemistry was performed as described before41• Subsequently, the amount 
of glomeruli with renin-positive juxtaglomerular cells were counted. In a second analysis, the 
amount of renin positive cells per glomerulus were counted. For both measurements, the 
complete cortex was analyzed in a blinded fashion. 
TissueFAXS analysis 
CSE-Alexa 488 / CD31-TRITC / DAPI triple stained sections were scanned using a fluorescent 
microscope fitted with an automated acquisition system (TissueFAXS, TissueGnostics GmbH, 
Vienna, Austria). Percentages of CSE+, CD31+ and CSE+ CD31+ cells were measured using TissueQuest 
software (TissueGnostics), using an algorithm based on the recognition of nuclei and their associated 
cytoplasm. Ki67 and yH2AX stained sections were quantified in this manner as well. 
Statistical analysis 
Data were analyzed using Mann-Whitney U tests, One-Way AN OVA or Kruskall Wallis tests where 
appropriate. Bonferroni or Dunns postcorrection was applied where multiple comparisons 
CSE MODULATES OXIDATIVE STRESS 
were made. Normality was tested using the Kolmogorov-Smirno test. A value of p<0.05 was 
considered statistically significant. Data are expressed as the mean ± SEM (Standard Error of the 
Mean) unless otherwise indicated. 
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FULL MATERIALS AND METHODS 
Collection of human renal transplant biopsies 
Cortical kidney needle biopsy specimens were taken from donors (n=50) during procurement, 
p re-implantation, and -45 min after reperfusion. Biopsy specimens were taken using a 16-gauge 
needle (Acecut, TSK Laboratory, Japan). Biopsies were fixed in 4% formalin for paraffin embedding 
or snap frozen in liquid nitrogen and stored at -80°C for mRNA isolation. Some donor kidneys 
were obtained outside our medical center, which impeded the collection of some biopsies at the 
p rocurement time point. Some kidneys were retrieved at our hospital, but allocated outside our 
medical center, obstructing the collection of some pre-implantation and reperfusion biopsies. 
Subjects were included when the following criteria were fulfilled: donor and recipient age 
between 18 and 70 years; cold ischemic time less than 25 hours; anastomosis time less than 60 
min; no reclamping after completing the anastomosis; and fi rst kidney recipients. 
Collection of control renal tissue 
Control human renal tissue used for analysis of normal CSE expression patterns was taken from 
the unaffected part of kidneys removed for the treatment of renal cell carcinoma (n=6). 
RNA isolation and real-time PCR analysis 
A nucleosin II RNA isolation kit (Macherey- Nagel GmbH, Germany) was used. RNA was 
eluted in 20 µI of RNase-free water. RNA concentration was measured using a Nanodrop 
spectrophotometer. RNA quality was confirmed by agarose gel electrophoresis. For cDNA 
synthesis, 1 µg of RNA was used and reverse transcription was performed with a Quantitect 
Reverse Transcription kit (Qiagen GmbH, Germany). Gene expression assays -were bought 
from Applied Biosystems. (Foster City, Ca, USA). For human PCR; CBS: Hs00163925_ml, CSE: 
Hs00542284_ml. HPRT was custom made, with sequence: F: 5'-GGCAGTATAATCCAAAGATG 
GTCAA-3'; R: 5'-GTCTGGCTTATATCCAACACTTCGT-3'. For rat material; CBS: Rn00560948_ml, 
CSE: Rn00567128_ml. HPRT was custom made, with sequence: F: 5'-GCCCTTGACTATAATGA 
G CACTTCA-3'; R: 5'-TCTTTTAGGCTTTGTA CTTGGCTTTT-3'. Changes in CSE, CBS and HPRT 
mRNA were confirmed by two-step quantitative RT-PCR on an AB Prism 7900HT Sequence 
detector (Applied Biosystems). The PCR profi le consisted of 15 min at 95° C, followed by 40 
cycles with heating of 95° C for l 5  s and cooling to 60° C for l min. Data were analysed with SDS2.3 
(Applied Biosystems). All results were normalized to the expression of HPRT in the sample. 
lmmunofluorescence 
lmmunofluorescent labeling was performed as described previously. Briefly, Cryosections (4 
µm) were dried and acetone fixed. Primary antibodies were applied for 1 hour, and thereafter 
incubated with appropriate secondary antibodies for 30 minutes. Slides were mounted in Aqua/ 
polymount (Polysciences Inc., Warrington, PA, U SA) containing DAPI (1. 5  µg/ml). The following 
primary antibodies were used: mouse monoclonal CSE (kindly donated by dr. N. Nishi, Kagawa 
Medical School, Japan). Mouse monoclonal CD31 (Dako), Rabbit polyclonal Ki67 (Abeam), and 
mouse monoclonal yH2AX (Millipore). Secondary antibodies include Alexa Fluor 488 rabbit anti-
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mouse lgG2a (lnvitrogen), TRITC-conjugated rabbit anti mouse lgGl (Southern Biotech), Alexa 
Fluor 488 goat anti-mouse lgGl (lnvitrogen), Cy3-conjugated goat anti-rabbit lgG (lnvitrogen) 
TissueFAXS analysis 
CSE-Alexa 488 / CD31-TRITC / DAPI triple stained sections were scanned using a fluorescent 
microscope (Zeiss AxioObserver.Zl, Carl Zeiss AG, Oberkochen, Germany) fitted with an 
automated acquisition system (TissueFAXS, TissueGnostics GmbH, Vienna, Austria). Non­
representative images of the section were removed (e.g. folds, edges). Percentages of CSE+, 
CD31+ and CSE+CD31+ cells were measured using TissueQuest software (TissueGnostics), 
using an algorithm based on the recognition of nuclei and their associated cytoplasm. In 
human renal transplant biopsies, intensity of the fluorescence signal was measured in the 
cytoplasm using the TissueQuest software. In addition, Ki67 and yH2AX stained sections were 
quantified in this manner. Random backgating analysis was performed in each sample, where 
negativity, positivity, and double positivity of cells in the scatterplots was confirmed by manual 
investigation of the associated photomicrograph. 
Ly-6G and renin immunohistochemistry 
lmmunohistochemical staining for Ly-6G/C positive granulocytes was performed as described 
previously1. In short, paraffin embedded sections were stained for Ly-6G using rat-anti-mouse 
Ly6G/C-FI TC lgG2b antibody, followed by rabbit-anti -FITC and HRP-conjugated goat-anti ­
rabbit antibodies. Full slide images were captured at  40x magnification using a Hamamatsu 
NanoZoomer 2.0HT, and images were analysed using HistoQuest software (TissueGnostics). 
For renin, we used a polyclonal antibody as described before2.3. 
Measurement of necrosis 
Formalin fixed, paraffin embedded coronal renal sections were stained using the Periodic Acid 
Schiff (PAS) method using standard procedures. Whole slides were digitized using an Aperio 
ScanScope digital slide scanner (Aperio Technologies inc, Vista, Ca, USA) at 20x magnification 
and the accompanying Aperio lmagescope software was used to measure the necrotic renal 
cortical area relative to the total renal cortical area. 
Plasma biochemical analysis 
Creatinine measurements were performed by our hospital clinical chemistry research services 
using conventional methods. 
Renin measurement 
Subsequently, the amount of glomeruli with renin-positive juxtaglomerular cells were counted. 
In a second analysis, the amount of renin positive cells per glomerulus were counted. For both 
measurements, the complete cortex was scanned in a blinded fashion. 
Animals 
For renal IRI and H2S production rate measurement studies, CSE deficient mice (CSE·1·) were 
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(WT) were used as control animals .  Time-course expression of CSE mRNA after IRI was examined 
in male Wistar rats (250-300 g; Harlan, Zeist, the Netherlands, n=6 per group). 
I R I protocol 
In mice, both renal pedicles of WT or CSE I- animals (n=9-14 per group) were clamped for 30 minutes 
using non-traumatic vascular clamps through a midline abdominal incision under general anesthesia 
(100 mg/kg ketamine, 8 mg/kg xylazine). After removing the clamps, kidneys were inspected for 
restoration of blood flow and the muscle and skin layers were sutured with 5-0 vicryl stitches (Eth icon, 
New Jersey, USA). Body temperature was maintained at 37° C using heat pads and lamps. Sham­
operated animals received the exact same procedure, without placement of the clamps on the renal 
pedicles.  Treatment with Na HS (1 mg/kg, freshly dissolved in sterile phosphate buffered saline (PBS)) 
was given 15 minutes before application of the clamps through an intra peritoneal injection. Control 
animals received an injection of PBS at that time. Mice were sacrificed 24 hours after reperfusion. 
In the Wistar rat model, a unilateral approach was used. Animals were anesthetized with 
2% isoflurane with a flow of 0.6 1/min of 100% oxygen and a left-flank incision was made. Renal 
vessels of the left kidney were dissected and clamped with non-traumatic vascular clamps for 
45 min. After removal of the clips, renal reperfusion was confirmed visually and muscle and skin 
layers were sutured using 4-0 vicryl stitches (Ethicon, New Jersey, USA). Reperfusion times 
were 30 min, 90 min, 6 h, 1 day, 4 days, 9 days, 14 days or 21 days (n=5-6 per group) . 
Cell culture 
Human embryonic kidney 293 (HEK293) cells were used for in vitro experiments, cultured 
under standard conditions using Dulbecco's Modified Eagle Medium (DMEM, Gibco) with 10% 
fetal bovine serum. All experiments were independently reproduced at least three times. 
Transfection 
For experiments utilizing overexpression of CSE, HEK293 cells were transfected with the pl RES2-
EGFP (mock) or p lRES2-EGFP-CSE vector. For this purpose, cells were seeded in 24- or 96-well 
plates and grown until subconfluent. Subsequently, transfection was performed according 
to manufacturers' instructions using Lipofectamine 2000 reagent (lnvitrogen). Transfection 
efficiency and time course of expression was determined using fluorescence microscopy for 
EGFP. For experiments investigating oxidative stress and the protein expression of CSE, cells 
were used or harvested 72 hours after transfection. 
Cell viab i l ity measurement 
Alamar Blue reagent (lnvitrogen) was used according to manufacturers' protocol to measure 
cellular viability in the first 96 hours after transfection. 
H2S prod uction rate measurement 
Whole kidneys were taken from untreated CSE I or WT mice and snap frozen in liquid nitrogen. 
For measurement of H2S production, renal tissue was homogenized and measurement was 
performed as described previously5. 
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H2S measurement in med ium 
Supernatants o f  control, p lRES2-EGFP and pl RES2- EGFP-CSE transfected cells was collected 72 
hours after transfection and H2S measurement was performed as described previously using 
the methylene blue assay6• 
Western Blot - rat tissue 
Total protein lysates in RIPA buffer (Thermo Scientific, MA, USA) were supplemented with 
protease inhibitor cocktail (Sigma-Aldrich, MA, USA). Protein concentrations were determined 
using the BioRad DC protein assay (Bio-Rad, VA, USA), according to manufacturer's protocol. 
Equal amounts of protein were loaded onto 12% SDS-polyacrylamide gels. Aspecific binding of 
the antibodies was prevented using 5% milk in Tris-buffered saline-0.1% Tween-20 (TBST). Then 
membranes were incubated with the primary antibody solution in 5% milk in TBST, overnight at 
4° C (for CSE: Proteintech rabbit polyclonal CSE antibody 12217-1-AP (1:1000), for Ywhaz (which 
was used as a housekeeping protein): Abeam anti 14-3-3 zeta rabbit polyclonal antibody ab51129 
(1: 500)). Afterwards membranes were incubated with secondary antibody (goat anti-rabbit lgG 
horseradish peroxidase) 1:500 in 5% milk in TBST. All antibody incubations were followed by 
washing with TBST. Membranes were immediately developed by luminol-chemiluminescence 
according to manufacturer's instructions, and digital images taken with the Bio-Rad ChemiDoc 
MP system quantified using Bio-Rad Image Lab 4.01. 
Western Blot - cu ltured cells 
Cultured HEK293 cells were obtained 72 hours after transfection and lysed in lysis buffer (0.5 M EDTA, 
1 M Tris-Cl, pH 7.4, 0.3 M sucrose, 1 µg/ml anti pain hydrochloride, 1 mM benzamidine hydrochloride 
hydrate, 1 µg/ml leupeptin hemisulfate, 1 mM 1,10-phenanthroline monohydrate, µl M pepstatin A, 
0.1 mM phenylmethylsulfonyl fluoride, and 1 mM iodoacetamide). Equal amounts of protein were 
boiled and electrophoretically separated by SDS-PAGE and transferred to nitrocellulose membrane 
as described previously7. The dilutions of primary antibody were 1:5000 for a-Tubulin and 1:1000 
for CSE. Horseradish peroxidase-conjugated antibody was used as secondary antibody. The 
immunoreactions were visualized by ECL and exposed to X-ray film (Kodak Scientific Imaging film). 
Model of Anti mycin A induced oxidative stress and measurement of reactive 
oxygen species 
HEK293 cells were cultured in 96-well plates until subconfluent and starved in serum-free medium 
for 24 hours. Antimycin A (50 µg/mL) with or without NaHS (1-1000 µM) was given for 30 min to 
induce intracellular production of ROS. Subsequently, cells were washed two times with PBS to 
remove Antimycin and NaHS and incubated with 15 µM dyhidroethidine (DHE, lnvitrogen) or 5 
µM MitoSOX (lnvitrogen) for 15 minutes and washed three times with PBS. Images were directly 
made using an inverted fluorescent microscope and analyzed for intensity of fluorescence. 
Statistical analys is 
Data were analyzed using Graph Pad PRISM S.0 (Graph Pad, San Diego, USA) or SPSS 16.0 (SPSS inc., 
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a ppropriate. Bonferroni  o r  Dunns  postcorrection was appl ied where m u lt ip le com parisons 
were made. Norma l ity was tested using the Kolmogorov-Smirno test. Association between 
m RNA and protein leve ls  and GFR  were ana lysed us ing l inear  reg ress ion.  For h istopathological  
scoring, both kidneys of each an ima l  were analysed and a mixed -effects model was used taking 
the an imal of origin into accou nt. A va lue of p<0.05 was considered statistica l ly s ign ificant. Data 
a re expressed as the mean ± SEM (Standard Error of the Mean) u n less otherwise ind icated . 
Approval 
For c l in ica l studies, a l l  procedures and use of anonymized human tissue were performed 
accord ing to recent nationa l  gu ide l i nes, and were approved by our institutiona l review board .  
F o r  t h e  animal  stud ies, experimental procedu res were i n  agreement with i nstitutiona l  and 
legis lator regu lations and approved by the loca l committee for an ima l  exper iments. 
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CHAPTER 6 
AB ST RACT 
Preeclampsia, a human pregnancy specific disorder, is  characterized by an anti-angiogenic state. 
As hydrogen sulfide (H2S) has pro-angiogenic and anti-oxidative characteristics, we hypothesized 
that H2S levels could play a role in the pathogenesis of preeclampsia and studied the placental 
expression of the H2S-producing enzymes cystathionine-y-lyase (CSE) and cystathionine-!3-
synthase (CBS). CBS and CSE protein are expressed in the fetal-placental endothelium and CBS 
only in Hofbauer-cells. CBS mRNA expression is decreased (p=0.002) in early-onset preeclampsia, 
while CSE mRNA is unchanged. Thus, down regulation of CBS during early onset preeclampsia 
may result in less H2S-production and may aid in the anti-angiogenic state. 
CSE/CBS EXPRESSION IN PREECLAMPSIA 
I NT RO D U CT I O N  
Preeclampsia (PE), a human pregnancy specific disorder, is characterized by placental ischemia 
and maternal endothelial dysfunction1 • The poorly perfused and ischemic placenta releases 
excess amounts of anti-angiogenic factors causing generalized endothelial damage2·3• 
Hydrogen sulfide (H2S) is produced from the amino acid L-cysteine by two pyridoxal 5' 
phosphate-dependent enzymes cystathionine y-lyase (CSE) and cystathionine �-synthase 
(CBS). H2S induces vasorelaxation by opening ATP-sensitive K-channels in smooth muscle cells 
and up regulates vascular endothelial growth factor4•5 • Furthermore, H2S also has antioxidant 
capacity by direct scavenging of nitrogen or reactive oxygen species6• CBS and CSE are 
down regulated in several cardiovascular and pulmonary diseases7• Exogenous H2S (NaHS) 
administration is proposed as a novel therapy in animal models of cardiovascular and ischemic 
diseases7•8• CBS is also an important enzyme in the homocysteine pathway, since homocysteine 
is converted to cystathionine by CBS. Pregnant CBS transgenic mice show a moderate increase 
of homocysteine which associated with blunted endothelial-dependent relaxation in arteries 9. 
We hypothesized that H2S, because of its pro-angiogenic and anti-oxidative characteristics 
and the involvement of CBS in homocysteine degradation, might play a role in the pathogenesis 
of PE. The aim of the present study was to identify and compare the expression and localization 
of CBS and CSE in placental tissue from both normotensive and early- and late-onset PE. 
MAT E R IALS  AN D M ET H O DS 
Collections of samples 
Placental biopsies were obtained from patients (n=36) with early-onset PE, late-onset PE and 
mode of delivery matched healthy pregnant controls after informed consent. The local UMCG 
Medical Ethical Committee approved the study. PE was defined according to the standards of 
the International Society for the Study of Hypertension in Pregnancy: diastolic blood pressure 
of > 90 mm Hg and proteinuria � 300 mg/24 hours 1°. PE present before 34 weeks of gestation 
was defined as early-onset, these patients delivered by Cesarean section. Intra-uterine growth 
restriction (IUGR) was defined as birth weight under the tenth percentile. 
As previously described, placental cryosections were stained11 with mouse monoclonal 
antibodies against CSE (1:100, donated by dr. N. Nishi, Kagawa Medical School, Japan) and CBS 
(1 :250, Abnova, Tapei, Taiwan). Primary antibody was replaced by PBS in negative controls. For 
immunofluorescence double staining, CD31 (1:100, Sigma-Aldrich, St. Louis, MO) was used. 
For real time RT-PCR, RNA was isolated from several parts of the placenta, pooled, and 
purified as previously described12• We analyzed mRNA expression of CBS and CSE using Assay­
on-Demand Gene Expression (Applied Biosystems, USA). PSMD4 (proteasome non-ATPase 
regulatory subunit 4) was used as a housekeeping gene, the expression of this gene was 
constant over the four study groups13• 
Total protein from placental biopsies was extracted and Western blotting analysis was 
performed according to published procedures14•15• CBS and CSE monoclonal antibodies 
(Abnova) were used at 1:500 dilution. 
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CSE/CBS EXPRESSION IN PREECLAMPSIA 
RESULTS AND DISCUSSION 
The major finding of this study is that CBS mRNA expression is significantly down regulated in 
placental villoustissue derived from pregnancies complicated by early-onset PE when comparing 
to mode of delivery matched controls (Figure la). Furthermore, we demonstrated that CBS and 
CSE are mainly localized in the endothelium in the fetal vessels from the chorionic- and stem­
villi (Figure 2a). The endothelial origin of both enzymes is confirmed by double staining with 
CD31 (Figure 2b). Hofbauer cells express CBS (Figure 2a). There were no differences in CBS/CSE 
in protein expression between PE and delivery matched controls (Figure lb). However, CBS/CSE 
protein expression was significantly down regulated in all placentae after spontaneous delivery 
compared to Cesarean delivery (Figure lb). 
Although protein expression of CBS and CSE was not affected by PE, we found a d own 
regulation of mRNA of CBS in early-onset PE. This discrepancy between mRNA and protein 
expression is remarkable, but has been reported previously16• In ischemic brain tissue, decrease 
in mRNA corresponded to decreased CBS-activity and H 2S-production, while protein levels did 
not 16• We did not evaluate CSE-and CBS-activity or H2S-production. However, Patel et al. showed 
that H2S is endogenously produced in the placenta, production rate was increased under 
low-oxygen levels17• Another study confirmed placental catalytic CBS-activity by converting 
homocysteine18• So far, in PE no CBS- and CSE-activity or H2S-production is reported. Therefore, 
the exact role of endogenous H2S in PE needs to be elucidated. 
Differential CBS mRNA expression may be gestation related, as has been previously 
documented for other genes, however no differences in CBS mRNA expression measured in 
first-trimester and term human placentae were reported 19• For late-onset PE, placental CBS 
mRNA expression is not altered compared to healthy pregnancies (Figure la). This is in line 
with the growing evidence that there are differences between the pathophysiology of early­
and late-onset PE20• In our total study group, 3 patients with a pregnancy complicated by IUGR 
were present. The data of these patients with respect to mRNA and protein expression fitted 
well within their study groups. 
CBS and CSE protein, but not mRNA expression was significantly down regulated in control 
and PE placentae after spontaneous delivery compared to Cesarean delivery. This is in line 
with a recent report of down regulation of the enzymes and reduced H2S-production in the 
myometrium during labor21 • Increased turnover of the enzymes could be involved in transition 
of the labor process. 
The fetal endothelial expression of CBS and CSE is in accord with the expressions in other 
organs22 • Moreover, we showed expression of CBS by Hofbauer cells. Hofbauer cells or fetal 
tissue macrophages are placental immune cells; several studies suggest that Hofbauer cells play 
a direct role in placental vasculogenesis23• Although CSE has been shown to be expressed by 
macrophages24, the expression of CBS by macrophages has not been reported. The expression 
of CBS by Hofbauer cells may be in line with the role of these cells in vasculogenesis. 
In conclusion, the present study provides novel insights into the expression of H2S-producing 
enzymes during normal and PE. Future studies will compare the placental CBS/CSE-activity and 
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Figure 1 - Placental expression of CBS and CSE mRNA and protein in healthy pregnancy and 
pregnancy complicated by early- and late-onset preeclampsia. 
(A) CBS m RNA expression is down regulated in  the ea rly-onset preeclampsia g roup, compared to 
the mode for del ivery matched g roup (del ivery by Cesa rean section) .  No differences were observed 
in CBS mRNA expression in  the late-onset PE g roup or in CSE m RNA expression in  a l l  fou r  g roups.  
There was no difference in  m RNA expression between the late- and ea rly-onset PE g roups of both 
enzymes.  (B) Quantitative Western blot ana lysis showed a sign ificant down regu lation of both C BS 
and CSE in a l l  spontaneous del ivery placentae, compared to the Cesarean g roups.  No d ifferences 
were o bserved i n  expression of both enzymes between both PE groups and mode of del ivery 
matched controls .  Bands 1 - 4 show representative Western blots for CBS in  p lacentae derived from 
respectively Cesa rea n  controls, early-onset P E, spontaneous controls and late-onset PE .  Bands 
5 - 8 s how representative Western blots for CSE in the same g roups .  For a l l  figures, median and 
i nterqua rti le range is g iven.  For statistical ana lysis, Mann-Whitney U test was used. Quantification of 
p rotein expression was performed by measu ring band i ntensity us ing N I H  lmageJ software. 
CSE/CBS EXPRESSION IN PREECLAMPSIA 
Figure 2 
Figure 2 - Placental local ization of CBS and CSE protein expression in healthy pregnancy IHC and 
IF staining was performed on al l  samples of the 4 groups (n=36). 
No d ifferences in localization were observed between groups; therefore only representative cryostat 
sections of control placental villous tissue stained for CBS (A, C, F) and CSE (B, E) are shown. Positive 
staining is shown in fetal endothelial cells in chorionic villi (long arrow), fetal endothelial cells in stem 
vi lli (closed short arrow) and in Hofbauer cells (arrow-head). Syncytio- and cytotrophoblasts are 
negative (open short arrow). No positive staining is observed in the negative control, in which the 
primary antibody was replaced by PBS (D). 
For the IF staining (E, F), nuclear staining (DAPI) is shown in blue, CD31 protein is shown in red, CSE 
and CBS protein in green, and co-localization of CD31 with CBS or CSE in white. I F  staining confirmed 
the endothelial expression of both CSE and CBS protein. All images were taken at the same exposure 
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Major improvements i n  immunosuppressive treatment, surg ical techniques, and treatment of 
post-transplant compl ications have contributed considerably to improved outcome in rena l  
transplantation over the past decades. Yet, these accom pl ishments have not led to  s imi lar 
improvements in transplant outcome when the resu lts of l iving and deceased donors are 
compared. The enormous demand for donor kidneys has a l lowed for the increase in acceptance of 
su boptimal donors. The use of bra in  dead patients as organ donors has had a tremendous positive 
infl uence on the number of rena l  transp lants. Unfortunately, the physiologica l ly abnorma l state 
of bra in death has a negative effect on transplant outcome. The fact that transplanted kidneys 
derived from brain dead donors have a decreased viab i l ity indicates that potential g rafts are 
a l ready damaged before retrieval and preservation .  In th is review, we present an overview of 
the current knowledge of (patho)-physiologica l effects of bra in  death and its relevance for renal  
transplant outcome. I n  addition, severa l options for therapeutic i ntervention during  bra in  death 
in the donor with the goal to improve organ viabi l ity and transp lant outcome are d iscussed . 
DONOR ORGAN PRECONDITIONING 
I N F E R I O R  S U RVI VA L  O F  D E C EAS E D  D O N O R  K I D N EYS 
AFT E R  T RAN S P LA N TAT I O N  
Transplant outcome achieved with kidneys from living donors is far superior when com pared 
to g rafts obtained from deceased donors1;2 (Table 1). The persistent donor organ shortage has 
caused longer waiting lists and an increasing percentage of patients that die while waiting. As a 
consequence, a g radual shift towards accepting suboptimal donors has taken place. The use of 
older and more marginal donors is now routine and the number of non-heart beating donors 
has increased significantly over the past years1;3_ Twenty years ago, the typica l donor was under 
the age of thirty, fairly healthy and died of traumatic cerebra l injury. Today, the average donor is 
over fifty years old and the ma in cause of death is intracranial hemorrhage. The improvements 
that were made in treatment regimen of the recipient, organ preservation, reduction of 
cold ischemia time, and better allocation of donor organs have been masked by the use of 
lower quality donors. In the past, much effort was directed towards post-transp lantation 
immunosuppression and preservation of organs during transport. Now, risk factors and 
conditions prior to organ retrieval in the donor need to be recognized for their impact on 
donor organ viability. The detrimental effects of brain death on renal transplant outcome4;5 have 
been convincing ly shown in the experimental setting. In clinical studies, though, it is difficult to 
reveal that brain death itself has an independent influence on transplant outcome, since living 
and deceased donors differ on more aspects than just the death of the brain. However, when 
survival rates a re stratified for age, grafts from deceased donors have worse survival within 
each age-g roup - even in the relatively young g roup of 25-36 year old donors2 • 
In 2003, 14.853 renal transplantations were performed in the United States. Of those, 8.389 
kidneys originated from deceased donors and 6.464 were retrieved from living donors 1 . Yet, at 
the end of 2003, 57.211 patients were on the waiting list to receive a renal transplant. For a patient 
enlisted in 2000, the median time to transplant was more than three years. Unfortunately, not 
every patient survived long enough to receive a transplant, which resulted in approximately 3 000 
deaths on the waiting list in that same year. The increased demand for donor kidneys has provoked 
Table 1 - 1- and 5-year graft survival for living and deceased donors following renal or liver 
transplantation. 
1-Year Survival 5-Year Survival 
Organ transplanted 2001-2002 2002-2003 1997-2002 1998-2003 
Kidney 
Living donor 94 .3% 94.6% 78 .6% 79.2% 
Deceased donor 88.7% 89.0% 65.7% 66.2% 
Liver 
Living donor 79 .3% 8 0.1% 78.1% 71.2% 
Deceased donor 80 .6% 81.4% 64.1% 65 .4% 





a l a rge sh ift towards l iving kid ney donation in the U .S .1 In fact, the number of l iving kidney donors 
in the U .S. surpassed the number of deceased donors in 20001;6 • Sti l l , the tota l number of kid neys 
obtained from living donors is  lower since in l iv ing donation only one kidney can be donated, 
wh i le  in deceased donors both kidneys are retrieved .  In many European countries the use of l iving 
donors has increased as wel l  over the past decade, a lbeit more modestly3• 
I n  their  1995 l andmark paper, Terasaki et a l . 2 showed that graft su rviva l for l iv ing un re lated 
donation (LU RD) is superior com pa red to deceased donation, even though the average 
H LA- haplotype matching is  worse in  LU RD.  Long-term outcome after LU RD is  s imi lar  to that 
of pa renta l or offspring donors7• This i nd icates that poor surviva l of cadaveric grafts can not 
be so le ly attributed to differences in immunogen ic ity. G raft performance is affected by many 
other  factors. Donor va r iab les such as age, gender, race, term ina l  seru m creatin ine, h istory 
of hypertension and cause of death a l l  affect tra nsp lantation outcome8•10 • Deceased d onors 
tend to be older than l iv ing donors 1, however with in  each age category, su rviva l rates of l iv ing 
donor g rafts are s ign ificantly h igher than those of deceased donor g rafts2 • Preservation and 
cold ischemia time (CIT) i nfl uence transp lant outcome, and for log istical reasons, CIT is longer 
on average in deceased donor transp lantation .  For rena l  transp la ntation, C IT of less than 24 
hours does not infl uence outcome after rena l  t ranspla ntation2:11:12 • 
Despite the fact that grafts obtained from deceased donors have i nferior outcome, 
these transp lants have prevented death for m a ny people on d ia lysis .  Deceased donor kidney 
rec ip ients have a 68% reduced risk of mortal ity compared to s im i l a r patients who stay on the 
wait ing l i st receiving dia lys is  treatment13• The shortage of donor organs cu lm inated in the use 
of extended criteria donation (ECD) .  ECO i nc ludes bra in dead donors who a re o lder than 60 
yea rs, o r  a re aged over 50 yea rs i n  combination with at least two of the fol lowing risk factors: 
a h i story of hypertension, a termina l  serum creatin ine  >1 .5 mg/d L  or a cerebrovascu lar  cause of 
death .  The number of ECO-derived kidneys has seen marg ina l  but steady increase over the past 
yea rs 1, even though long term a l lograft su rviva l of ECO-derived k idneys is i nferior compared to 
non-ECO kidneys1:14 (Fig u re 1 ) .  I n it ia l  doubt a bout the advantages of th is  type of donor has not 
been s usta ined . Relative morta l ity risk ana lysis has  shown that the short-term risk of death i n  
E C O  kid ney recipients i s  more than five t imes h i g h e r  when compared t o  standard therapy with 
d ia lysis whi le waiting for a non- ECO kidney. At 226 days after transp lantation, however, the 
risk becomes equal  and is lower thereafter. In add it ion, the long term cu mu lative morta l ity is 
s ign ificantly lower in ECO kidney rec ip ients 15• K idneys d iscarded by transp lant centers twice or 
more for reasons of poor organ  qua l ity showed worse in itia l  non-fu nction and long term rena l  
performance. Five yea r g raft and patient s u rviva l, however, were not s ign ificantly d ifferent 
from contro l  kidneys that were immediate ly accepted 16• Direction  of ECO kidneys towards 
those patients with a high risk of mortal ity on the waiti ng l i st cou ld therefore be beneficia l .  On 
the other  hand, caution i s  advised, s ince a l l ocati ng compromised kid neys towa rds the most 
vu lnerab le  patients could have its own negative effects on outcome.  Prog ressively increas ing 
wait ing l ists and subsequent prolonged wa it ing t ime in the years to come wi l l  fu rther extend 
the benefit of ECO transplantation.  When ECD k idneys a re optim a l ly a l located, they can be 
a va l uab le  source to reduce the wide gap between the number of donor organs needed and 
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those that actually become available. Counteracting the deleterious effects that the state of 
brain death has on these organs could increase the benefit even further. 
BRA I N  D EATH,  SYSTEMIC C HANGES  AN D CL IN ICAL COU RS E 
The beating heart has always been considered the classic sign of life. An unconfirmed story 
about the famous 1 6th century anatomist Andreas Vesalius reports about an incident that 
happened at a public dissection on a Spanish nobleman during the times of the Inquisition. On 
opening the thorax, Vesalius found, to the shock of the crowd, that the heart was still beating. 
Vesalius was taken to court by the deceased man's family, appalled about this crime to their 
relative, who must have been alive as his heart was still beating. Myth or not, it illustrates that 
the presence of a heartbeat was synonymous with life in those days. 
After the report by Mollaret and Goulon in 195917 which described comatose patients with 
vital functions sustained by mechanical ventilation, the definition of death became a major point 
of discussion. Due to improved techniques, the heart was kept functioning in these patients while 
mechanical ventilation oxygenated the blood. Judged by their appearance, patients did not look 
deceased, however, it was clear that normal, self-sustained function would never be regained. In 
1963, before a consensus had been reached on the implications of this i rreversible coma, the first 
kidney was retrieved from a brain dead, heart-beating donor and transplanted by the Belgian 
surgeon Alexandre18• In an effort to overcome problems that led to controversy in obtaining 
organs from deceased donors, but also to decrease the burden on the relatives of brain dead 
patients on life support, an ad hoc committee of the Harvard Medical School proposed to add 
irreversible coma to the death criterion in 1 96819• This report generated considerable medico­
legal discussion and resulted in most countries adopting a concept of death that originates from 
this proposition. The definition of brain death that the committee proposed concerned the 
following mandatory criteria: (1) unawareness of and unresponsiveness to external stimuli, (2) no 
spontaneous movements or breathing, (3) absent reflexes and (4) a flat electroencephalogram 
(EEG). Caution is required for conditions that can elicit similar symptoms, such as hypothermia, 
hypotension or intoxication, and therefore these have to be ruled out. 
Brain death as such is the terminal phase of a sequence of events frequently commencing 
with cerebral trauma or cerebrovascular hemorrhage. When the patient is declared brain dead, 
this chain of events has already affected the organs. Systemic and hormonal changes arise 
immediately when intracranial pressure increases. Hence, brain death is not the stationary 
condition as perceived from the outside, but a dynamic and rather unphysiological course of 
events that influences a number of (patho-)physiological processes in the human body. 
Hemodynamic changes 
Following cerebral trauma or injury, the primary rise in intracranial pressure causes additional 
damage to the cerebrum, which triggers parasympathetic activity and results in a decreased 
systemic blood pressure. The continued rise in intracranial pressure leads to herniation of the 
brain stem through the foramen magnum, which is accompanied by arterial compression and 
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Figure 1 - Graft survival over a period of 5 years for living-, non-ECD- and ECD derived renal grafts. 
Source: U NOS/OPTN. 
stem becomes ischemic, sympathetic stimulation, together with the persisting parasympathetic 
activity, wi l l  cause the Cushing reflex, which was al ready described in 1902 by the American 
neurosurgeon Harvey Cushing20• The Cushing reflex consists of multiple disturbances in the 
physiology of cerebrally injured patients, including bradycardia, hypertension and an irregular 
breathing pattern .  Ultimately, when the entire brain stem has become ischemic, the vagal 
cardiomotor nucleus is affected and solitary sympathetic stimulation will occur. As a result, 
massive catecholamine release, systemically as well as from myocardial sympathetic nerve 
endings, cause an increase in heart rate and leads to vasoconstriction with increased vascular 
resistance and blood pressure21-23• This process is referred to as the sympathetic- or catecholamine 
storm and is considered to be an attempt of the body to raise arterial blood pressure above the 
elevated intracranial pressure as an ultimate effort to restore perfusion of the cerebrum. 
The rise in serum epinephrine levels has been reported to be as high as 100-1,000 fold higher 
compared to normal values in animal models of brain death23-26• The magnitude of catecholamine 
release is related to the severity of brain damage. The faster the rise in intracranial pressure, 
the higher the peak in catecholamine levels23• Also, serum norepinephrine and dopamine 
concentrations are vastly increased after onset of brain death. The values of catecholamine release 
in animal experiments appear to be similar to those described in the clinical situation27• In addition, a 
parallel cardiac response to brain injury is seen, as demonstrated by even higher levels of myocardial 
catecholamines compared to the serum28 leading to injury of myocytes21;29• The catecholamine 
induced increase in  vascular resistance can be severe, reaching four times higher levels than basal 
values in the rat kidney26• This causes renal blood flow to decrease by a factor of 2.4 and supports the 
hypothesis that the rigorous decline in organ perfusion leads to ischemic damage of potential grafts. 
Over time, sympathetic pathways are deactivated due to ischemia of the spinal cord. This 
leads to a gradual decrease of the hyperdynamic state with a subsequent decline in blood 
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pressure, heart rate and cardiac output to normal or subnormal values. Ultimately, a state of 
hypoperfusion is reached, which is harmful to the potential donor kidneys. Prolonged brain 
death results in high rates of tubular necrosis30• Many brain dead patients need hemodynamic 
support during this phase, and receive vasopressors and/or anti-diuretic hormone (ADH). 
Hormonal changes 
In addition to the catecholamines, other, hormonal alterations take place. There is evidence that 
some residual cerebral blood flow and hypothalamic function can persist after brain death31•33_ 
In most brain dead patients, however, a gradual decrease in the release of adrenocorticotropic 
hormone (ACTH) and ADH is seen24:25:34, which is associated with cardiovascular failure that 
eventually causes the requirement of hemodynamic support. The failure to keep ADH levels 
in the range needed for a normal osmolarity24:25:31 has been suggested as the cause of diabetes 
insipidus in up to 78% of patients34;35• A more recent explanation is the downregulation of 
aquaporin-2 (AQP-2) channels36 which could affect water re-uptake in the renal collecting 
ducts. Free circulating triiodothyronine (T3) gradually decreases after bra in death34:35:37•40, but 
not every study has found comparable results concern ing the serum concentrations of T3 and 
T3-related hormones, such as T4 and TSH 32:39-41 _ 
Any acute stress will enhance the condition known as "diabetes of injury", consisting mainly 
of hyperglycemia caused by increased gluconeogenesis and insulin resistance. Intensive insulin 
therapy is now applied in many intensive care units (ICU) and as a result mortality in surgical 
ICU's has been greatly reduced when strict glycemic control is achieved42• A recent study has 
indicated that in the medical ICU, overall mortality was only decreased after intensive insul in 
therapy i n  patients who stayed in the I CU for three or more days43• Morbidity, however, was 
reduced among all patients. A lower incidence of newly acquired renal injury, earlier weaning 
from mechanical ventilation, and a quicker discharge from the I CU and from the hospital were 
observed43 • The rise in serum creatin ine was attenuated by the maintenance of normoglycemia. 
Also, evidence now exists that insulin therapy reduces the inflammatory response. I CAM-1 and 
(-reactive protein are both decreased in the serum of I CU patients receiving intensive insulin  
treatment44;45• Thus, the use of  intensive i nsulin therapy i n  brain dead patients could therefore 
attenuate renal damage, reduce inflammation and enhance donor organ viability resulting in a 
better transplantation outcome. 
EXPERIMENTAL BRAIN DEATH MODELS 
To obtain a better insight in the (patho-)physiological processes that occur during brain death, 
standardized models are necessary to explain the discrepancies in outcome between deceased 
and living donor transplantation.  In transplant studies, the use of a brain death model is important, 
since the deceased donor is still the major source of donor organs. The i nduction of injury to 
the central nervous system under controlled conditions closes the gap between experimental 
transplant models and daily clinical reality. Valid experimental models have been developed 
in which the detrimental effects of brain death can be studied and possible interventions 
evaluated46-49• Various research groups have studied brain death in the rat model. Epidural 
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Figure 2 - Proposed model for the (patho)-physiological changes associated with brain death. 
brain death, we found that K IM-1 is massively upregulated. Interestingly enough, it can be 
detected on the luminal side of the renal cortical tubule, but is a lso shed into the urine54 which 
may simplify viability assessment of potential donor organs. 
I m m u nolog ica l activation 
In ischemia/reperfusion injury, a clear-cut correlation was found between endothelial injury 
and acute rejection. This association between the innate immune response and subsequent 
alloreactivity could be explained by Matzinger's danger hypothesis55• It is of importance that an 
increased immunogenicity is also observed in the brain dead donor organ as wel l. Endothelia l 
activation is present with the upregulation of adhesion molecules (E-selectin, P-selectin, ICAM-1, 
VCAM-1) that promote the rolling, adhesion, diapedesis and subsequent leukocyte migration 
into the interstitium of the kidney46=56-59• Multiple cytokines and chemokines do play a role in the 
immunological response to cerebral injury. Upregulation of I L-1, IL-2, I L-6, TNF-a, TGF-�, IFN-y, 
VEGF, MIP-la, MI P-1�, MCP-1 and osteopontin have been reported36=56=58•60• The expression of the 
major histocompatibility complex (MHC) class I I  is increased as wel56. Amplification of cytokines, 
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leukocytes to the kidney. T-cells, macrophages and polymorphonuclear leukocytes are all found 
in higher quantities in donor kidneys during brain death46;56:57:61 • 
After reperfusion, a large difference in neutrophil infiltration and P-selectin expression can 
be observed between living and cadaveric grafts. Koo et al.62 showed that 53% of cadaveric 
renal allografts had increased neutrophil infiltration, against 0% of living related grafts. 
P-selectin expression was increased in 44% of cadaveric grafts, and 9% of living related grafts. 
In a syngeneic animal model of renal transplantation, short-term inflammatory changes to 
the kidneys were investigated by Kusaka et al 58 • The extent of leukocyte infiltration reaches 
its peak at 24 hours after transplantation in this syngeneic transplant model and corresponds 
with the levels of E- and P-selectin. After this period, the extent of immunological activation 
gradually decreases, but histological changes to the kidney can still be observed. Allotransplant 
experiments have shown that after experimental brain death, recipients of brain dead donor 
kidneys suffered from a greatly increased acute rejection rate4. Similar effects have been 
observed in other organs, such as lung63 and heart64• When kidney allografts are treated with 
cyclosporine to prevent acute rejection, long-term renal function is adversely affected by brain 
death compared to syngeneic transplants. Thus, the state of brain death can also enhance the 
development of chronic renal transplant dysfunction5 • 
Protection a nd Repa i r  
Interestingly, not only detrimental or degenerative changes take place during brain death. 
Protective or recuperative mechanisms are induced as well. This is reflected by increased 
expression of the cytoprotective genes heme oxygenase-1 (HO-1), heat-shock protein 70 
(HSP70) and manganese superoxide dismutase (MnSOD2)36;67;65 • Kunzendorf et al.66 showed 
that a prolonged duration of brain death positively influences long-term graft survival. The 
mechanism behind this observation could well be the delayed induction of protection or 
initiation of repair. In another study, increased HO-1 expression at organ retrieval was correlated 
with outcome after renal transplantation in the living donor setting61• Expression of HO-1 was 
not related to graft survival in deceased donor kidneys. Donor HO-1 gene polymorphisms have 
been associated with transplantation outcome67• Surprisingly, in a liver transplant study, livers 
with an initial low HO-1 expression prior to transplantation, but a high HO-1 expression after 
reperfusion, had superior outcome when compared to livers with high HO-1 expression at 
organ harvest68 • These observations indicate that the ability to induce HO-1 is important, and 
not a high expression of HO-1 per se. Two different mechanisms should be considered here: 
while the increase in expression of HO-1 in living donors may initiate protection against the hits 
to the kidney during transplantation and thereafter, in deceased donors, on the other hand, 
HO-1 may well be a reflection of the level of stress to the kidney due to brain death. 
EXPERIMENTAL AND CLINICAL INTERVENTIONS 
Different concepts and approaches have been considered to counteract the detrimental effects 
caused by brain death (Table 2). Some research groups focus on the induction of protective proteins, 
while others aim at reducing the immune response. In a case-control study performed by Schnuelle 
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et al.69, treatment of the donor with the vasopressors dopamine or noradrenalin was identified as an 
independent beneficial factor in renal transplant outcome. They confirmed these results in a study 
using the Eurotransplant database70 and also in a recent study, where donor dopamine was found 
to be associated with a more rapid decrease in serum creatinine and better long-term survival71 • 
Experimentally, dopamine treatment has shown beneficial effects in a model of brain death induced 
renal damage. Dopamine treatment resulted in H0-1 induction as well as an inhibition of P-selectin 
expression and decreased mononuclear infiltration48• In other experiments, the effects of ischemia/ 
reperfusion and cold preservation were attenuated by low-dose dopamine treatmentn73• In vitro, 
decreased production of chemokines GRO-a, ENA78 and I L-8 in proximal tubular epithelial cells 
(PTEC) has been observed after dopamine treatment74• In endothelial cells, production of GROa 
and ENA78 was reduced, but I L-8 increased. In addition, dopamine pretreatment delayed expression 
of ICAM-1 and VCAM-1 after TNFa stimulation in these cells. These immunological effects seen in 
experimental conditions could be part of the explanation for the improved renal transplantation 
outcome after catecholamine treatment of the brain dead donor. 
Selective upregulation of H0-1 has proven to be beneficial in different models of stress or 
damage, including ischemia/reperfusion75 and experimental renal transplantation76• Due to its 
antioxidative, antiapoptotic and immune regulatory effects, H0-1 has become an extensively 
investigated protein in the search for protection against insults during and prior to the transplant 
Table 2 - Overview of studies that investigated the effects of specific interventions on bra in 





Treatment Main outcome 
Steroids 
Dopamine 
Reduced expression of proinflammatory cytokines 
Improved graft survival, less acute rejection 
Norepinephrine Improved graft survival, less acute rejection 















Improved graft survival, improved short-term renal function 
Reduced expression of proinflammatory factors 
Improved graft survival, reduced chronic rejection 
Improved graft survival, reduced leukocyte infiltration 
Improved graft survival, reduced acute rejection 
Improved graft survival, reduced acute rejection 
Reduced monocyte infiltration, reduced expression 
of proinflammatory factors 
§Catecholamine treatment was defined as administration of any of the following adrenergic substances:  
dopamine, norepinephrine, epinephrine, dobutamine .. 
CEPO, carbamylated erythropoietin; rPSGL-lg, recombinant P-selectin glycoprotein ligand; CoPP, cobalt 




process. Experimental transplantation after upregulation of H0-1 by Co PP treatment in the brain 
dead donor resulted in improved renal allograft survival77• Also, a reduction was seen in the 
infiltration of EDl+ monocytes/macrophages, CD4+ T-cells and cos+ T-cells in the CoPP treated 
group. The application of novel and existing approaches in the field of H0-1 induction can 
therefore be regarded as a promising possibility to improve clinical renal transplant outcome. 
Inhibition of the immunological activation due to brain death is one of the strategies to 
improve transplant outcome in experimental models. Glucocorticosteroid treatment of brain 
dead rats improved graft survival after transplantation to a level comparable with living donor 
transplants78• Steroids suppress cellular infiltration and expression of cytokines and the intensity 
of morphological changes are noticeably different in the recipients of a graft from an untreated 
brain dead donor. The only prospectively designed human study known to us has reported 
some promising results in reducing the expression of proinflammatory cytokines using steroid 
therapy79• Long term results after kidney transplantation, however, have yet to be reported. 
Table 3 - Interventions that can counteract the negative effects of bra in death on the kidney, or 
could be used for this purpose in the future. 
Potential interventions for use in the brain dead organ donor 
Hemodynamic 
Catecholamines (Dopamine, Epinephrine, Norepinephrine) 
Antidiuretic hormone (ADH) 
Anti-inflammatory 
lmmunosuppressants (Glucocorticoids, Calcineurin inhibitors) 
Monoclonal antibodies against cytokines (TNF-a, I FN -y, I L-2, I L-6) 
Inhibitors of chemokines (MCP-1, MIP-l a, M IP-1�) 
Carbamylated recombinant human Erythropoietin (CEPO) 
Recombinant P-Selectin Glycoprotein Ligand - lg (rPSGL-lg) 
Induction of cytoprotection 
HO-1 induction (Cobalt Protoporphyrin (CoPP)) 
HSP induction (Pyrrolidine Dithiocarbamate (PDTC), Geranylgeranylacetone (GGA)) 
Signal transduction 
Selective inhibitors of kinases (JNK, p38, ERK, RhoA) 
Gaseous substances 
Hydrogen Sulfide (H2S) 
Carbon Monoxide (CO) 
Nitrous Oxide (NO) 
Modulation of gasotransmitter production 
Hormonal 
Intensive insulin therapy 
DONOR ORGAN PRECONDITION ING 
Treatment of the donor with the recombinant soluble P-selectin glycoprotein ligand 
(rPSGL-lg), an inhibitor of P- and E- and L-selectin, has also been shown as advantageous in 
experimental models78•80• Three days after transplantation, untreated brain dead donor kidneys 
showed severe tubular necrosis and mononuclear infiltration, whereas recipients where the 
donor was treated with rPSGL-lg showed similar serum creatinine levels to living donor iso­
and allograft recipients. In addition, rPSGL-lg treatment was able to affect chronic transplant 
dysfunction in animals that received brain dead donor kidneys, reducing long-term graft injury 
to a level seen in the living donor situation. 
Carbamylated recombinant human erythropoietin (CEPO) is an EPO derivative that does not 
have hematopoietic effects, but has tissue protective capacities in different models of neural 
damage such as stroke81 • Recently, we found that CEPO can reduce the renal inflammatory 
response and attenuate the increase in serum creatinine levels due to brain death82•83• Also, an 
improved GFR was observed in kidneys derived from CEPO treated brain dead rats compared 
to untreated controls. The combination of immunomodulation and tissue protection could be 
effective in reducing brain death related damage. 
In recent years, hydrogen sulfide (H2S) has come to the attention of researchers in the field 
of ischemia/reperfusion injury. Many protective properties of the gas have been discovered, 
including induction of a hypometabolic state resembling hibernation. This state has been 
used for protection of kidneys during ischemia/reperfusion injury. Also, deficiency of CSE, 
one of the H2S producing enzymes in the body, causes increased damage after renal ischemia. 
Interestingly, the amount of CSE mRNA expression in the donor prior to ischemia is associated 
with short term renal function after transplantation. Modulation of H2S producing proteins in 
the brain dead organ donor, or addition of gaseous H2S to the ventilator gases before organ 
retrieval might prevent renal ischemic injury and improve outcome after transplantation. These 
results must be first confirmed in the human setting, however. 
P E RS P ECT IVE S  O N  D O N O R  MA N AG E M E NT 
A N D  P RETREATM E N T 
The deleterious effects of brain death on the donor kidney provoke pathophysiological changes 
that have a negative impact on the outcome after transplantation. lschemia of the brain results 
in non-function of the central nervous system and is associated with pertinent hemodynamic 
instabil ity, hormonal changes and diminished perfusion. This abnormal physiological state 
induces pro-inflammatory changes in the potential donor organs that negatively affect function 
and cause an increased chance of acute rejection. These compromising changes in the donor 
urge us to develop treatment regimens for application during brain death. 
The use of pharmacological interventions to provide optimal conditions for the donor 
organ and prevent the decline of renal function will become an important part of the entire 
donation and transplantation process. Reducing hemodynamic instability is crucial to maintain 
normal perfusion of organs. The use of catecholamines for this purpose would benefit renal 
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one organ may be detrimental t o  another. This was demonstrated by Schnuelle et al. in their 
analysis of catecholamine use in the donor70• Although renal transplant survival was increased, 
liver transplant outcome was not improved and cardiac results appeared to be adversely 
influenced by catecholamine administration in the donor. A randomized prospective clinical 
trial is currently underway to assess the effects of donor pretreatment with dopamine. 
The application of intensive insulin therapy for strict glycemic control will be beneficial to 
prevent damage to the organs during brain death. It is not clear yet if the effect will be large 
enough, however, to have consequences for graft viability and transplant outcome. 
The use of immunomodulators such as steroids or rPSGL-lg has shown some promising 
results in experimental models. Counteracting inflammatory changes in the deceased donor 
kidney improved function and survival after transplantation. In fact, steroid treatment is 
effective in modulating the immune response in human organ donors79• Since all organs exhibit 
inflammatory changes as a result of brain death, immunomodulating treatment has a high 
probability to be of benefit for all transplanted organs. 
The induction of protective mechanisms, such as H0-1 upregulation, is an important 
development in donor pretreatment. Initiation of protective pathways can diminish brain 
death related damage and ischemia/reperfusion injury. The products created during heme 
degradation by H0-1 are involved in cytoprotective processes. In addition, immunomodulating 
effects of H0-1 could be of use in the improvement of deceased donor transplantation. Another 
option is the addition of gaseous substances to the breathing air of brain dead donors. Carbon 
monoxide (CO) has demonstrated a beneficial effect in modulating ischemia/reperfusion 
injury84 and low dose inhalation of CO after experimental renal transplantation prevents 
the development of chronic allograft nephropathy85• In addition, the use of H2S donors or 
upregulation of H2S producing enzymes hold promise in this field. 
To date, many challenging opportunities do exist to counteract the deleterious effects 
of brain death on the donor kidney. A better characterization and understanding of the 
mechanisms of injury and repair that play a role during massive cerebral injury and its effect 
on potential donor organs will lead to novel treatment options. As a result, the outcome after 
deceased donor organ transplantation may improve, and approach that of living donors. 
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AND FUTURE PERSPECTIVES 

SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES 
SUMMARY 
Chapter 1 is a general introduction about the known physiological effects of H2S and its 
producing enzymes, followed up by an comprehensive review about the currently available 
data on the effects of H2S in settings of ischemia and oxidative stress. 
In Chapter 2, a state of hypometabolism was induced in mice before and/or after exposing their 
kidneys to a period of ischemia. The results show highly protective effects of H2S treatment 
when given prior to ischemia. Posttreatment had effects on some outcome parameters, but 
could not reduce renal failure related mortality, as pretreatment could. 
In Chapter 3 pretreatment with gaseous H2S was used to assess the protective effects in liver 
ischemia, and study the time-course behind this. All measured components of ischemia related 
damage were attenuated by H2S pretreatment, including necrosis, apoptosis, inflammation and 
the formation of reactive oxygen species. 
I n  Chapter 4 we show that pretreatment with gaseous H2S can protect hearts from myocardial 
infarction. In this experiment, we used hypometabolic as well as sub-hypometabolic 
concentrations, to separate the effects of a state of reduced metabolism from the other effects 
of H2S. The results show that non-hypometabolic concentrations of H2S have protective effects 
in the setting of fibrosis and inflammation. Necrosis could only be prevented by hypometabolic 
concentrations of H2S. In vivo, Na HS treatment effectively reduced the formation of ROS. 
In Chapter 5 we demonstrate that CSE, one of the major enzymes responsible for endogenous H2S 
production, acts as an endogenous modulator of oxidative stress in the kidney. First, we assessed the 
localization of CSE in normal human kidneys, showing expression in a large proportion of endothelial 
cells - glomerular as well as vascular and peritubular - in addition to tubular and mesangial cells. In 
CSE-I- mice with reduced renal H2S production ischemic damage is increased compared to control 
littermates, showing increased mortality and necrosis, and reduced renal function. csE-1- mice could 
be rescued by pretreatment with NaHS injection prior to ischemia. In vitro, overexpression of CSE 
reduces the amount of antimycin-induced oxidative stress in cytoplasm and mitochondria. The 
expression of CSE mRNA in human kidneys prior to transplantation is associated with renal function 
14 days after transplantation, indicating a possible protective effect of pre-transplant CSE levels 
in transplantation related ischemia. These results render CSE as an enzyme that is involved in the 
response to oxidative stress, likely through the production of H2S. 
In Chapter 6 we investigated the expression of CSE and CBS in human placental tissue in the 
setting of preeclampsia. CBS expression is decreased in early-onset preeclampsia, while CSE is 
unchanged. This indicates that CBS might be involved in the pathophysiology of the condition. 
Chapter 7 reviews the current state of organ donation using kidneys from brain dead donors. 
The detrimental effects of brain death itself on donor organs as well as the opportunities it 
brings for pretreatment to deflect the harmful effects of cold- and warm ischemia are discussed. 
In our view, one of the most promising clinical settings for the use of H2S is pretreatment of the 






The notion that hydrogen sulfide (H2S) is an endogenously produced gaseous signaling 
molecule with multiple heterogeneous functions has been firmly exablished in the last few 
decades. In addition, exogenous administration of H2S in various conditions has highly beneficial 
effects. The present work on H2S in ischemic settings was instigated after the discovery that 
it can induce a reversible hypometabolic state in mice that resembles hibernation. This led 
to our working hypothesis that H2S has protective effects in transplant related ischemia. The 
detrimental effects of cold- and warm ischemia on the transplanted organ are one of the major 
determinants of transplant outcome. In this thesis, multiple aspects of hydrogen sulfide in the 
setting of oxidative stress have been investigated. 
We show that H2S can have significant protective effects in the setting of predictable 
ischemia, i.e. where treatment can be instigated before the onset of hypoxia. We convincingly 
show this in Chapter 2 and 3, where hypometabolism induced by H2S greatly reduces the 
ischemic damage to the kidney and liver when given before the onset of clamping. Others have 
gained similar protective results of H2S treatment in cardiac-, renal-, hepatic-, intestinal-, lung­
and cerebral ischemic models. Most of these studies use soluble donors of H2S, such as Na HS 
or Na2S. The unique perspective of our studies is the application of gaseous H2S administration 
to cause the induction of a hypometabolic state and the measurement of 02-consumption and 
CO2-production during treatment. In addition, we have focused on pretreatment in the light 
of organ transplantation, while others have predominantly used posttreatment in the setting 
of ischemic disease. 
The mechanism behind these protective effects is still unclear, but it might be a combination 
of various simultaneously occurring effects. Unfortunately, by using the techniques available to 
us today, it is not quite possible to discriminate between the various mechanisms. From our 
results it seems that H2S prevents the onset of ischemic damage and its related processes, rather 
than affecting singular components of ischemic damage (such as apoptosis, inflammation). 
This might be related to the modulation of metabolism, where the balance between oxygen 
demand and availability is sustained during hypoxia, and concurrently less oxidative stress is 
induced and apoptosis and inflammation are not instigated. In addition, H2S might be used as an 
energy substrate during these situations of low oxygen availability. Whether other components 
are also of influence, is unclear. Sulfhydration and concurrent modulation of protein activity, in 
addition to changes in intracellular signaling could play a role. Also, the direct scavenging of 
ROS by H2S and increased GSH levels might be involved. 
In Chapter 4, we tried to imp rove our insight in these processes by com paring hypo metabolic 
and sub-hypometabolic concentrations of H2S in the setting of cardiac ischemia. The results 
indicated that H2S-induced hypometabolism was associated with significantly more protection 
than sub-hypometabolic concentrations of H2S. However, these lower concentrations did 
modulate ischemic damage, indicating that hypometabolism is not required for H2S-induced 
protection. In addition, hypometabolism-inducing concentrations of H2S have hemodynamic 
effects that might also be related to the reduction in damage by reducing cardiac load during 
ischemia. Furthermore, hypometabolism might not be a fitting explanation for the effects of H2S 
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in the post-ischemic phase. We and others have shown the protective effects of posttreatment 
with H2S in the reperfusion phase. Our results from inducing hypometabolism during the 
reperfusion phase of renal ischemia showed some protection on outcome parameters such 
as necrosis and apoptosis, but showed no effect on renal function and mortality. Others have 
shown more prominent protection, which could be due to our method and duration of H2S 
treatment. It seems, though, that H2S is not only promising in settings of predictable onset 
ischemia (e.g. transplantation, temporary vascular clamping during surgery), but also when 
given after the ischemic event, such as in the setting of myocardial infarction or stroke. This 
significantly increases the value of hydrogen sulfide as a therapeutic agent. 
The endogenous production of H2S is still an unfamiliar physiological process. In recent 
years many different functions of endogenous H2S and their associated producing enzymes have 
been specified. These processes include, but are not limited to, vasorelaxation, angiogenesis, 
proliferation, signaling, neuromodulation, oxidative stress, metabolism, modulation of 
the renin-angiotensin-aldosterone system and last - but not least - erectile function. The 
development of the CSE·1· mouse has confirmed the actual vasodilator function of H2S and 
given us insight in the vasorelaxation-, signaling-, antioxidative- and angiogenic properties. 
The endogenous production of H2S has been investigated in Chapter 5, where genetic 
modulation of CSE expression is associated with the amount of oxidative stress. It seems that 
H2S produced by CSE acts as an endogenous modulator of oxidative stress. Increased damage 
and mortality is seen in CSE-;. mice exposed to renal ischemia, whereas overexpression of 
CSE in vitro potently reduces the amount of reactive oxygen species in a model of oxidative 
stress. Others have shown that cardiac-specific overexpression of CSE is protective in the 
setting of myocardial infarction, and protects cardiac mitochondrial function. In a study of 
renal transplant biopsies, we additionally show that CSE expression before transplantation is 
positively associated with renal function in the short term after transplantation, indicating a 
role for CSE in human transplant related oxidative stress. 
The explosive increase in the knowledge about the properties of this gaseous molecule 
have been met with appropriate skepticism, since there are serious uncertainties about the 
measurement techniques used for measuring this volatile and reactive molecule. The introduction 
of fluorescent probes for the measurement of H2S levels in live cells might be the development 
the field needs for advancing knowledge about what intracellular concentrations are really 






The most relevant clinical settings with predictable onset ischemia are transplant related, and 
pretreatment of the brain dead organ donor is one of the first viable options for H2S based 
therapy, especially since the well known toxic effects of H2S are a major hurdle for acceptance 
by physicians and associated medical personnel. If the gaseous form is preferred, the brain 
dead organ donor is always intubated and mechanically ventilated, so addition of H2S to the gas 
mixture can be performed relatively easily. In addition, these patients are strictly monitored in 
the intensive care unit, and not seldom need inotropic support for blood pressure regulation. 
Fears about hypotension and hemodynamic instability caused by vasodilatory action of H2S can 
be quickly obviated by adjusting the inotropic medication. 
When we can show protective effects for various organs by pretreating the multi-organ 
donor, it may lead the way for acceptance in other settings where the subject receiving 
treatment might be affected by long-term toxicity, and these risks might outweigh the benefits 
of H2S mediated protection. One of the main goals of our current project is developing 
advanced preservation solutions for transplanted organs. The use of machine perfusion 
equipment reduces delayed graft function in human renal transplantation; adding H2S to the 
preservation solution might protect the organ from warm- and cold ischemic injury, 
Other settings include surgery of the abdominal aorta where clamping can lead to renal 
ischemia,  or cerebral aneurysm surgery where temporary clipping of major cerebral arteries 
leads to ischemia with sometimes devastating and irreversible neurological outcome. In 
addition, postoperative vasospasm in cerebrovascular surgery might be treated using H2S­
induced vasorelaxation, while simultaneously protecting the brain from ischemic damage. 
From our data, the effects of posttreatment seem smaller when compared to the pretreatment 
effects, but still should not be disregarded, since this may be effective in major and destructive 
ischemic syndromes such as myocardial infarction or stroke. Other groups have shown 
promising effects in these models, indicating a role for H2S based therapeutics in these settings. 
Protection against renal disease is another promising setting for H2S-based therapy. Current 
experiments from our group show antihypertensive and renoprotective effects in a model 
of Angiotensin II nephropathy. Other hypertension-related renal diseases could potentially 
benefit as well. 
Our group has moved forward in investigating the role of CSE as an endogenous modulator 
of oxidative stress. In neurodegenerative syndromes, oxidative stress is one of the culprits 
in disease progression. We used Drosophila melanogaster models of CSE overexpression to 
investigate whether CSE could modulate disease activity in models of pantothenate kinase 
deficiency and spinocerebellar ataxia syndromes, and found promising results. 
The physiological functions of H2S that have recently been discovered and are being exposed 
continuously may prompt many more applications beyond ischemia and hypoxia. The many 
functions that exogenous H2S seems to affect might lead the way to many applications of H2S or 
H2S-donors that are being developed. Ultimately, the therapeutic potential of H2S is broad and 





Het gas waterstofsu lfide (H25) staat bekend om zijn  penetrante geur - d ie va n rotte e iere n  - en 
zijn g iftige eigenschappen.  Bij m ensen kan bootste l l i ng  aan toenemende concentraties va n het 
gas zorgen voor i rritatie van de ogen, p roblemen met het ruiken, ademha l ingsmoei l ij kheden 
en u iteindel ijk  bewustzijnsver l ies en de dood. Deze effecten hebben voor  een be langrijk dee!  
te maken met de remming van de energ ieproductie i n  de m itochondrieen .  
Dankzij een aanta l n ieuw-ontdekte functies van het H 2S in  het l ichaam i s  het gas  i n  de 
afgelopen jaren steeds meer onder de aa ndacht gekomen van wetenschappers. A l lereerst 
is ontdekt dat H25 in b ijna a l l e  celtypen in het l ichaam wordt geproduceerd door een 
d rieta l enzymen : CSE - cystath ion ine y- lyase; CBS - cystathion ine [3-synthase en M PST -
3-mercaptopyruvate su lfu rtransferase. D it in ce l len en organen geproduceerde  H 2S s peelt 
een be langrijke rol b ij een aanta l fys io logische processen in  het l ichaam zoa l s  het reg u le ren 
van de b loeddruk, het afremmen van ontstekingsprocessen, het afgeven van s igna len en  het 
modificeren van de activiteit van versch i l lende eiwitten .  De tot nu toe bekende  eigenschappen 
van H2S warden u itgebreid besproken i n  hoofdstu k  1 .  
Het onderzoek i n  d it proefschrift heeft zich i n  eerste i nstantie gericht o p  een opva l lend effect 
dat H2S kan hebben: het induceren van een winters laap-achtige staat, waa rb ij het oxidatieve 
metabol isme met meer dan 90% wordt verminderd. In 2005 werd ontdekt dat mu izen d ie  aan 
H25-gas warden b lootgesteld, b innen 5 m inuten 60% minder  zuurstof (02) gebru iken en  ook 
minder koolstofd ioxide (CO2) produceren.  Tijdens d it p roces daa l t  de l ichaamstemperatu u r  naar  
s lechts twee g raden boven de omgevingstemperatuu r. Wanneer de toediening van H 25 weer 
wordt gestopt, keren  de mu izen weer snel terug naar hun normale metabol isme en temperatuu r, 
zonder dat er schadelijke effecten op de lange term ijn  waarneembaar zijn .  Deze bevind ing 
hebben wij gebru i kt om organen te beschermen tegen perioden van zuurstofgebrek, zoa ls  dat 
voorkomt tijdens bijvoorbeeld orgaantransplantatie. In hoofdstuk 2, 3 en 4 laten wij zien dat 
wanneer een mu is met H2S in deze winters laap-achtige, hypometabole staat wordt gebracht er 
zeer sterke beschermende effecten optreden wan neer de n ieren, de lever en het hart tijde l ij k  
warden afgesloten van de bloedtoevoer (ischemie / reperfusieschade) .  
I n  hoofdstuk 2 werd gekeken naar  ischemie / reperfusieschade van de n ier. Muizen werden 
op verschi l lende manieren behandeld met H25 (voor het afklemmen van de nierarterie, na het 
afklemmen, en voor- en na het afklemmen). U it d it experiment bleek dat wanneer er H 2S wordt 
gegeven voor de periode van zuurstofgebrek er zeer sterk beschermende effecten zijn op de nier: er 
werd nog am per schade vastgesteld. Behandeling na het afklemmen had wel effect, maarveel m inder 
uitgesproken. Deze bevindingen passen bij het idee dat het remmen van de zuurstofvraag met H 25 
bescherming kan b ieden in situaties van zuurstofgebrek, zoals  bijvoorbeeld bij transplantatie. 
In hoofdstuk 3 hebben wij gekeken naar de lever, waa r  ook zeer sterk beschermende 
effecten van H25 tijdens na ischemie / reperfus ie werden gezien .  I n  d it experiment lag de 
nadruk op het tijdsverloop van de  beschermende effecten. H ieru it b leek dat  zowel i n  de  eerste 
uren na het zuurstofgebrek a l s  na 24 uu r  er bescherming was door behande l ing met H 25 .  Ook 
l ieten wij zien dat er m inder zuurstofradica len ontstaan  door de behande l ing met H 25, moge lijk 
een belangrijk onderdeel van de  beschermende effecten .  
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In hoofdstuk 4 is  onderzocht wat de effecten zijn van H 2S op zuu rstofgebrek van het hart. 
Een mooi  model voor het hart infarct b ij mensen .  Het focus  in deze experimenten lag op het 
o ntrafe len van de toegevoegde waarde van de winters l aap-achtige staat. Er werd een dos is H 2S 
verge leken waarmee deze laag meta bole staat werd veroorzaakt, en een dosis H 2S d ie net geen 
effect had op  het metabol isme.  Hieru it bleek dat het onderdru kke n  van het metabol isme zeker 
effecten heeft die bovenop de andere functies van H 2S werken, met name op de korte termijn .  
I n  hoofdstuk 5 hebben we onderzocht of  CSE, een  van de H2S producerende e iwitten, effect 
h eeft op zuu rstofgebrek. H iervoor hebben wij m u izen gebru ikt d ie  het CSE-gen m issen en deze 
verge leken met normale m u izen .  Muizen  d ie  geen CSE produceren hebben s lechts een fractie 
van de hoeveelheid H2S productie in de versch i l lende o rganen .  Na het afk lemmen van de nier 
b l  eek dat m u izen zonder CSE meer n ierschade  had den dan  normale m uizen .  Wan neer de dieren  
behande ld  werden met extra H2S v i a  een  injectie was  er geen versch i l  meer. D i t  betekent dat  de 
H2S d ie  i n  h et l ichaam wordt geproduceerd door CSE een rol spee lt  in  de bescherming tegen 
zuurstofgebrek. I n  gekweekte ce l len hebben wij vervolgens aa ngetoond dat overproductie van 
CSE ju ist sterk beschermende effecten heeft tegen zuurstofradica len .  Als l aatste is gekeken 
i n  b iopten van getransplanteerde n ieren bij m ensen. U it ana lyse van de hoeveel heid CSE d ie 
in  deze n ieren werd geproduceerd bleek dat  er  een verband was tussen CSE en  de werking 
va n de  n ier  na  transpla ntatie: meer CSE gaf een betere n ierfunctie 14  dagen na transp lantatie. 
Dit a l le s  wijst op een rol van CSE en  endogeen geproduceerd H2S bij de bescherming tegen 
zu u rstofgebrek, zowel bij d ieren als bij mensen.  
In  hoofdstuk 6 is onderzocht of er versch i l len  zijn i n  de hoeveelheid CSE en  CBS i n  de 
p lacenta van patienten met pre-eclam psie, een vascu la i re ziekte d ie zorgt voor hoge b loeddru k 
en n ierschade tijdens de zwa ngerschap.  H ieru it b leek dat er m inder va n het CBS-gen in de 
p lacenta tot express ie komt bij patienten met p re-ec lampsie, wat een gedeeltel ij ke verklar ing 
ka n zij n  voor het ontstaan van de  ziekte. 
In hoofdstuk 7 wordt besproken wat de moge l ijkheden zijn voor  het verbeteren van de 
kwa l iteit van donororganen, gericht op het voorbehandelen van de hersendode orgaandonor 
voo r  de  u itname van organen.  I n  onze opt iek i s  de voorbehande l ing van de hersendode 
orgaandonor met H2S een van de  be langwekkendste mogel ijkheden voor het verbeteren va n 
de u itkomst van orgaantransp lantatie op d it moment. 
A l les samengenomen i s  het i n  deze d issertatie du ide l ij k  geworden dat behande l ing met H 2S 
een bel ang rijke rol kan spelen bij de bescherming tegen  zuurstofgebrek. In de toekomst zou 
behande l ing met H25 bescherming kunnen b ieden bij orgaantransp lantatie, tijdens ch i rurg ische 
ingrepen waa rbij vaten tijde l ij k  worden  afges loten (zoals  aortach i rurgie of het beha ndelen van 
hersenaneurysmata), maar ook b ij het hart- of h erseninfa rct .  
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Op de afdel ing Pathologie en Medische Biologie heb ik mijn basis gelegd. De eerste stapjes in het 
onderzoek, de eerste keer een pi pet in de hand en, een coupe geplakt, een kleuring gedaan, achter 
de microscoop. De praktische kant had ik  n iet kunnen volbrengen zonder de hu lp  van Marian 
Bulthuis. Zij leerde me hoe vei l ig om te gaan met gevaarl ijke stoffen, waarvan i k  waarschijn l ijk  wel 
iets heb onthouden aangezien ik  relatief onbeschadigd deze periode ben doorgekomen. Maar zij 
heeft ook, soms samen met m ij maar ook vaak  a I leen, ontzettend veel werk verricht om de data 
in dit proefschrift rond te krijgen, en natuur l ijk veel werk verricht voor de vele mis lukte projecten 
die het n iet hebben gehaald.  Vele ma len snijden, plakken, kleuren, scannen en analyseren .  Altijd 
vrolijk en bereid om te helpen.  Marian, ik ben je ontzettend dankbaar voor al je hu lp. Hiernaast 
had ik het niet rond ku nnen krijgen zonder de hu lp  van Sippie Hu itema, die a ltijd binnen een paar 
dagen met resu ltaten op de proppen kwam in  de tijd van dead l ines. 
Op de AIO-kamer va n de pathologie heb i k  ve le mensen zien komen en gaan, maa r ge lu kkig was 
er een b l ijvend goede sfeer op de kamer. Als ik  nadenk over de  hoeveelheid p lastic bekertjes 
met matige koffie die zijn  verbru ikt voel ik  me zeer schu ld ig over de gevolgen voor het m i l ieu .  
Gelukkig hebben we het aanta l stappen tot e lke koffieautomaat nauwkeu rig gemeten, om 
te voorkomen dat de vele tr ipjes i n  deze richting te veel energ ie zouden ops l u rpen, met 
duurza me gevolgen voor het ta pijt tussen de AIO kamer en automaat op de koop toe. Met heel 
veel p lezier heb ik lange tijd naast Gemma Mu lder mogen zitten, met aan m ijn andere zijde 
Jelena Ka mi l ic .  Het u itzicht op de wachttoren van de bewa king is  voorgoed op m ijn netvl ies 
gebrand, en het idee dat we a ltijd bekeken werden door bewa pende mannetjes heeft zeer 
veel geholpen in de productiviteit. Nadat Wynand Melen horst tot m ijn  verdriet was vertrokken 
werd h ij gelu kkig verva ngen door een andere man, te weten Joris van Ark. Hoewel erg geze l l ig  
was het vrouwengeha lte op de ka mer iets te ver doorgestegen, waardoor er te wein ig koffie 
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en te veel  thee werd verorberd. Gelukkig kon J i l l  Moser ons a ltijd een goede whisky aan raden 
aan het einde van de m iddag, naast het inbrengen van haar  b rede wetenschappel ijke ervar ing 
en vele babyfoto's. Ook ben i k  dank  verschu ld igd aan Mirjan van Tim meren, I nge H a m m ing, 
Martin de Borst, Andrea Kramer, Anne Roos Frenay, Ki m Holwerda, Far iba Poosti, Henr ike Jeke l, 
Joost van den Born, Michie !  van Veen, N iels H u izing, Jan-Luuk H i l lebra nds, Marcory van Dijk, 
Lyd ia Visser, Hans Vos, Anke van den Berg, en Marijke Faas. 
Op het Chirurg isch Onderzoeks laboratori um kon ik a ltijd b innenva l len voor experimenten 
of advies. Mede dankzij de goede sfeer en de vrije werkomgeving heb ik  er vele u ren 
doorgebracht, overdag en  's  avonds laat .  Wanneer i k  er was werd er he laas niet a ltijd vro l ij k  
gekeken omdat i k  het l ab  nog  we l  eens b lauw wist te  zetten met de geu r  van rotte eieren tijdens 
goed bedoelde experim enten .  Mijn dank gaat u it naar  Jacco Zwaagstra, Petra Ottens, J anneke 
Wiersema - Bu ist, Jel le Adelmeijer, Renee G ras, Susanne Veldhu is, Antony van Dijk, Ton Lisman, 
Theo Schuu rs, Geert van Rijt, Jeffrey Damman, Welmoet Westendorp, Astrid K looster, Edwin 
Dierse lhu is, Michael Sutton, Lyan Koudstaal ,  Tan Hongtao, Mijntje N ijboer, Cyri l  Moers, Car l ijn 
Bu is, Jayant Ja inandu nsing en H ugo Maathuis .  
My experience in  Thu nder  Bay at Lakehead University was wonderfu l .  The experience of being in  
a lab as renowned as that of Rui Wang was impressive and inspir ing. Be ing able to use the faci l ities 
and the CSE-deficient an ima ls  has g iven my project a hefty boost. During my short time there I 
have made many friends ,and I am very thankfu l for having had the opportunity to not on ly learn 
a tremendous amount, but to a lso spend time working and making fun with Guangdong Yang, 
Yaoge H uang, Ming Fu, Sheena Wood, Kartar S ingh Kalsi, Zaid Altaany, Peipei Wang, Guanghua 
Tang, Bo Jiang, H uajian Teng, Weihua Zhang, Quihu i  Cao, L ing Zhang, Sarathi Mani  and Lisa Wilson. 
Zonder de hu lp van  Pieter Klok had ik mijn vele dierexperimenten niet kunnen voltooien. Zolangje 
op tijd voor je afspraak in het d ierenlab was kon je rekenen op excellente microchirurgische h u lp. 
Dankzij het microchiru rgisch team hebben een aantal van mijn proeven s lechts dagen ged u u rd, 
in plaats van weken. H iervoor moet ik de !eden, Annemieke Smit - Van Oosten, Michel Weij en 
Andre Zantvoort zeer dankbaar zijn .  Maar ook N iels Kloosterhuis heeft een belangrijk aandeel  
gehad in  mijn eerste g rote dierproef, en zonder hem hadden de operaties n iet zo soepel gelopen, 
en was het een stuk minder gezel l ig in  de operatiekamer. In het kader van a l  deze proeven ben 
ik ook dank verschu ld igd aan Catriene Thu ring, Miriam van der Meulen - F rank, Flip Klatter, Alex 
K luppel, Arie N ijmeijer en natuurl ijk a l le dierverzorgers en and er medewerkers van het CDL / CDP. 
Ook b innen het Kidney Center heb ik veel insp iratie opgedaan, en de mooie reisjes naar  de ASN 
in de Verenigde Staten en natuu rl ij k  de p rachtige ervaring op het WCN in Rio de Janeiro hebben 
een  mooie herinneringen geproduceerd .  Veel  dank  aan Gerjan Navis, Stephan Bakker, Wi l l em 
van Son ,  Jaap van den Born, Marc Seelen, Fem ke Waanders, H i lde Tent, Jan Krikken, E lse van 
den Berg, Arjan Kwakernaak, Leendert Oterdoom, Folkert Visser, Mien eke Rook, Titia Lely, Aiko 
de Vries en Liffert Vogt 
I cou ld not have perform ed the resp irometry experiments without the excel l ent team at Sab le  
Systems I nternationa l ,  especia l ly John Lighton, Robbin Turner and  Barbara Joos .  I massively 
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enjoyed the respi rometry cou rse, which was not on ly due  to it being held i n  Las Vegas, as  
the whole setting was insp i ring  and very accommodati ng .  Without you r  care and gu ida nce 
this project would have went in a d ifferent d i rection, and your  technica l  support was a lways 
q u ick and helpfu l, even at such a d i stance (even though not a l l  of the equ ipment survived our  
a mbitious experiments, but that is  due  to ou r  own doing . . .  ) .  
Tijdens m ijn  rondzwervi ngen door het UMCG op zoek naar  de j u iste apparatuur, reagentia, 
ant i l ichamen, dieren en andere materia len  heb ik ve le  labs aangedaan .  N iet a l l es heeft tot 
iets tastbaars geleid, maar a l l e  samenwerkingen hebben zeker bijged ragen tot het leerproces 
waa r het u iteindel ijk  om d raait .  De volgende mensen ben ik dank  verschu ld igd vanwege hun  
u itstekende hu lp  of  insp i ratie: M i ri am Boersema, Maxi Meissner, Harrie Kampinga, Ody  S ibon, 
Rudolf de Boer, I nge Vreeswijk - Baudoin,  Wi l lem-Peter Ruifrok, Li l i  Yu, Klaas Sjo l l ema, Geert 
Mesander en Marco van der Toorn.  
Dankzij de  Jun ior Scientific Masterc lass en g raduate school GU IDE heb ik  het MD / PhD traject 
kunnen u itvoeren. De vele  cursussen en de begeleid ing  zij n  zeer  behu l pzaam geweest. De 
volgende mensen hebben h ieri n een bela ng rijke rol gespeeld :  Hauw The, Hanneke K lu in  -
Ne lemans, Michie!  Hooiveld  en Cresje Wachters - Kaufmann .  Riekje Banus, dank  voor je h u l p  
bij voorbereiden van m ijn  periode in  Canada .  
Ook bu iten het Gron ingse ben i k  dank  verschu ld igd aan  de volgende mensen :  Sandrine 
F lorqu in, Jak l ien Leemans, Gwen Teske en Loes Butter u it het AMC i n  Amsterdam, Sebastiaan 
Wessel i ng en Jaap Jo les  u it het UMC U trecht en Benito Yard u it Mannheim - Heidel berg .  
Mijn  tijd i n  het ISCOMS bestuur  was  een  zeer  gedenkwaard ige tijd, vanwege het mooie congres 
wat we hebben neergezet, maa r met nam e  vanwege de sfeer b innen de groep, met daar in 
Moniek Gorter, You lan  Gu,  Leontien ter Horst, Jan-Renier Moonen,  Al ida Weidenaar, Roderick 
Wouters en natuur lijk ook Wynand Melen horst. Floris l mhann, dank dat je me hebt wi l len  
betrekken bij je vele bezigheden, i nc l u sief de  Economic Ta lent Board .  
Tijdens deze lange periode heb ik veel bemoediging maar  met name afleiding gehad van mijn  goede 
vrienden van mijn Jaarclub en natuurlijk de jongens van Huize OK. Ook ben ik veel dank verschuldigd 
aan Repke, Simone, Roel en Evel ine voor hun l ieve ondersteuning in  de afgelopen periode. 
Natuu r l ij k  heb ik oak nog m ijn  fam i l i e, die ik  wil bedanken voor a l l e  steun.  Sjoerd en Meike, i k  
ben ontzettend trots op a l  j u l l ie  prestaties. Lieve Oma, ik  weet da t  ik n iet vaa k  genoeg langs 
kom i n  Oude Tonge, maar nu  deze periode voorbij i s  gaat dat veranderen !  
Het verl ies van m ijn l ieve moeder heeft een zware periode ontketend voor ons a l ien .  Ook in  
de tijden dat zij ziek was heeft zij m ij a ltijd gesteu nd, en er  voor gezorgd dat  i k  d it  project 
n iet wi lde opgeven. Ze heeft het nooit met zoveel woorden gezegd, maar ik weet dat ze trots 
zou zij n als ze m ij op deze dag zou z ien .  Pa, het is n iet a ltijd ma kke l ijk geweest de afgelopen 
j a ren, en som mige tijden waren rondu it moei l ijk .  l k  hoop dat je  trots bent op wat i k  h ier  heb 
neergezet. Sam en met Marja ben je  begonnen aan een mooie n ieuwe start. 
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